CrossRef Extract of Articles Possibly Related to Alzheimer's

1. Advances in the roles and mechanisms of lignans against Alzheimer’s disease
2. Corrigendum to “Global cognitive effects of second-generation antidepressants in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials” [J. Psychiatr. Res. 155 (2022) 371–379]
3. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
4. Effects of Depression on Changes in Cognitive Function in Older Adults
5. Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia study

1. A Retrospective Study on Clinical Assessment of Cognitive Impairment in a Swedish Cohort: Is There Inequality Between Natives and Foreign-Born?
2. A scoping review of post-diagnostic dementia supports for people with intellectual disability
3. Acceptability and Preliminary Effectiveness of a Remote Dementia Educational Training Among Primary Care Providers and Health Navigators
4. Amyloid Pathology in the Central Auditory Pathway of 5XFAD Mice Appears First in Auditory Cortex
5. Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease
6. Antimicrobial, Polarizing Light, and Paired Helical Filament Properties of Fragmented Tau Peptides of Selected Putative Gingipains
7. Are phosphodiesterase type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
8. B Vitamin Supplementation Slows Cognitive Decline in Mild Cognitive Impairment Patients with Frontal Lobe Atrophy
9. Bifidobacterium breve MCC1274 Supplementation Increased the Plasma Levels of Metabolites with Potential Anti-Oxidative Activity in APP Knock-In Mice
10. Biomarkers of Inflammation Increase with Tau and Neurodegeneration but not with Amyloid-β in a Heterogenous Clinical Cohort
11. Book Review
12. Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer disease mice
13. Circulating Cell-Free Genomic DNA Is Associated with an Increased Risk of Dementia and with Change in Cognitive and Physical Function
14. Cognitive Improvement After Multi-Domain Lifestyle Interventions in an APOE ɛ4 Homozygous Carrier with Mild Cognitive Impairment: A Case Report and Literature Review
15. Decline in Cognition from Mid-Life Improves Specificity of Mini-Mental State Examination: Diagnostic Test Accuracy in Caerphilly Prospective Study (CaPs)
16. Disentangling the relationship of subjective cognitive decline and depressive symptoms in the development of cognitive decline and dementia
17. Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium
18. Editorial: Apoptosis, autophagy, and mitophagy dysfunction in Alzheimer's disease: Evolving emergence and mechanisms
19. Effects of Medicare Part D medication therapy management on racial/ethnic disparities in adherence to antidementia medications among patients with Alzheimer’s disease and related dementias: An observational study
20. Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer’s dementia
21. Epigenetic Changes and Chromatin Reorganization in Brain Function: Lessons from Fear Memory Ensemble and Alzheimer’s Disease
22. Evaluating the Bidirectional Causal Association Between Daytime Napping and Alzheimer’s Disease Using Mendelian Randomization
23. Evaluation of Possible Antioxidant, Anti-Hyperglycaemic, Anti-Alzheimer and Anti-Inflammatory Effects of Teucrium polium Aerial Parts (Lamiaceae)
24. Glucometabolic Changes Are Associated with Structural Gray Matter Alterations in Prodromal Dementia
25. Hyperorality in Frontotemporal Dementia: Cognitive and Psychiatric Symptom Profiles in Early-Stage Disease
26. Hypnosis Intervention for Couples Confronted with Alzheimer’s Disease: Promising Results of a First Exploratory Study
27. Identification of Early Onset Dementia in Population-Based Health Administrative Data: A Validation Study Using Primary Care Electronic Medical Records
28. Impaired Facial Emotion Recognition and Gaze Direction Detection in Mild Alzheimer’s Disease: Results from the PACO Study
29. Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice
30. Longitudinal Associations of Plasma TMAO and Related Metabolites with Cognitive Impairment and Dementia in Older Adults: The Cardiovascular Health Study
31. Management Strategy of Alzheimer’s Patients under the Medical-Care Integration Model Based on Big Data Evaluation
32. Microglia-mediated neurovascular unit dysfunction in Alzheimer’s disease
33. Monitoring Alzheimer’s Disease Progression in Mild Cognitive Impairment Stage Using Machine Learning-Based FDG-PET Classification Methods
34. Neuropathological and Clinical Correlates of Lewy Body Disease Survival by Race and Ethnicity in the National Alzheimer’s Coordinating Center
35. Neurotoxicity of Diesel Exhaust Particles
36. Objective Sleep Quality and the Underlying Functional Neural Correlates Among Older Adults with Possible Mild Cognitive Impairment
37. Ovariectomy-induced hormone deprivation aggravates Aβ1-42 deposition in the basolateral amygdala and cholinergic fiber loss in the cortex but not cognitive behavioral symptoms in a triple transgenic mouse model of Alzheimer’s disease
38. Patterns of Limitation in Physical Function in Late Midlife Associated with Late-Onset Alzheimer’s Disease and Related Dementias: A Cluster Analysis
39. Personalized Prediction of Alzheimer’s Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials
40. Plasma Myeloperoxidase as a Potential Biomarker of Patient Response to Anti-Dementia Treatment in Alzheimer’s Disease
41. Plasma Neurofilament Light Chain and Clinical Diagnosis in Frontotemporal Dementia Syndromes
42. Probiotics Treatment Can Improve Cognition in Patients with Mild Cognitive Impairment: A Systematic Review
43. Retinal Pathological Features and Proteome Signatures of Alzheimer’s
44. Risk Models Based on Non-Cognitive Measures May Identify Presymptomatic Alzheimer’s Disease
45. Serum total TDP-43 levels are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant motoneuron disease phenotype
46. Sleep Disturbances, Cognitive Status, and Biomarkers of Dementia
47. TREM2 Gene Compound Heterozygosity in Neurodegenerative Disorders
48. Tau seeding in cases of multiple sclerosis
49. The Association Between Alzheimer's Disease and Epilepsy: A Narrative Review
50. The Association Between Osteoarthritis with Risk of Dementia and Cognitive Impairment: A Meta-Analysis and Systematic Review
51. The Parietal Lobe in Alzheimer’s Disease and Blindness
52. Validation of the Informant Quick Dementia Rating System (QDRS) among Older Adults in Singapore

1. Age-linked suppression of lipoxin A4 associates with cognitive deficits in mice and humans
2. Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer’s disease in TgF344-AD rats
3. Biological characterization of natural peptide BcI-1003 from Boana cordobae (anura): role in Alzheimer’s Disease and microbial infections.
4. Blood Leukocyte Counts in Alzheimer Disease
5. CSF Alzheimer Disease Biomarkers
6. Cinnamaldehyde Regulates Insulin and Caspase-3 Signaling Pathways in the Sporadic Alzheimer’s Disease Model: Involvement of Hippocampal Function via IRS-1, Akt, and GSK-3β Phosphorylation
7. Comunicación del diagnóstico de enfermedad de Alzheimer: reflexiones bioéticas
8. Default-Mode Network Connectivity Changes During the Progression Toward Alzheimer's Dementia: A Longitudinal Functional Magnetic Resonance Imaging Study
9. Editorial: Translational advances in Alzheimer's, Parkinson's, and other dementia: Molecular mechanisms, biomarkers, diagnosis, and therapies, volume II
10. Effect of psychological first aid program on stress level and psychological well-being among caregivers of older adults with alzheimer’s disease
11. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
12. Influence of Gender on Tau Precipitation in Alzheimer’s Disease According to ATN Research Framework
13. Inhibition of β-Amyloid Aggregation in Alzheimer’s Disease: The Key Role of (Pro)electrophilic Warheads
14. Insights into disease and pharmacotherapy knowledge of Alzheimer’s disease among community pharmacists: a cross-sectional study
15. LYECs: lysosome-enhancing compounds as potential therapeutic approaches for Alzheimer disease
16. Multimodal Classification Technique for Fall Detection of Alzheimer’s Patients by Integration of a Novel Piezoelectric Crystal Accelerometer and Aluminum Gyroscope with Vision Data
17. Network pharmacology and bioinformatics approach reveals the therapeutic activity and action mechanism of curcumin in Alzheimer disease
18. OBSERVAÇÃO DOS CASOS DE INTERNAÇÕES POR DOENÇA DE ALZHEIMER DE 2014 A 2019
19. Potential biomarkers of Alzheimer’s disease and cerebral small vessel disease
20. Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients
21. Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer’s disease
22. Suppression of Wnt/β-Catenin Signaling Is Associated with Downregulation of Wnt1, PORCN, and Rspo2 in Alzheimer’s Disease
23. The Role of Clusterin Transporter in the Pathogenesis of Alzheimer’s Disease at the Blood–Brain Barrier Interface: A Systematic Review
24. The associations of APP , PSEN1 , and PSEN2 genes with Alzheimer's disease: A large case–control study in Chinese population
25. The gut microbiota affects amyloid deposition in Alzheimer’s disease models by suppressing immune-mediated Aβ clearance
26. Therapeutic implications of glycogen synthase kinase-3β in Alzheimer’s disease: a novel therapeutic target
27. Trametinib activates endogenous neurogenesis and recovers neuropathology in a model of Alzheimer’s disease
28. Transcriptional Coordination between Mitochondrial and Nuclear Genomes for Oxidative Phosphorylation Is Disrupted in Alzheimer’s Brain
29. ¿Tratamos la demencia tipo Alzheimer o la enfermedad de Alzheimer?Fármacos antidemenciales en la era de los biomarcadores

1. Association between Cerebral Coordination Functions and Clinical Outcomes of Alzheimer’s Dementia
2. Domino-like Effect of C112R Mutation on APOE4 Aggregation and Its Suppression by Alzheimer's Disease Drug Candidate
3. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase
4. Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4
5. Proteomics of resilience to Alzheimer's disease identifies brain regional soluble Aβ levels, actin filament processes, and response to injury
6. Research on computer-aided diagnosis of Alzheimer's disease based on PET images
7. Structural synaptic signatures of Alzheimer's disease and dementia with Lewy bodies in the male brain
8. Voting Ensemble Approach for Enhancing Alzheimer’s Disease Classification

1. Association of Kidney Function with Risk of Incident Dementia: A Prospective Cohort Study of 275,167 UK Biobank Participants
2. Deep-Learning-Based System for Assisting People with Alzheimer’s Disease
3. Different phenotypes of microglia in animal models of Alzheimer disease
4. Effectiveness and safety of anti‐tau drugs for Alzheimer's disease: Systematic review and meta‐analysis
5. Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer’s disease
6. Sex-dependent neuro-deconvolution analysis of Alzheimer's disease brain transcriptomes according to CHI3L1 expression levels
7. Tolerability and safety with aducanumab in Alzheimer's disease in a community‐based setting on a slower titration schedule
8. Weak Social Networks in Late Life Predict Incident Alzheimer’s Disease: The Kuakini Honolulu-Asia Aging Study
9. White Button Mushroom (Agaricus bisporus) Supplementation Ameliorates Spatial Memory Deficits and Plaque Formation in an Amyloid Precursor Protein Mouse Model of Alzheimer’s Disease

1. Alzheimer’s disease: insights from a network medicine perspective
2. An Ontology-based approach for Modelling and Querying Alzheimer’s Disease Data
3. Associations between affective/vegetative neuropsychiatric symptoms and brain morphology in aging people with mild cognitive impairment and Alzheimer’s disease
4. Circadian modulation by time-restricted feeding restores brain transcription and slows amyloid deposition in a mouse model of Alzheimer’s disease
5. Correlative Chemical Imaging Identifies Amyloid Peptide Signatures of Neuritic Plaques and Dystrophy in Human Sporadic Alzheimer's Disease
6. DMSENet: Deep multi-modal squeeze and excitation network for the diagnosis of Alzheimer's disease
7. Differential Diagnosis of Alzheimer Disease vs Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypomethabolism on 18F-FDG PET/CT and Automated Classifiers
8. Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals
9. Prediction of misfolded proteins spreading in Alzheimer’s disease using machine learning
10. Recruitment and Data Collection Challenges of Research Focused on Older Adults and Family Caregivers from Asian American Communities: A Case Study Series
11. Stigma among UK family carers of people living with dementia
12. Super-resolution ultrasound imaging of cerebrovascular impairment in a mouse model of Alzheimer’s disease
13. Triglyceride Level- and MTHFR- Specific Mediation Effect of Handgrip Strength on the Association of Dietary Protein Intake and Cognitive Function in the Chinese Elderly
14. Vascular Brain Lesions, Cognitive Reserve, and Their Association with Cognitive Profile in Persons with Early-Stage Cognitive Decline

1. A Bibliometric and Visual Analysis of Exercise Intervention Publications for Alzheimer’s Disease (1998–2021)
2. Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors
3. Calcium‐channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients
4. Can you find it? Novel oddity detection task for the early detection of Alzheimer’s disease.
5. Cerebrospinal Fluid sTREM2 in Alzheimer’s Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status
6. Classification on Alzheimer’s Disease MRI Images with VGG-16 and VGG-19
7. Decreased Hemodynamic Responses in Left Parietal Lobule and Left Inferior Parietal Lobule in Older Adults with Mild Cognitive Impairment: A Near-Infrared Spectroscopy Study
8. Design, Fabrication, optimization and characterization of Memantine loaded biodegradable PLGA nanoscaffolds for treatment of Alzheimer’s disease
9. Editorial: Infection, inflammation, and neurodegeneration: A critical path to Alzheimer's disease, Volume II
10. Editorial: Mechanisms, markers and therapeutics of synaptic pathology in Alzheimer's disease
11. Effect of sacubitril/valsartan on cognitive impairment in colchicine‐induced Alzheimer’s model in rats
12. Estimating Likelihood of Dementia in the Absence of Diagnostic Data: A Latent Dementia Index in 10 Genetically Informed Studies
13. Excretion of Amyloid-β in the Gastrointestinal Tract and Regulation by the Gut Microbiota
14. Extremely Early-Onset Frontotemporal Dementia: A Case Report and Literature Review
15. Fecal Microbiota Transplantation Role in the Treatment of Alzheimer's Disease: A Systematic Review
16. Geometric Control of Cell Behavior by Biomolecule Nanodistribution
17. Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance
18. Impacto emocional da doença de Alzheimer para familiares do doente e como o diagnóstico afeta as atividades diárias: revisão integrativa
19. In vivo Tau Burden Is Associated with Abnormal Brain Functional Connectivity in Alzheimer’s Disease: A [18F]-Florzolotau Study
20. Inhibition of Alzheimer's Aβ _1‐42 Fibrillogenesis and Removal of Copper Ions by Polypeptides Modified Gold Nanoparticles
21. Intra-beat biomarker for accurate continuous non-invasive blood pressure monitoring
22. Isolation, In Vitro and In Silico Anti-Alzheimer and Anti-Inflammatory Studies on Phytosteroids from Aerial Parts of Fragaria × ananassa Duch
23. Machine Learning Workflow to Explain Black-Box Models for Early Alzheimer’s Disease Classification Evaluated for Multiple Datasets
24. Mesenchymal stromal cells for the treatment of Alzheimer’s disease: Strategies and limitations
25. Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer’s disease
26. Multi-Omics, an Integrated Approach to Identify Novel Blood Biomarkers of Alzheimer’s Disease
27. Neuroprotective effect of phytoconstituents via nanotechnology for treatment of Alzheimer diseases
28. News at a glance: AI regulation, renewable energy, and Alzheimer’s therapy
29. Novel molecular mechanisms in Alzheimer’s disease: The potential role of DEK in disease pathogenesis
30. Proof of concept for a multimethod approach to evaluate the usability of websites with public health content: The case of Alzheimer association websites.
31. The Effects of Bilingualism and Multilingualism on Alzheimer’s Disease Progression: A Systematic Review
32. Uncovering mechanisms of brain inflammation in Alzheimer's disease with APOE4 : Application of single cell‐type lipidomics
33. Unsupervised co-optimization of a graph neural network and a knowledge graph embedding model to prioritize causal genes for Alzheimer’s Disease
34. Validation and Comparison of the Informant-Rated and Self-Rated Versions of the Mild Behavioral Impairment Checklist
35. Willin/FRMD6 Mediates Mitochondrial Dysfunction Relevant to Neuronal Aβ Toxicity

1. A deep learning based convolutional neural network model with VGG16 feature extractor for the detection of Alzheimer Disease using MRI scans
2. A transfer learning approach based on gradient boosting machine for diagnosis of Alzheimer’s disease
3. Altered secretion, constitution, and functional properties of the gastrointestinal mucus in a rat model of sporadic Alzheimer’s disease
4. Alzheimer’s disease-related transcriptional sex differences in myeloid cells
5. An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease
6. Associations of resting heart rate with incident dementia, cognition, and brain structure: a prospective cohort study of UK biobank
7. Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment
8. Contributions of extracellular-signal regulated kinase 1/2 activity to the memory trace
9. DFT study of regio- and stereo-selective 13DC reaction between diazopropane and substituted chalcone derivatives: Molecular docking of novel pyrazole derivatives as Anti-Alzheimer’s Agents
10. Decreased locus coeruleus signal associated with Alzheimer’s disease based on neuromelanin-sensitive magnetic resonance imaging technique
11. Dendritic Branching of Retinal Ganglion Cells as a Biomarker of Glaucomatous Optic Neuropathy and Alzheimer’s Disease and a Target of Neuroprotective Therapy
12. Educating students while recruiting underrepresented populations for Alzheimer’s disease research: the Student Ambassador Program
13. Effects on Autophagy of Moxibustion at Governor Vessel Acupoints in APP/PS1double-Transgenic Alzheimer’s Disease Mice through the lncRNA Six3os1/miR-511-3p/AKT3 Molecular Axis
14. Excitation-inhibition imbalance in Alzheimer’s disease using multiscale neural model inversion of resting-state fMRI
15. Fe₃O₄/MXene Nanosphere-Based Microfluidic Chip for the Accurate Diagnosis of Alzheimer’s Disease
16. Investigating the association between cancer and dementia risk: a longitudinal cohort study
17. Multi-Perspective Feature Extraction and Fusion Based on Deep Latent Space for Diagnosis of Alzheimer’s Diseases
18. Müller cell degeneration and microglial dysfunction in the Alzheimer’s retina
19. Practice effects in cognitive assessments three years later in non-carriers but not in symptom-free mutation carriers of autosomal-dominant Alzheimer's disease: Exemplifying procedural learning and memory?
20. Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model
21. Retraction Note to: Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer’s disease
22. Reward-related activation of fronto-striatal regions scaled negatively with C-reactive protein but showed no association with anhedonia in depression
23. Roles of ZnT86D in Neurodevelopment and Pathogenesis of Alzheimer Disease in a Drosophila melanogaster Model
24. The effects of fenugreek seed extract supplementation in patients with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled trial
25. The impact of patient travel time on disparities in treatment for early stage lung cancer in California
26. The individuality of shape asymmetries of the human cerebral cortex
27. Thyroid-stimulating hormone and the risk of Alzheimer's disease: an ADNI cohort study
28. Using Deep Learning to Determine Amyloid Deposition through PET and Clinical Data for Alzheimer’s Prognosis
29. Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer’s disease

1. A causal association of ANKRD37 with human hippocampal volume
2. Advances in stromal cell therapy for management of Alzheimer’s disease
3. Associations between blood-based biomarkers of Alzheimer’s disease with cognition in motoric cognitive risk syndrome: A pilot study using plasma Aβ42 and total tau
4. Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
5. Bioinformatics analysis of diagnostic biomarkers for Alzheimer's disease in peripheral blood based on sex differences and support vector machine algorithm
6. Brain copper may protect from cognitive decline and Alzheimer’s disease pathology: a community-based study
7. Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
8. Deep-learning-based human activity recognition for Alzheimer’s patients’ daily life activities assistance
9. Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer's disease
10. Digital culturally tailored marketing for enrolling Latino participants in a web‐based registry: Baseline metrics from the Brain Health Registry
11. Engineered Extracellular Vesicles with SHP2 High Expression Promote Mitophagy for Alzheimer's Disease Treatment
12. Ensemble of convolutional neural networks and multilayer perceptron for the diagnosis of mild cognitive impairment and Alzheimer's disease
13. Faculty Opinions recommendation of Reducing Nav1.6 expression attenuates the pathogenesis of Alzheimer's disease by suppressing BACE1 transcription.
14. Gender-specific relationship between thigh muscle and fat mass and brain amyloid-β positivity
15. High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations
16. Higher amyloid correlates to greater loneliness during the COVID-19 pandemic
17. Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease
18. Liver-ing in your head rent free: peripheral ApoE4 drives CNS pathology
19. Longitudinal Predictors of Informant-Rated Involvement of People with Dementia in Everyday Decision-Making: Findings from the IDEAL Program
20. Mid‐ and later‐life risk factors for predicting neuropathological brain changes associated with Alzheimer's and vascular dementia: The Honolulu Asia Aging Study and the Age, Gene/Environment Susceptibility‐Reykjavik Study
21. Multilayer brain connectivity analysis in Alzheimer’s disease using functional MRI data (Conference Presentation)
22. No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer’s disease and related dementia: results from the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study
23. Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease
24. Prenatal alcohol exposure causes persistent microglial activation and age- and sex- specific effects on cognition and metabolic outcomes in an Alzheimer’s Disease mouse model
25. Saúde do idoso acamado com Alzheimer durante a pandemia da COVID-19: revisão integrativa
26. Single nucleus multiomics identifies ZEB1 and MAFB as candidate regulators of Alzheimer’s disease-specific cis regulatory elements
27. Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer’s disease
28. Zebrafish as an Experimental and Preclinical Model for Alzheimer’s Disease

1. A novel framework for the diagnosis of Alzheimer's continuum using embedded features of brain networks
2. An empirical study of digital signal filtering to improve Alzheimer’s disease detection
3. Assignment of Absolute Configuration to Enantiomers of Anti-Alzheimer Drug Candidate Blarcamesine
4. Associations of Pulmonary Function with MRI Brain Volumes: A Coordinated Multi-Study Analysis
5. Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
6. C-terminal fragment of APP interacts with p62, forms an aggregate, and induces autophagic degradation in Alzheimer's cell model
7. COVID-19 and Alzheimer's Disease: Neuroinflammation, Oxidative Stress, Ferroptosis, and Mechanisms Involved
8. Classification between early onset Alzheimer's disease and frontotemporal dementia using a single neuroimaging feature
9. Computer-based Eye-tracking Analysis of King-Devick Test Differentiates Persons With Idiopathic Normal Pressure Hydrocephalus From Cognitively Unimpaired
10. Coping in Mid- to Late Life and Risk of Mild Cognitive Impairment Subtypes and Dementia: A JPHC Saku Mental Health Study
11. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value
12. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value
13. Creating a Dementia Friendly Community in an African American Neighborhood: Perspectives of People Living with Dementia, Care Partners, Stakeholders, and Community Residents
14. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: A systematic Review and meta-analysis
15. Early death in a mouse model of Alzheimer’s disease exacerbated by microglial loss of TAM receptor signaling
16. Early detection of Alzheimer’s via machine learning with multi-modal data
17. Flavonoids from Stems and Leaves of Scutellaria baicalensis Georgi Improve Composited Aβ-induced Alzheimer's Disease Model Rats’ Memory and Neuroplasticity Disorders
18. Herpes simplex virus and rates of cognitive decline or whole brain atrophy in the Dominantly Inherited Alzheimer Network
19. Immuno-digital invasive cleavage assay for analyzing Alzheimer’s amyloid ß-bound extracellular vesicles
20. Interaction between autophagy and the NLRP3 inflammasome in Alzheimer’s and Parkinson’s disease
21. Long-term depressive symptoms and midlife brain age
22. Neurodegenerative disease associated pathways in brain of the triple transgenic Alzheimer’s model are reversed in vivo following two weeks peripheral administration of fasudil
23. Nilotinib: from animal-based studies to clinical investigation in Alzheimer’s disease patients
24. Peripheral level of CD33 and Alzheimer’s disease: a bidirectional two-sample Mendelian randomization study
25. Progression Prediction and Classification of Alzheimer’s Disease using MRI
26. Spatial proteomics and iPSC modeling uncover mechanisms of axonal pathology in Alzheimer’s disease
27. Stacked binding of a small molecule PET tracer to Alzheimer’s tau paired helical filaments
28. Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cells (ADMSCs) with/without Taurine in Aluminum Chloride-Induced Alzheimer's Disease Rat Model
29. Therapeutic non-invasive brain treatments in Alzheimer’s disease: recent advances and challenges
30. Translation of Collaborative Dementia Care Management into Different Healthcare Settings: Study Protocol for a Multicenter Implementation Trial (DCM:IMPact)
31. Uma abordagem geral da demência: Doença de Alzheimer e Demência Vascular
32. Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease
33. VHHs as tools for therapeutic protein delivery to the central nervous system
34. p-Coumaric acid ameliorates cognitive and non-cognitive disturbances in a rat model of Alzheimer’s disease: The role of oxidative stress and inflammation
35. “Altered CD8⁺ T cell associated aging gene signature in the peripheral blood of patients with Alzheimer’s disease”

1. Alzheimer’s Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound
2. Multi-class classification of Alzheimer’s disease through distinct neuroimaging computational approaches using Florbetapir PET scans
3. Opening the box of PANTHORA in Alzheimer’s disease
4. Regional neuroanatomic effects on brain age inferred using magnetic resonance imaging and ridge regression
5. The Potential Neuroprotective Effects of Extracts from Oat Seedlings against Alzheimer’s Disease

1. Accuracy of the Brazilian version of the Prefrontal Symptoms Inventory (PSI-16) in the neuropsychological assessment of patients diagnosed with Alzheimer's disease
2. Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer’s Disease Patients in Japan: LIFE Study
3. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment
4. Brain Tissue-Derived Extracellular Vesicles in Alzheimer’s Disease Display Altered Key Protein Levels Including Cell Type-Specific Markers
5. Brain Tumour Lessons From Alzheimer’s Disease: Beta-Amyloid and SorLA Expression in Glioblastoma
6. Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old
7. Differential effects of high-altitude exposure on markers of oxidative stress, antioxidant capacity, and iron profiles
8. Exploring a Link Between Alzheimer’s and Glioma by Investigating SORL1 Network
9. Exploring the causal effects of genetic liability to ADHD and Autism on Alzheimer’s disease
10. Fractional order epidemiological model of SARS-CoV-2 dynamism involving Alzheimer’s disease
11. Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria
12. Increased Type I interferon signaling and brain endothelial barrier dysfunction in an experimental model of Alzheimer’s disease
13. Lemborexant add-on further improves the effect of galantamine on sleepwake disorder in Alzheimer’s disease
14. Nanoporous Membranes for the Filtration of Proteins from Biological Fluids: Biocompatibility Tests on Cell Cultures and Suggested Applications for the Treatment of Alzheimer’s Disease
15. Single Nucleus Transcriptome Data from Alzheimer’s Disease Mouse Models Yield New Insight into Pathophysiology
16. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition
17. The ATN Framework—Moving Preclinical Alzheimer Disease to Clinical Relevance
18. Unfairness to Patients With Alzheimer Disease in Medicare’s Coverage of Antiamyloid Immunotherapy

1. 136 Ambulatory Follow-up After Emergency Department Discharge and Association With Outcomes Among Older Adults With Alzheimer’s Disease and Related Dementia
2. 44. PROTEOME-WIDE MENDELIAN RANDOMIZATION IDENTIFIES CAUSAL LINKS BETWEEN BLOOD PROTEINS AND ALZHEIMER'S
3. A scalable Bayesian functional GWAS method accounting for multivariate quantitative functional annotations with applications for studying Alzheimer disease
4. A selective degeneration of cholinergic neurons mediated by NRADD in an Alzheimer's disease mouse model
5. A standardised methodology for the extraction and quantification of cell-free DNA in cerebrospinal fluid and application to evaluation of Alzheimer’s disease and brain cancers
6. A systematic review of the validity of non-invasive sleep-measuring devices in mid-to-late life adults: Future utility for Alzheimer's disease research
7. APOE4 homozygote females are resistant to the beneficial effects of 17β-estradiol on memory and CA1 dendritic spine density in the EFAD mouse model of Alzheimer's disease
8. Advances in Alzheimer's disease research over the past two decades
9. Altered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress
10. Alzheimer's disease failed clinical trials
11. Alzheimer's disease genes and proteins associated with resistance and aerobic training: An in silico analysis
12. Alzheimer's disease/dementia-associated brain pathology in aging DPP6-KO mice
13. Alzheimer's drug shows promise
14. Amylin Pharmacology in Alzheimer’s Disease Pathogenesis and Treatment
15. Amyloid-ß plaque formation and BACE1 accumulation in the brains of a 5xFAD Alzheimer's disease mouse model is associated with altered distribution and not proteolysis of BACE1 substrates Sez6 and Sez6L
16. An integrated genome and phenome-wide association study approach to understanding Alzheimer's disease predisposition
17. Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia
18. Anti-Alzheimer's disease active components screened out and identified from Hedyotis diffusa combining bioaffinity ultrafiltration LC-MS with acetylcholinesterase
19. Anti-Alzheimer's disease potential of traditional chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes
20. Anti-epileptogenic effects of synaptic vesicle protein 2A modulation in a mouse model of Alzheimer’s disease
21. Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid
22. Assessing the Cost-effectiveness of a Hypothetical Disease-Modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease
23. Astrocyte Progenitors Derived From Patients With Alzheimer Disease Do Not Impair Stroke Recovery in Mice
24. Astrocyte energy and neurotransmitter metabolism in Alzheimer’s disease: Integration of the glutamate/GABA-glutamine cycle
25. Aβ peptides stabilize GPCRs in inactive form and trigger inverse agonism in Alzheimer's disease
26. Beneficial effects of apigenin on the transgenic Drosophila model of Alzheimer's disease
27. Bidirectional communication between brain and visceral white adipose tissue: Its potential impact on Alzheimer's disease
28. Biosynthesis of zinc oxide nanoparticles using aqueous extract of Andrographis alata: characterization, optimization and assessment of their antibacterial, antioxidant, antidiabetic and anti-Alzheimer's properties
29. Calycosin ameliorates advanced glycation end product-induced neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease
30. Carbohydrate-derived bicyclic selenazolines as new dual inhibitors (cholinesterases/OGA) against Alzheimer’s disease
31. Clasping, ledge-score coordination and early gait impairments as primary behavioural markers of functional impairment in Alzheimer's disease
32. Conjugated linoleic acid downregulates Alzheimer's hallmarks in aluminum mouse model through an Nrf2-mediated adaptive response and increases brain glucose transporter levels
33. Current understanding of the interactions between metal ions and Apolipoprotein E in Alzheimer’s disease
34. DISTINCT GENOMICS OF PERSEVERATIVE NEGATIVE THINKING IN MEN AND WOMEN: SPECIFIC ROLES OF IMMUNE PROCESSES, ION CHANNELS AND ALZHEIMER'S GENES
35. Decabromodiphenyl ethane induces locomotion neurotoxicity and potential Alzheimer’s disease risks through intensifying amyloid-beta deposition by inhibiting transthyretin/transthyretin-like proteins
36. Decreases of ethanolamine plasmalogen and phosphatidylcholine in erythrocyte are a common phenomenon in Alzheimer’s, Parkinson’s, and coronary artery diseases
37. Deep active learning for suggestive segmentation of biomedical image stacks via optimisation of Dice scores and traced boundary length
38. Design, Synthesis and Biological Evaluation of Pyranocarbazole Derivatives against Alzheimer’s Disease, with Antioxidant, Neuroprotective and Cognition Enhancing Properties
39. Design, synthesis, biological activity evaluation and in silico studies of new nicotinohydrazide derivatives as multi-targeted inhibitors for Alzheimer's disease
40. Development of a potential PET probe for HDAC6 imaging in Alzheimer's disease
41. Development of high quality T1-weighted and diffusion tensor templates of the older adult brain in a common space
42. Discovery of carbamate-based N-salicyloyl tryptamine derivatives as novel pleiotropic agents for the treatment of Alzheimer's disease
43. Dityrosine Cross-links are Present in Alzheimer’s Disease-derived Tau Oligomers and Paired Helical Filaments (PHF) which Promotes the Stability of the PHF-core Tau (297–391) In Vitro
44. Does culture shape our understanding of others’ thoughts and emotions? An investigation across 12 countries.
45. EFFECT OF A NOVEL TREATMENT OF OSA WITH COMPLIANCE AND COGNITIVE FUNCTION IN PATIENTS WITH COMORBID ALZHEIMER DISEASE: A CASE REPORT
46. Early alterations in brain glucose metabolism and vascular function in a transgenic rat model of Alzheimer’s disease
47. Elevated levels of tripeptidyl peptidase 1 do not ameliorate pathogenesis in a mouse model of Alzheimer disease
48. Embodied cognition and emotion, two variables improving memory abilities in Parkinson’s and Alzheimer’s diseases.
49. Erste Resultate aktueller Studien: neue Therapien gegen Alzheimer
50. Estrés oxidativo, respuesta inmune, plasticidad sináptica y cognición en modelos transgénicos de la enfermedad de Alzheimer
51. Expert appraisal and prioritization of barriers to mHealth use for older adults living with Alzheimer's disease and related Dementias: A Delphi study
52. GENETIC OVERLAP BETWEEN ALZHEIMER'S DISEASE AND PSYCHIATRIC DISORDERS: SPECIFYING THE SHARED GENETIC DETERMINANTS AND CAUSALITY BETWEEN ALZHEIMER'S DISEASE, MAJOR DEPRESSIVE DISORDER, BIPOLAR DISORDER, AND SCHIZOPHRENIA
53. Gelatin/polyvinyl alcohol loaded magnesium hydroxide nanocomposite attenuates neurotoxicity and oxidative stress in Alzheimer's disease induced rats
54. Generation of human induced pluripotent stem cell lines SPPHIi003-A and SPPHIi004-A from two patients with sporadic Alzheimer’s disease in Southwestern China
55. Glia-neuron interplay drives circadian glycosphingolipid homeostasis and structural brain plasticity
56. Glucose enrichment impair neurotransmission and induce Aβ oligomerization that cannot be reversed by manipulating O-β-GlcNAcylation in the C. elegans model of Alzheimer's disease
57. Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A Review
58. Hippocampal neural circuit connectivity alterations in an Alzheimer's disease mouse model revealed by monosynaptic rabies virus tracing
59. INVESTIGATING THE GENETIC OVERLAP BETWEEN DIFFERENT DEPRESSION SYMPTOMS AND ALZHEIMER'S DISEASE: FROM GENETIC CORRELATION TO COLOCALIZATION
60. In vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer's disease
61. Increased KIF11/Kinesin-5 expression offsets Alzheimer Aβ-mediated toxicity and cognitive dysfunction
62. Increased occurrence of Treponema spp. and double-species infections in patients with Alzheimer's disease
63. Increased regional white matter hyperintensity volume in objectively-defined subtle cognitive decline and mild cognitive impairment
64. Inferring Effective Connectivity Networks From fMRI Time Series With a Temporal Entropy-Score
65. Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease
66. Insights for Alzheimer's disease pharmacotherapy and current clinical trials
67. Interferon beta attenuates recognition memory impairment and improves brain glucose uptake in a rat model of Alzheimer's disease: Involvement of mitochondrial biogenesis and PI3K pathway
68. Interpreting acoustic features for the assessment of Alzheimer’s disease using ForestNet
69. Involvement of astrocyte senescence in Alzheimer's disease
70. Isolation and characterization of neurotoxic astrocytes derived from adult triple transgenic Alzheimer's disease mice
71. Light-controlled fluorescent probes for precisely monitoring brain amyloid-β aggregates in Alzheimer's disease
72. Longitudinal trajectories and normative language standards in older adults with normal cognitive status.
73. Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules
74. Nao Tan Qing ameliorates Alzheimer's disease-like pathology by regulating glycolipid metabolism and neuroinflammation: a network pharmacology analysis and biological validation
75. Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: Potential significance in Alzheimer's disease pathology
76. Neuer Test für Alzheimer-Früherkennung
77. Neuropathologic Changes Provide Insights into Key Mechanisms of Alzheimer Disease and Related Dementia
78. Neuroprotective Potential of Curcuminoids in Modulating Alzheimer’s Disease via Multiple Signaling Pathways
79. Neuropsychological profiles and neural correlates in typical and atypical variants of Alzheimer disease: A systematic review
80. New oxadiazole bearing thiosemicarbazide analogues: Synthesis, anti-alzheimer inhibitory potential and their molecular docking study
81. Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer's agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies
82. O003 / #714 COGNITIVE RESTORATION IN ALZHEIMER’S PATIENTS BY LOCAL INTRACEREBRAL CELL-MEDIATED NERVE GROWTH FACTOR DELIVERY: CLINICAL EFFICACY AND FURTHER METHOD OPTIMIZATION
83. Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound
84. Oxidative stress, the immune response, synaptic plasticity, and cognition in transgenic models of Alzheimer disease
85. PC016 / #697 PERTURBATION-BASED TACS-EEG BIOMARKERS OF GAMMA ACTIVITY IN ALZHEIMER’S DISEASE
86. PO010 / #932 NOVELTY-RELATED LOCUS COERULEUS ACTIVATION RESCUES COGNITIVE DECLINE IN A PRETANGLE TAU ALZHEIMER’S DISEASE RAT MODEL
87. PO109 / #748 THE EFFECT OF TRANSCRANIAL DIRECT CURRENT STIMULATION IN ALZHEIMER’S DISEASE PATIENTS: A SYSTEMATIC REVIEW
88. Pharmacological targeting of microglia dynamics in Alzheimer’s disease: Preclinical and clinical evidence
89. Pivotal role of nitrogen heterocycles in Alzheimer’s disease drug discovery
90. Plasma Exchange in Alzheimer's Disease
91. Proteomic analysis for the effects of non-saponin fraction with rich polysaccharide from Korean red ginseng on Alzheimer's disease in a mouse model
92. RNA-binding protein ELAVL4/HuD ameliorates Alzheimer's disease-related molecular changes in human iPSC-derived neurons
93. Rational drug design strategies for the development of promising multi-target directed indole hybrids as Anti-Alzheimer agents
94. Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease
95. Redefining oxidative stress in Alzheimer's disease: Targeting platelet reactive oxygen species for novel therapeutic options
96. Relations of neuropsychiatric symptoms with disease stage, sex, and daily function in mild cognitive impairment and dementia due to Alzheimer's disease: A cross-sectional study
97. Relationships between diabetes-related vascular risk factors and neurodegeneration biomarkers in healthy aging and Alzheimer's disease
98. Reply – Letter to the editor “Comment on “Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism Clinical nutrition 2022”
99. Retinal organoids from human-induced pluripotent stem cells: From studying retinal dystrophies to early diagnosis of Alzheimer’s and Parkinson’s disease
100. Retraction Notice to “MicroRNA-16-5p/BTG2 axis affects neurological function, autophagy and apoptosis of hippocampal neurons in Alzheimer's disease” [Brain Res. Bull. 175 (2021) 254–62]
101. Rural and urban disparities in potentially preventable hospitalizations among US patients with Alzheimer's Disease and Related Dementias: Evidence of hospital-based telehealth and enabling services
102. Social engagement and its links to cognition differ across non-Hispanic Black and White older adults.
103. Synthesis and biological evaluation of 4-hydroxy-methylpiperidinyl-N-benzyl-acylarylhydrazone hybrids designed as novel multifunctional drug candidates for Alzheimer’s disease
104. T17. IDENTIFYING INDIVIDUALS WITH HIGH RISK FOR ALZHEIMER'S DISEASE BASED ON TRANSCRIPTOMIC RISK SCORES IN BLOOD AND BRAIN
105. T31. A MULTI-TRAIT ASSOCIATION ANALYSIS OF PLATELET TRAITS AND BRAIN DISORDERS IDENTIFIES NOVEL SUSCEPTIBILITY LOCI FOR MAJOR DEPRESSION, ALZHEIMER AND PARKINSON DISEASE
106. T82. RARE VARIANT AGGREGATION IN 148,508 EXOMES IDENTIFIES GENES ASSOCIATED WITH PROXY ALZHEIMER'S DISEASE/DEMENTIA
107. TFEB in Alzheimer's disease: From molecular mechanisms to therapeutic implications
108. TREML2 IN THE CONTEXT OF WHITE MATTER HYPERINTENSITIES AND ALZHEIMER'S DISEASE
109. Tanshinone IIA loaded chitosan nanoparticles decrease toxicity of β-amyloid peptide in a Caenorhabditis elegans model of Alzheimer's disease
110. Tenuigenin ameliorates cognitive dysfunction in Alzheimer’s disease via hippocampal neurogenesis enhancement
111. The AT(N) system for describing biological changes in Alzheimer's disease: a plain language summary
112. The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer’s Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials
113. The gut microbiome and Alzheimer’s disease: Complex and bidirectional interactions
114. The novel estrogen modulator STX attenuates Amyloid-β neurotoxicity in the 5XFAD mouse model of Alzheimer's disease
115. The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary
116. Therapeutic Potential of Ferulic Acid in Alzheimer's Disease
117. Top-down and bottom-up sources of eye-movement guidance during realistic scene search in Alzheimer’s disease.
118. Towards development of disease-modifying therapy for Alzheimer's disease using redox chemical biology pathways
119. Transcriptomic and epigenomic landscapes of Alzheimer's disease evidence mitochondrial-related pathways
120. Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer's disease therapy
121. Treatment effects of Radix ginseng-Schisandra chinensis herb pair on Alzheimer’s disease: An investigation of MS-based metabolomics investigation
122. Update on new trend and progress of the mechanism of polysaccharides in the intervention of Alzheimer's disease, based on the new understanding of relevant theories: A review
123. miRNA-Based Signature to Predict the Development of Alzheimer’s Disease
124. β-Amyloid promotes platelet activation and activated platelets act as bridge between risk factors and Alzheimer’s disease
125. γ-Secretase as a drug target for familial Alzheimer's disease: the road less traveled
126. “The Community That Takes Care of Itself”

1. A DATA-DRIVEN EXAMINATION OF APATHY AND DEPRESSIVE SYMPTOMS IN DEMENTIA WITH INDEPENDENT REPLICATION
2. A Description of Persons With Alzheimer Disease and Related Dementias Receiving Home Health Care
3. A Pathophysiological Intersection of Diabetes and Alzheimer’s Disease
4. A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease
5. A flexible modeling approach for biomarker‐based computation of absolute risk of Alzheimer's disease dementia
6. A global view of aging and Alzheimer’s pathogenesis-associated cell population dynamics and molecular signatures in the human and mouse brains
7. ALZHEIMER'S DISEASE PREDICTION USING ENHANCED U-NET ARCHITECTURE
8. Accurate Bayesian segmentation of thalamic nuclei using diffusion MRI and an improved histological atlas
9. Alterations of resting-state Gamma frequency characteristics in aging and Alzheimer’s disease
10. Alzheimer, vieillesse et renaissance dans le roman Small World de Martin Suter
11. Alzheimer’s disease related single nucleotide polymorphisms and correlation with intracerebral hemorrhage incidence
12. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time
13. Bacopa monnieri protects neuronal cell line and Caenorhabditis elegans models of Alzheimer’s disease through sigma-1 receptor antagonist sensitive and antioxidant pathways
14. Biological Activity of Some Thiazolyl‐thiadiazines as BACE‐1 Inhibitors for Alzheimer’s Disease in the Light of DFT based Quantum Descriptors
15. Biomarkers in Alzheimer Disease and Other Dementias: What’s Next into Pathophysiology to Support Clinical Practice and Drug Development
16. Characteristics Scanning of Brain Structure and Function Changes in Patients with Different Degrees of Alzheimer’s Disease
17. Clinical efficacy of acupuncture combined with Western medicine in the treatment of mild to moderate Alzheimer disease: A protocol of a randomized controlled trial
18. Combination of Astrogliosis and Phosphorylated Tau for the Preclinical Diagnosis of Alzheimer Disease Using 3-Dimensional Stereotactic Surface Projection Images With 18F-THK5351
19. Communicating and Using Dementia Risk Evidence
20. Comparative Metagenomics and Metabolomes Reveals Abnormal Metabolism Activity Is Associated with Gut Microbiota in Alzheimer’s Disease Mice
21. Correlation between Ratios of Word-finding Behavior and CIU in Patients with Mild Cognitive Impairment and Dementia of Alzheimer’s Type
22. Design, Synthesis and Biological Evaluation of Biscarbamates as Potential Selective Butyrylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disese
23. Development of a deep learning network for Alzheimer’s disease classification with evaluation of imaging modality and longitudinal data
24. Dramatic impacts on brain pathology, anxiety, and cognitive function in the knock-in APPNL-G-F mouse model of Alzheimer disease following long-term voluntary exercise
25. Evaluation of cannabinoid type 2 receptor expression and pyridine-based radiotracers in brains from a mouse model of Alzheimer’s disease
26. Evaluation of the mechanism of action of rosemary volatile oil in the treatment of Alzheimer's disease using gas chromatography-mass spectrometry analysis and network pharmacology
27. Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease
28. First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor
29. Fuzzy Logic-Based Disease Classification Using Similarity-Based Approach with Application to Alzheimer’s
30. Gene dosage determines the behavioural phenotype in the 5xFAD mouse model of Alzheimer’s disease: analysis of the contribution of brain insulin signalling and gut microbiota
31. Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics
32. HSPA1A, HSPA2, and HSPA8 Are Potential Molecular Biomarkers for Prognosis among HSP70 Family in Alzheimer’s Disease
33. Heightened emotion processing as a compensatory mechanism in persons with Alzheimer's disease: Psychological insights from the tri-network model
34. Identification of network-based differential gene expression signatures and their transcriptional factors to develop progressive blood biomarkers for Alzheimer’s disease 
35. Imaging markers of cerebral amyloid angiopathy and hypertensive arteriopathy differentiate Alzheimer disease subtypes synergistically
36. Impact of Older Age Adiposity on Incident Diabetes: A Community-Based Cohort Study in China
37. Implications of Microorganisms in Alzheimer’s Disease
38. Intravesical BCG and Incidence of Alzheimer Disease in Patients With Bladder Cancer
39. Late-life onset psychotic symptoms and incident cognitive impairment in people without dementia: modification by genetic risk for Alzheimer’s disease
40. Loss of swallow tail sign on susceptibility-weighted imaging in neurosyphilis mimicking Alzheimer’s disease: a case report
41. Machine learning and deep learning models for early-stage detection of Alzheimer's disease and its proliferation in human brain
42. Marked Cognitive and Activities of Daily Living Improvement by Shunt Embolization in a Very Old Man with Portosystemic Encephalopathy Mimicking Alzheimer Disease: A Case Report
43. Memory markers in the continuum of the Alzheimer’s clinical syndrome
44. Mining on Alzheimer’s diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing
45. Multiple gene variants linked to Alzheimer's-type clinical dementia via GWAS are also associated with non-Alzheimer's neuropathologic entities
46. Neural correlates of delusion in Alzheimer's disease and Mild Cognitive Impairment
47. Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease
48. Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner
49. Photobiomodulation for Hypertension and Alzheimer’s Disease
50. Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care
51. Prediction of Alzheimer’s Disease Using Patterns of Methylation Levels in Key Immunologic-Related Genes
52. Research status, hotspots and trends of acupuncture and moxibustion in the treatment of Alzheimer’s disease: A bibliometric analysis
53. Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study
54. UCLan academics make stronger connections between gum disease and Alzheimer's disease
55. [18F]NOS PET Brain Imaging Suggests Elevated Neuroinflammation in Idiopathic Parkinson’s Disease

1. A multimodal intervention for Alzheimer's disease results in multifaceted systemic effects reflected in blood and ameliorates functional and cognitive outcomes
2. Alzheimer’s Disease as a Disease of Evolutionary Mismatch, with a Focus on Reproductive Life History
3. Alzheimer’s drug slows mental decline in trial — but is it a breakthrough?
4. Association of autoimmune diseases with Alzheimer's disease: A mendelian randomization study
5. Clinical impact of microbleeds in patients with Alzheimer’s disease
6. Deep multiview learning to identify imaging-driven subtypes in mild cognitive impairment
7. Detection of dementia progression from functional activities data using machine learning techniques
8. Differences in treatment for Alzheimer's disease between urban and rural areas in China
9. Effect of Vildagliptin on Cognitive Deficits in an Experimental Model of Alzheimer’s Disease
10. Experimental Alzheimer’s treatment nails Phase 3 clinical trials
11. Faculty Opinions recommendation of Warburg-like metabolic transformation underlies neuronal degeneration in sporadic Alzheimer's disease.
12. Five big questions about the new Alzheimer’s treatment
13. Identification of hsa-miR-365b-5p’s role in Alzheimer’s disease: A combined analysis of miRNA and mRNA microarrays
14. Investigating a Genetic Link Between Alzheimer’s Disease and CADASIL-Related Cerebral Small Vessel Disease
15. Mechanisms of Influence of Intestinal Microbiota on the Processes of Aging of the CNS and the Formation of Cognitive Disorders in Alzheimer’s Disease
16. Medium-chain Fatty Acids for the Prevention or Treatment of Alzheimer’s Disease: A Systematic Review and Meta-analysis
17. Periodontitis-related salivary microbiota aggravates Alzheimer’s disease via gut-brain axis crosstalk
18. Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
19. Study on Nano Drug Particles in the Diagnosis and Treatment of Alzheimer’s Disease in the Elderly
20. Temporal Pattern of Neuroinflammation Associated with a Low Glycemic Index Diet in the 5xFAD Mouse Model of Alzheimer’s Disease
21. The Aqueous Extract of Humulus japonicus Ameliorates Cognitive Dysfunction in Alzheimer's Disease Models via Modulating the Cholinergic System
22. The Dilemma of the Clinical Utility of Alzheimer Biomarker Evaluation in Everyday Clinical Practice: My Favorite PETs
23. The Therapeutic Effects of Seven Lycophyte Compounds on Cell Models of Alzheimer’s Disease
24. Three Class Classification Of Alzheimer’s Disease Using Deep NEURAL Networks
25. Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer’s Disease

1. A breakthrough in Alzheimer’s Disease
2. Acupuncture Interventions for Alzheimer’s Disease and Vascular Cognitive Disorders: A Review of Mechanisms
3. Alzheimer's disease diagnosis by blood plasma molecular fluorescence spectroscopy (EEM)
4. Anti-Alzheimer and Antioxidant Effects of Nelumbo nucifera L. Alkaloids, Nuciferine and Norcoclaurine in Alloxan-Induced Diabetic Albino Rats
5. Application of multiple testing procedures for identifying relevant comorbidities, from a large set, in traumatic brain injury for research applications utilizing big health-administrative data
6. Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites
7. Corrigendum to “Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease” [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82]
8. Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice
9. Discovery of novel β-carboline-1,2,3-triazole hybrids as AChE/GSK-3β dual inhibitors for Alzheimer's disease treatment
10. Economic evaluation of the screening for Alzheimer’s disease in China
11. Effects of Reminiscence Therapy on Cognition, Depression and Quality of Life in Elderly People with Alzheimer’s Disease: A Systematic Review of Randomized Controlled Trials
12. Eficacia del programa gradior para la estimulación cognitiva de personas con alzheimer (Effectiveness of Gradior software and cognitive stimulation in people with alzheimer’s disease)
13. Gamma Frequency Inhibits the Secretion and Aggregation of Amyloid-β and Decreases the Phosphorylation of mTOR and Tau Proteins in vitro
14. Highly Sensitive and Specific Amyloid-β Oligomers Detection Using CRISPR-Cas12a Probe System aided by Graphene Oxide for Early Diagnosis of Alzheimer’s Diseases
15. Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer’s disease
16. Is non-invasive brain stimulation effective for cognitive enhancement in Alzheimer’s disease? An updated meta-analysis
17. Landscape of immune infiltration in entorhinal cortex of patients with Alzheimerʼs disease
18. Machine learning models identify ferroptosis-related genes as potential diagnostic biomarkers for Alzheimer’s disease
19. MicroRNAs as a new target for Alzheimer's disease treatment
20. Modelling Cognitive Scores for Alzheimer’s Disease Progression Prediction Using Longitudinal MRI Data
21. Multi-modal sequence learning for Alzheimer’s disease progression prediction with incomplete variable-length longitudinal data
22. Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer's disease neuropathological changes
23. Neuroprotective Effect of Artichoke-Based Nanoformulation in Sporadic Alzheimer’s Disease Mouse Model: Focus on Antioxidant, Anti-Inflammatory, and Amyloidogenic Pathways
24. Phyto-therapeutic and nanomedicinal approaches: A new hope for management of Alzheimer’s disease
25. Recent progress in the graphene-based biosensing approaches for the detection of Alzheimer's biomarkers
26. Tau Paired Helical Filament from Alzheimer's Disease incubated 1 hr. with EGCG
27. Tau Paired Helical Filament from Alzheimer's Disease incubated with EGCG for 3 hours
28. Tau Paired Helical Filament from Alzheimer's Disease not incubated with EGCG
29. The Impact of Race–Ethnicity and Diagnosis of Alzheimer’s Disease and Related Dementias on Mammography Use
30. The Innate and Adaptive Immune Cells in Alzheimer’s and Parkinson’s Diseases
31. The three-dimensional landscape of cortical chromatin accessibility in Alzheimer’s disease
32. Therapeutic approaches of nutraceuticals in the prevention of Alzheimer's disease
33. Vascular-water-exchange MRI (VEXI) enables the detection of subtle BBB breakdown in Alzheimer’s disease without MRI contrast agent
34. Virtual histology of Alzheimer’s Disease: why are amyloid-β plaques visible with X-ray phase-contrast imaging?

1. 1 A WINDOW TO ACT? Revisiting the Conceptual Foundations of Alzheimer’s Disease in Dementia Prevention
2. 2 THE VASCULARIZATION OF ALZHEIMER’S DISEASE Prevention in “Glocal” Geriatric Care
3. 3 IF DEMENTIA PREVENTION IS THE ANSWER, WHAT WAS THE QUESTION? Observations from the German Alzheimer’s Disease Debate
4. Single‐cell analysis reveals transcriptomic reprogramming in aging primate entorhinal cortex and the relevance with Alzheimer's disease
5. A Mini-Mental State Examination Formula May Help to Distinguish Alzheimer’s Disease from Dementia with Lewy Bodies
6. A Mitochondrial DNA Haplogroup Defines Patterns of Five-Year Cognitive Change
7. Alzheimer's disease as an innate autoimmune disease (AD ² ): A new molecular paradigm
8. Amyloid and Tau Pathology are Associated with Cerebral Blood Flow in Nondemented Older Adults with and without Vascular Risk Factors for Alzheimer’s Disease
9. An in-silico approach to studying a very rare neurodegenerative disease using a disease with higher prevalence with shared pathways and genes: Cerebral adrenoleukodystrophy and Alzheimer’s disease
10. Association of Peak Expiratory Flow with Cognitive Function in the Chinese Middle-Aged and Elderly Population: A 7-Year Longitudinal Study
11. Associations Between Intrathecal Levels of Vitamin D, Cytokines, and Core Biomarkers of Alzheimer’s Disease: A Cross-Sectional Study
12. Associations Between Sub-Threshold Amyloid-β Deposition, Cortical Volume, and Cognitive Function Modulated by APOE ɛ4 Carrier Status in Cognitively Normal Older Adults
13. Attention, Praxis, and Reasoning Are Associated with Risk of Undernutrition in Older People with Cognitive Impairment
14. Blood Pressure and Later-Life Cognition in Hispanic and White Adults (BP-COG): A Pooled Cohort Analysis of ARIC, CARDIA, CHS, FOS, MESA, and NOMAS
15. Building in vitro models of the brain to understand the role of APOE in Alzheimer’s disease
16. Cognitive Reserve Modulates Brain Structure and Cortical Architecture in the Alzheimer’s Disease
17. Combination of Serum and Plasma Biomarkers Could Improve Prediction Performance for Alzheimer’s Disease
18. Comorbidity‐driven multi‐modal subtype analysis in mild cognitive impairment of Alzheimer's disease
19. Consumer Assessment of Healthcare Providers and Systems Among Racial and Ethnic Minority Patients With Alzheimer Disease and Related Dementias
20. Creating connections: developing an online space for cross-regional mentorship and network building in the dementia research field
21. Current naturopathy to combat Alzheimer’s disease
22. DTI Connectometry Analysis Reveals White Matter Changes in Cognitively Impaired World Trade Center Responders at Midlife
23. Dementia Risk Reduction in Primary Care: A Scoping Review of Clinical Guidelines Using a Behavioral Specificity Framework
24. Diagnostic Accuracy of the Swedish Version of the Rowland Universal Dementia Assessment Scale (RUDAS-S) for Multicultural Cognitive Screening in Swedish Memory Clinics
25. Discriminating Aging Cognitive Decline Spectrum Using PET and Magnetic Resonance Image Features
26. Does Sex Matter? High Semantic Autobiographical Retrieval in Women and Men With Alzheimer’s Disease
27. Early detection of Alzheimer’s disease using neuropsychological tests: a predict–diagnose approach using neural networks
28. Effect of co-treatment with mesenchymal stem cells and polyvinyl alcohol- coated selenium nanoparticles on rats with streptozotocin-induced Alzheimer's disease
29. Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer’s disease mouse model
30. Exercise as a Potential Therapeutic Strategy to Target the Clinical Link Between Depression and Alzheimer’s Disease: A Narrative Review
31. Factors Influencing Long-Term Physical Activity Maintenance: A Qualitative Evaluation of a Physical Activity Program for Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Follow-Up Study
32. Frequency, Severity, and Duration of Autonomic Symptoms in Patients of Prodromal Dementia with Lewy Bodies
33. Genetic Spectrum and Clinical Heterogeneity of Chinese Frontotemporal Dementia Patients: Data from PUMCH Dementia Cohort
34. Genetic correlations between gut microbiota genera and Alzheimer’s Disease
35. Identification of Major Cognitive Disorders in Self-Reported versus Administrative Health Data: A Cohort Study in Quebec
36. Image-based cross-calibration method for multiple spectrometer-based OCT
37. Impact of cellular prion protein expression on disease progression and pathology in two mouse models of Alzheimer’s disease
38. In Memorium
39. Machine Learning Approach Predicts Probability of Time to Stage-Specific Conversion of Alzheimer’s Disease
40. Met and Unmet Needs of Older Adults With Cognitive Impairment, and Burden and Benefits of Their Family Caregivers
41. MicroRNA-650 regulates the pathogenesis of Alzheimer’s Disease through targeting Cyclin-Dependent Kinase 5
42. Nationally Informed Recommendations on Approaching the Detection, Assessment, and Management of Mild Cognitive Impairment
43. Non-Pharmacologic Interventions for Hispanic Caregivers of Persons with Dementia: Systematic Review and Meta-Analysis
44. Pharmaceutical Potential of Casein-Derived Tripeptide Met-Lys-Pro: Improvement in Cognitive Impairments and Suppression of Inflammation in APP/PS1 Mice
45. Polymorphisms of nicotinic acetylcholine receptors in Alzheimer’s disease: a systematic review and data analysis
46. Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
47. Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
48. Prevalence of Dementia and Main Subtypes in Mexico: The Study on Aging and Dementia in Mexico (SADEM)
49. Quantitative MRI Evidence for Cognitive Reserve in Healthy Elders and Prodromal Alzheimer’s Disease
50. Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging
51. Scutellarin Modulates the Microbiota-Gut-Brain Axis and Improves Cognitive Impairment in APP/PS1 Mice
52. Selecting Multitarget Peptides for Alzheimer’s Disease
53. Sex, Neuropsychiatric Profiles, and Caregiver Burden in Alzheimer’s Disease Dementia: A Latent Class Analysis
54. Sleep disturbances in Lewy body dementia: A systematic review
55. The Association of Serum Uric Acid Level, Gout, and Alzheimer’s Disease: A Bidirectional Mendelian Randomization Study
56. The Dementia Assessment of Service Needs (DEMAND): Development and Validation of a Standardized Needs Assessment Instrument
57. The Role of Amyloid-β, Tau, and α-Synuclein Proteins as Putative Blood Biomarkers in Patients with Cerebral Amyloid Angiopathy
58. The genetic overlap between Alzheimer’s disease, amyotrophic lateral sclerosis, Lewy body dementia, and Parkinson’s disease
59. The role of upstream lipid and metabolic systems in Alzheimer’s disease, Parkinson’s disease and dementias
60. Thyroid hormone levels in Alzheimer disease: a systematic review and meta-analysis
61. Timapiprant, a prostaglandin D2 receptor antagonist, ameliorates pathology in a rat Alzheimer’s model
62. Time of Day Effects on Inhibitory Functioning: Cognitive and Neural Evidence of Sundowning in Amnestic Mild Cognitive Impairment
63. Ultrastructural characterization of dark microglia during aging in a mouse model of Alzheimer’s disease pathology and in human post-mortem brain samples
64. Urokinase-Type Plasminogen Activator Triggers Wingless/Int1-Independent Phosphorylation of the Low-Density Lipoprotein Receptor-Related Protein-6 in Cerebral Cortical Neurons
65. Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease
66. Weakly activated core neuroinflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer’s disease
67. “It made me feel like I wasn’t alone in the darkness”: exploring dementia care network communication and coordination through a digital health platform

1. A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance
2. A guide for researchers seeking training in retrospective data harmonization for population neuroscience studies of Alzheimer's disease and related dementias
3. Astrocyte, Lipid Metabolism in Alzheimer’s Disease and Glioblastoma
4. Development of framework by combining CNN with KNN to detect Alzheimer’s disease using MRI images
5. Engaging caregivers to use an evidence-based intervention for medicaid beneficiaries with Alzheimer’s disease: a pilot study
6. Epigenetic aging and perceived psychological stress in old age
7. Extracellular vesicles in the study of Alzheimer’s and Parkinson’s diseases: methodologies applied from cells to biofluids
8. G protein–biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer’s disease mouse model
9. Genetic, Social, and Lifestyle Drivers of Healthy Aging and Longevity
10. How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?
11. Ischemia as a common trigger for Alzheimer’s disease
12. Neuropsychological, Metabolic, and Connectivity Underpinnings of Semantic Interference Deficits Using the LASSI-L
13. Nucleosome disruption by 5‐bromodeoxyuridine leads to senescence
14. Oxidative Stress Kinase Activation and Impaired Insulin Receptor Signaling Precede Overt Alzheimer’s Disease Neuropathology
15. Populations of Tau Conformers Drive Prion-like Strain Effects in Alzheimer’s Disease and Related Dementias
16. Potential of fluorescent nanoprobe in diagnosis and treatment of Alzheimer's disease
17. Purification, crystallization and crystallographic analysis of the PorX response regulator associated with the type IX secretion system
18. Recent developments in the design and synthesis of benzylpyridinium salts: Mimicking donepezil hydrochloride in the treatment of Alzheimer’s disease
19. Small-molecule ketone esters treat brain network abnormalities in an Alzheimer’s disease mouse model
20. Special issue on blood biomarkers in neurology
21. Study on Multi-target Synergistic Treatment of Alzheimer’s Disease Based on Metal Chelators
22. Sulfanegen stimulates 3-mercaptopyruvate sulfurtransferase activity and ameliorates Alzheimer's disease pathology and oxidative stress in vivo
23. The Differential Effect of Schooling and Physical Activity on Dementia in Older Women and Men from Brazil: Implications for Policymaking
24. The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease
25. Zinc Chloride-Catalyzed Synthesis of Carbamates: An Application for the Synthesis of the Anti-Alzheimer’s Drug Rivastigmine

1. Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimer ʼs dementias
2. Exploration of cortical ß-Amyloid load in Alzheimer’s disease using quantitative susceptibility mapping at 9.4T
3. Global cognitive effects of second-generation antidepressants in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials
4. Medicinal Herbs and Their Derived Ingredients Protect against Cognitive Decline in In Vivo Models of Alzheimer’s Disease

1. A Combined Cell-Worm Approach to Search for Compounds Counteracting the Toxicity of Tau Oligomers In Vivo
2. A influência de fatores sociodemográficos na qualidade do sono do cuidador familiar de idosos com Doença de Parkinson e/ou Doença de Alzheimer no estado do Amapá
3. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases
4. Amyloid‐related imaging abnormalities in the DIAN‐TU ‐001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease
5. Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players
6. Associations of grip strength, walking pace, and the risk of incident dementia: A prospective cohort study of 340212 participants
7. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
8. DNA methylation signatures of Alzheimer’s disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types
9. Disrupted Maturation of Prefrontal Layer 5 Neuronal Circuits in an Alzheimer’s Mouse Model of Amyloid Deposition
10. Efficacy difference of antipsychotics in Alzheimer’s disease and schizophrenia: explained with network efficiency and pathway analysis methods
11. Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
12. Interaction Mechanism Between the HSV-1 Glycoprotein B and the Antimicrobial Peptide Amyloid-β
13. Lead-exposure associated miRNAs in humans and Alzheimer’s disease as potential biomarkers of the disease and disease processes
14. Prevalence of Comorbid Dementia in Late-life Depression and Bipolar Disorder: A Retrospective Inpatient Study
15. Pyridine derivatives as anti-Alzheimer agents
16. Pyridines in Alzheimer's disease therapy: Recent trends and advancements
17. Recent developments in the synthesis of pyridine analogues as a potent anti-Alzheimer's therapeutic leads
18. Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study
19. Spoken Word Recognition in Listeners with Mild Dementia Symptoms
20. Stable CSF neurogranin and BACE1 levels differentiate predementia Alzheimer’s disease patients
21. Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review
22. Synthetic strategies of functionalized pyridines and their therapeutic potential as multifunctional anti-Alzheimer's agents
23. TDP-43 CSF Concentrations Increase Exponentially with Age in Metropolitan Mexico City Young Urbanites Highly Exposed to PM2.5 and Ultrafine Particles and Historically Showing Alzheimer and Parkinson’s Hallmarks. Brain TDP-43 Pathology in MMC Residents Is Associated with High Cisternal CSF TDP-43 Concentrations
24. Use of handgrip strength measurement as an alternative for assessing chewing function in people with dementia

1. A Haptoglobin (HP) Structural Variant Alters the Effect of APOE Alleles on Alzheimer’s Disease
2. AdipoRon induces AMPK activation and ameliorates Alzheimer's like pathologies and associated cognitive impairment in APP/PS1 mice
3. Altered Gut Microbiota and Its Clinical Relevance in Mild Cognitive Impairment and Alzheimer’s Disease: Shanghai Aging Study and Shanghai Memory Study
4. Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
5. Association of liver fibrosis with cognitive test performance and brain imaging parameters in the UK Biobank study
6. BACE1 Aptamer-Modified Tetrahedral Framework Nucleic Acid to Treat Alzheimer’s Disease in an APP-PS1 Animal Model
7. Cerebral arteriolar and neurovascular dysfunction after chemically-induced menopause in mice
8. Clinical performance and robustness evaluation of plasma amyloid‐β _42/40 prescreening
9. Clusterin transduces Alzheimer-risk signals to amyloidogenesis
10. Complement dysregulation and Alzheimer's disease in Down syndrome
11. Consistency analysis and conversion model establishment of mini-mental state examination and montreal cognitive assessment in Chinese patients with Alzheimer’s disease
12. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity
13. Deep Learning Techniques for the Effective Prediction of Alzheimer’s Disease: A Comprehensive Review
14. Derin Evrişimli Sinir Ağlarını Kullanarak MRG Modalitesinde Alzheimer Hastalığının Sınıflandırılması ve Segmentasyonu
15. Development of new Alzheimer's disease drug candidates using donepezil as a key model
16. Differential WMH progression trajectories in progressive and stable mild cognitive impairment
17. Editorial: Advances in drug discovery for anti-Alzheimer’s agents
18. Effects of Familial Alzheimer’s Disease Mutations on the Folding Free Energy and Dipole–Dipole Interactions of the Amyloid β-Peptide
19. Effects of apolipoprotein E4 genotype on cerebro-cerebellar connectivity, brain atrophy, and cognition in patients with Alzheimer's disease
20. Free-standing vertically aligned tin disulfide nanosheets for ultrasensitive aptasensor design toward Alzheimer’s diagnosis applications
21. Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer's Coordinating Center (2006–2019)
22. Leveraging mHealth and Virtual Reality to Improve Cognition for Alzheimer’s Patients: A Systematic Review
23. Multi-modal Vision-and-Language Analysis of Communication Deficits due to Alzheimer’s Disease
24. Multimodal attention-based deep learning for Alzheimer’s disease diagnosis
25. Neuropathological correlates of neuropsychiatric symptoms in dementia
26. Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer’s disease and mild cognitive impairment
27. Plasma glycocholic acid and linoleic acid identified as potential mediators of mitochondrial bioenergetics in Alzheimer’s dementia
28. Publisher Correction: Brain charts for the human lifespan
29. Quality of Life and the Experience of Living with Early-Stage Alzheimer’s Disease
30. Related amyloid burden and cortical atrophy in individuals with subtle cognitive decline
31. Single-nucleus RNA sequencing reveals the shared mechanisms inducing cognitive impairment between COVID-19 and Alzheimer’s disease
32. The Alzheimer's disease 5xFAD mouse model is best suited to investigate pretargeted imaging approaches beyond the blood-brain barrier
33. The Link Between Periodontitis and Alzheimer’s Disease: Reality or Yet Another Association
34. The functional connectivity of language network across the life span: Disentangling the effects of typical aging from Alzheimer’s disease
35. Transcranial alternating current stimulation combined with sound stimulation improves the cognitive function of patients with Alzheimer's disease: A case report and literature review

1. A Deep Learning for Alzheimer’s Stages Detection Using Brain Images
2. A Recent Appraisal of Small-Organic Molecules as Anti-Alzheimer’s Agents
3. A sex-stratified analysis of neuroimmune gene expression signatures in Alzheimer’s disease brains
4. Alzheimer PHF-tau aggregates do not spread tau pathology to the brain via the Retino-tectal projection after intraocular injection in male mouse models
5. Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia
6. Changes in Levels of Homocysteine and C-Reactive Protein in Patients with Alzheimer's Disease and Their Correlation with Cognitive and UPDRS Functions
7. Characteristics of very late-onset schizophrenia-like psychosis as prodromal dementia with Lewy bodies: a cross-sectional study
8. Characterizing subgroup performance of probabilistic phenotype algorithms within older adults: A case study for dementia, mild cognitive impairment, and Alzheimer’s and Parkinson’s diseases
9. Comprehensive characterization of multi-omic landscapes between gut-microbiota metabolites and the G-protein-coupled receptors in Alzheimer’s disease
10. Conditional GAN with 3D discriminator for MRI generation of Alzheimer’s disease progression
11. Correlation between CD4 / CD8 ratio and neurocognitive performance during early HIV infection
12. Design and synthesis of new indole drug candidates to treat Alzheimer’s disease and targeting neuro-inflammation using a multi-target-directed ligand (MTDL) strategy
13. Differential expression of m5C RNA methyltransferase genes NSUN6 and NSUN7 in Alzheimer’s disease and Traumatic Brain Injury
14. Effects of oral health intervention strategies on cognition and microbiota alterations in patients with mild Alzheimer's disease: A randomized controlled trial
15. FTH1- and SAT1-Induced Astrocytic Ferroptosis Is Involved in Alzheimer’s Disease: Evidence from Single-Cell Transcriptomic Analysis
16. Genetic Screening in Korean Patients with Frontotemporal Dementia Syndrome
17. Human antimicrobial peptide LL-37 contributes to Alzheimer’s disease progression
18. Impact of Sociodemographic Features and Lifestyle on Cognitive Performance of Peruvian Adults
19. Loss of Cholinergic Receptor Muscarinic 1 (CHRM1) Protein in the Hippocampus and Temporal Cortex of a Subset of Individuals with Alzheimer’s Disease, Parkinson’s Disease, or Frontotemporal Dementia: Implications for Patient Survival
20. Minocycline attenuates cholinergic dysfunction and neuro-inflammation-mediated cognitive impairment in scopolamine-induced Alzheimer’s rat model
21. Modulation of Amyloid-β and Tau in Alzheimer’s Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil
22. Regional precuneus cortical hyperexcitability in Alzheimer's disease patients
23. Regression-based cognitive change norms applied in biochemically defined predementia Alzheimer’s disease.
24. Selecting Multiple Node Statistics Jointly from Functional Connectivity Networks for Brain Disorders Identification
25. Smart home automation technology to support caring of individuals with Alzheimer’s disease and related dementia: an early intervention framework
26. Supplemental Material for Regression-Based Cognitive Change Norms Applied in Biochemically Defined Predementia Alzheimer’s Disease
27. The MK2 cascade mediates transient alteration in mGluR‐LTD and spatial learning in a murine model of Alzheimer's disease
28. We are preventing some dementias now—But how? The Potamkin lecture

1. "THE DRUG APPROACHES AND THE ROLE OF HEALTHCARE PROFESSIONALS IN THE MANAGEMENT OF ALZHEIMER’S DISEASE"
2. Altered Microcirculation in Alzheimer’s Disease Assessed by Machine Learning Applied to Functional Thermal Imaging Data
3. Altered O-GlcNAcylation and mitochondrial dysfunction, a molecular link between brain glucose dysregulation and sporadic Alzheimer’s disease
4. Analysis of SOD2 rs4880 Genetic Variant in Patients with Alzheimer’s Disease
5. Better conversations: a language and communication intervention for aphasia in posterior cortical atrophy
6. Caspase-2 mRNA levels are not elevated in mild cognitive impairment, Alzheimer’s disease, Huntington’s disease, or Lewy Body dementia
7. Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer's disease: Mechanisms and possible therapeutic interventions
8. Coupling of the spatial distributions between sMRI and PET reveals the progression of Alzheimer’s disease
9. Design and In-silico Molecular Docking of NMDA NR2B Receptor Antagonist and Pharmacokinetic Prediction of Some Piperazine Sulfonyl Amine Derivatives for Alzheimer’s Disease
10. Dual-Task-Based Music Therapy to Improve Executive Functioning of Elderly Patients with Early Stage Alzheimer’s Disease: A Multiple Case Study
11. Effect of Unloaded and Curcumin-Loaded Solid Lipid Nanoparticles on Tissue Transglutaminase Isoforms Expression Levels in an Experimental Model of Alzheimer’s Disease
12. Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity
13. Ethnomedicinal Plants with Protective Effects against Beta-Amyloid Peptide (Aβ)1-42 Indicate Therapeutic Potential in a New In Vivo Model of Alzheimer’s Disease
14. Evaluating Web-Based Automatic Transcription for Alzheimer Speech Data: Transcript Comparison and Machine Learning Analysis
15. Exploring nursing students’ knowledge of Alzheimer’s disease
16. Gliovascular alterations in sporadic and familial Alzheimer's disease: APOE3 Christchurch homozygote glioprotection
17. Gut inflammation associated with age and Alzheimer’s disease pathology
18. Identification of feature genes and pathways for Alzheimer's disease via WGCNA and LASSO regression
19. Inhibition of Glycogen Synthase Kinase and the Neuroprotective Function of Conjugated ZnO-Osthol Nanoparticles in Alzheimer’s Disease
20. Inhibition of the dopamine transporter promotes lysosome biogenesis and ameliorates Alzheimer's disease–like symptoms in mice
21. Latent feature representation learning for Alzheimer’s disease classification
22. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
23. Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE
24. Nanoscale alterations in GABAB receptors and GIRK channel organization on the hippocampus of APP/PS1 mice
25. Nilotinib: from animal-based studies to clinical investigation in Alzheimer’s disease patients
26. Prospective role of Citicoline and nanotechnology as drug delivery approaches for Alzheimer’s disease: Review of the literature
27. Relationship of serum beta‐synuclein with blood biomarkers and brain atrophy
28. Signaling interactions among neurons impact cell fitness and death in Alzheimer’s disease
29. Sleep exerts lasting effects on hematopoietic stem cell function and diversity
30. Synthesis of Spiro‐oxindole Analogs Engrafted Pyrazole Scaffold as Potential Alzheimer's Disease Therapeutics: Anti‐oxidant, Enzyme Inhibitory and Molecular Docking Approaches
31. Targeting neuroinflammation in Alzheimer’s disease: from mechanisms to clinical applications
32. The Transcranial Light Therapy Improves Synaptic Plasticity in the Alzheimer’s Disease Mouse Model
33. The landscape of m6A regulators in multiple brain regions of Alzheimer's Disease
34. The preventive effects of probiotic Akkermansia muciniphila on D-galactose/AlCl3 mediated Alzheimer's disease-like rats

1. A Computational approach to uncover the missense mutations in candidate genes of late-onset Alzheimer’s disease
2. A new K+channel-independent mechanism is involved in the antioxidant effect of XE-991 in an in vitro model of glucose metabolism impairment: implications for Alzheimer’s disease
3. Alterations in resting-state functional connectivity associated to the age-related decline in time-based prospective memory
4. Alzheimer's disease-associated inflammatory pathways might contribute to osteoporosis through the interaction between PROK2 and CSF3
5. An insight into the neuroprotective effects and molecular targets of pomegranate (Punica granatum) against Alzheimer’s disease
6. Aptamer-conjugated graphene oxide-based surface assisted laser desorption ionization mass spectrometry for selective extraction and detection of Aβ1–42 in an Alzheimer’s disease SH-SY5 cell model
7. Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer's disease
8. Automatic detection of Alzheimer’s disease progression: An efficient information fusion approach with heterogeneous ensemble classifiers
9. Bifidobacterium breve intervention combined with environmental enrichment alleviates cognitive impairment by regulating the gut microbiota and microbial metabolites in Alzheimer’s disease mice
10. Characteristics of Drawing Process Differentiate Alzheimer’s Disease and Dementia with Lewy Bodies
11. Cognitive advantage of bilingualism over monolingualism in older adults: A meta-analysis
12. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer’s disease mouse models
13. Editorial: Non-coding RNA in Alzheimer's pathology and diagnosis
14. Effects of Hypertension on Alzheimer’s Disease and Related Disorders
15. High Cerebrospinal Fluid CX3CL1 Levels in Alzheimer’s Disease Patients but Not in Non-Alzheimer’s Disease Dementia
16. High frequency repetitive transcranial magnetic stimulation improves cognitive performance parameters in patients with Alzheimer’s disease – an exploratory pilot study
17. Identification of the molecular subgroups in Alzheimer's disease by transcriptomic data
18. JUMPptm: Integrated software for sensitive identification of post‐translational modifications and its application in Alzheimer's disease study
19. Lithium Benzoate Exerts Neuroprotective Effect by Improving Mitochondrial Function, Attenuating Reactive Oxygen Species, and Protecting Cognition and Memory in an Animal Model of Alzheimer’s Disease
20. Loss of estrogen unleashing neuro-inflammation increases the risk of Alzheimer’s disease in women
21. Neighborhood characteristics and dementia symptomology among community-dwelling older adults with Alzheimer’s disease
22. Non-Pharmacological Therapeutic Options for the Treatment of Alzheimer’s Disease
23. Porphyromonas gingivalis Conditioned Medium Induces Amyloidogenic Processing of the Amyloid-β Protein Precursor upon in vitro Infection of SH-SY5Y Cells
24. Progressive attenuation of visual global precedence across healthy aging and Alzheimer’s disease
25. Protective effect of irisin against Alzheimer’s disease
26. Sensing red blood cell nano-mechanics: Toward a novel blood biomarker for Alzheimer’s disease
27. Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia
28. Sulfatide Deficiency, An Early Alzheimer’s Lipidomic Signature, Causes Brain Ventricular Enlargement in the Absence of Classical Neuropathological Hallmarks
29. Toxoplasma Gondii a risk factor for Alzheimer’s disease infection, in Al-Diwaniyah Governorate, Iraq
30. Why the Ala-His-His Peptide Is an Appropriate Scaffold to Remove and Redox Silence Copper Ions from the Alzheimer’s-Related Aβ Peptide

1. A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease
2. Association of Data-Driven White Matter Hyperintensity Spatial Signatures With Distinct Cerebral Small Vessel Disease Etiologies
3. Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease
4. Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy
5. Correlation between parameters related to sarcopenia and gray matter volume in patients with mild to moderate Alzheimer's disease
6. Curcumin-Loaded Mesoporous Silica Nanoparticles Dispersed in Thermo-Responsive Hydrogel as Potential Alzheimer Disease Therapy
7. Determining Whether Sex and Zygosity Modulates the Association between APOE4 and Psychosis in a Neuropathologically-Confirmed Alzheimer’s Disease Cohort
8. Diagnosis of Alzheimer’s Disease and In Situ Biological Imaging via an Activatable Near-Infrared Fluorescence Probe
9. Economic hardships of Korean American family caregivers of persons with dementia: a mixed-methods study
10. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease
11. Expression of SLC25A18 is positively correlated with Alzheimer's disease
12. Genetic, clinical underpinnings of subtle early brain change along Alzheimer’s dimensions
13. Inflammation-Related microRNAs-146a and -155 Are Upregulated in Mild Cognitive Impairment Subjects Among Older Age Population in Montenegro
14. Learning Cognitive-Test-Based Interpretable Rules for Prediction and Early Diagnosis of Dementia Using Neural Networks
15. Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology
16. Magnesium may be an effective therapy for Alzheimer’s disease
17. Mitochondrial Alterations in Neurons Derived from the Murine AppNL-F Knock-In Model of Alzheimer’s Disease
18. Nano-mediated Strategies for Metal Ion–Induced Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases
19. Platelet Activation and Alzheimer’s Disease: The Probable Role of PI3K/AKT Pathway
20. Presenilin 1 gene mutations: a potential marker to help diagnose early onset Alzheimer’s disease
21. Repeated High-Definition Transcranial Direct Current Stimulation Modulated Temporal Variability of Brain Regions in Core Neurocognitive Networks Over the Left Dorsolateral Prefrontal Cortex in Mild Cognitive Impairment Patients
22. Sex Differences in Resilience and Resistance to Brain Pathology and Dysfunction Moderated by Cerebrovascular Response to Exercise and Genetic Risk for Alzheimer’s Disease
23. Somatic Mutations and Alzheimer’s Disease
24. Structural dynamics and catalytic modulations of Aβ regulating enzymes as future outlook for Alzheimer's
25. Trimethylamine N-Oxide Reduces Neurite Density and Plaque Intensity in a Murine Model of Alzheimer’s Disease
26. Weight for It: Resistance Training Mitigates White Matter Hyperintensity-Related Disruption to Functional Networks in Older Females

1. A Mini-Review of Strategies for Recruiting Older African Americans to Alzheimer’s Disease Research
2. Alzheimer's Detection from English to Spanish Using Acoustic and Linguistic Embeddings
3. Augmented Adversarial Self-Supervised Learning for Early-Stage Alzheimer's Speech Detection
4. CURCUMINA E DOENÇA DE ALZHEIMER: UMA REVISÃO
5. Conformer Based Elderly Speech Recognition System for Alzheimer’s Disease Detection
6. Deep Learning Approaches for Detecting Alzheimer’s Dementia from Conversational Speech of ILSE Study
7. Functional Therapeutic Strategies Used in Different Stages of Alzheimer’s Disease—A Systematic Review
8. Multipotent Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease: Synthesis, Biological Analysis and Molecular Docking Study of Benzimidazole-Based Thiazole Derivatives

1. An Alzheimer’s Disease Mechanism Based on Early Pathology, Anatomy, Vascular-Induced Flow, and Migration of Maximum Flow Stress Energy Location with Increasing Vascular Disease
2. Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation
3. Cerebrospinal Fluid Sphingomyelins in Alzheimer’s Disease, Neurodegeneration, and Neuroinflammation
4. Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease
5. Dementia Research on Facebook and Twitter: Current Practice and Challenges
6. Disentangling Clinical Profiles of Apathy in Behavioral Variant Frontotemporal Dementia
7. Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimer’s Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis
8. GC/MS-Based Urine Metabolomics Study on the Ameliorative Effect of Xanthoceras sorbifolia Extract on Alzheimer’s Disease in Mice
9. Medicinal plants: A promising breakthrough in the management of Alzheimer's disease progression compared to than NSAID
10. Persistent Failure to Recover from Proactive Semantic Interference on the Cognitive Stress Test Differentiates Between Amnestic Mild Cognitive Impairment, Pre-Mild Cognitive Impairment, and Cognitively Unimpaired Older Adults
11. Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires

1. Alzheimer’s Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers
2. Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders
3. Brain Deep Medullary Veins on 7T MRI in Dutch-Type Hereditary Cerebral Amyloid Angiopathy
4. Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
5. Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil
6. Digital Technologies to Prevent Social Isolation and Loneliness in Dementia: A Systematic Review
7. Dissecting genetic links between Alzheimer’s disease and type 2 diabetes mellitus in a systems biology way
8. Editorial: Molecular mechanisms of Alzheimer’s disease: From top to bottom
9. Editorial: New developments in understanding brain and cerebromicrovascular aging: Toward prevention of vascular cognitive impairment and Alzheimer's disease
10. Efficient multiple change point detection for high‐dimensional generalized linear models
11. Fusobacterium nucleatum infection-induced neurodegeneration and abnormal gut microbiota composition in Alzheimer’s disease-like rats
12. Identification of a pleiotropic effect of ADIPOQ on cardiac dysfunction and Alzheimer’s disease based on genetic evidence and health care records
13. Impaired Dopamine Release and Latent Learning in Alzheimer’s Disease Model Zebrafish
14. Investigation of Anxiety- and Depressive-like Symptoms in 4- and 8-Month-Old Male Triple Transgenic Mouse Models of Alzheimer’s Disease
15. Iron dyshomeostasis and ferroptosis in Alzheimer’s disease: Molecular mechanisms of cell death and novel therapeutic drugs and targets for AD
16. Miconazole Promotes Cooperative Ability of a Mouse Model of Alzheimer Disease
17. Plasma metabolites associated with cognitive function across race/ethnicities affirming the importance of healthy nutrition
18. Plasma microRNAs as potential biomarkers in early Alzheimer disease expression
19. Predicting conversion to Alzheimer’s disease in individuals with Mild Cognitive Impairment using clinically transferable features
20. ROCK2 inhibition: A futuristic approach for the management of Alzheimer’s disease
21. Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro
22. Survey on Feature Detection of Alzheimer’s disease in Early Stage by Particle Size Distribution in Feature Selection Optimization Procedure
23. TREM2 risk variants are associated with atypical Alzheimer’s disease
24. Targeting neuronal calcium channels and GSK3β for Alzheimer’s disease with naturally-inspired Diels-Alder adducts
25. The Immune System as a Therapeutic Target for Alzheimer’s Disease

1. In Vivo Prenylomic Profiling in the Brain of a Transgenic Mouse Model of Alzheimer’s Disease Reveals Increased Prenylation of a Key Set of Proteins
2. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias
3. A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
4. A review of brain imaging biomarker genomics in Alzheimer’s disease: implementation and perspectives
5. Alleged Fabrication in Alzheimer's Studies Worries Patients, Not Researchers in the Field
6. Alzheimer’s disease classification using distilled multi-residual network
7. Alzheimer’s disease: Pathophysiology and dental pulp stem cells therapeutic prospects
8. Anosmia, mild cognitive impairment, and biomarkers of brain aging in older adults
9. Are infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records
10. Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline
11. Association of Whole-Person Eigen-Polygenic Risk Scores with Alzheimer’s Disease
12. Associations between psychological therapy outcomes for depression and incidence of dementia
13. CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease
14. Cannabidiol in the treatment and prevention of Alzheimer’s disease – a comprehensive overview of in vitro and in vivo studies
15. Cholinesterase Inhibitors Response Might Be Related to Right Hippocampal Functional Connectivity in Mild Alzheimer's Disease
16. Circulating Amyloid-β and Methionine-Related Metabolites to Predict the Risk of Mild Cognitive Impairment: A Nested Case-Control Study
17. Crosstalk of Alzheimer’s disease-phenotype, HPA axis, splenic oxidative stress and frailty in late-stages of dementia, with special concerns on the effects of social isolation: A translational neuroscience approach
18. Deep and hybrid learning of MRI diagnosis for early detection of the progression stages in Alzheimer’s disease
19. Deep anonymization of medical imaging
20. Differences in Motivators, Barriers, and Incentives between Black and White Older Adults for Participation in Alzheimer’s Disease Biomarker Research
21. Different oral and gut microbial profiles in those with Alzheimer's disease consuming anti-inflammatory diets
22. Dispersion-based cognitive intra-individual variability in dementia with Lewy bodies.
23. Distinct sex-specific DNA methylation differences in Alzheimer’s disease
24. Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial
25. Faculty Opinions recommendation of Genetics of the human microglia regulome refines Alzheimer's disease risk loci.
26. Hospital-treated infections in early- and mid-life and risk of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden
27. Long-term gamma transcranial alternating current stimulation improves the memory function of mice with Alzheimer’s disease
28. Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease
29. Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation
30. Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease
31. Neurosciences and Nuclear Medicine: Modeling and Predicting Neurorehabilitation of Alzheimer’s Disease
32. Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model
33. Non-steroidal Anti-Inflammatory Drugs as protective Factor in Alzheimer's Diseases: a Systematic Review and Meta-Analysis Protocol (Preprint)
34. Novel Roles of RNA m6A Methylation Regulators in the Occurrence of Alzheimer’s Disease and the Subtype Classification
35. Prediction value of the genetic risk of type 2 diabetes on the amnestic mild cognitive impairment conversion to Alzheimer’s disease
36. Pyroptosis as a candidate therapeutic target for Alzheimer’s disease
37. Recall and recognition subtests of the repeatable battery for the assessment of neuropsychological status and their relationship to biomarkers of Alzheimer’s disease
38. Relationships Between the Deposition of Amyloid-β and Tau Protein and Glymphatic System Activity in Alzheimer’s Disease: Diffusion Tensor Image Study
39. Screening of Anti-Alzheimer’s Activity against Scopolamine-Induced Amnesia in Mice Model
40. Static and Dynamic Functional Connectivity Alterations in Alzheimer's Disease and Neuropsychiatric Diseases
41. Style Transfer Generative Adversarial Networks to Harmonize Multi-Site MRI to a Single Reference Image to Avoid Over-Correction
42. Synthesis and Virtual Screening of Some Novel Quinazolinone Derivatives as Potent Cholinesterase Inhibitors against Alzheimer’s Disease
43. Unbiased metabolome screen links serum urate to risk of Alzheimer's disease

1. In vivo tau staging in Alzheimer’s disease
2. A CHCHD6–APP axis connects amyloid and mitochondrial pathology in Alzheimer’s disease
3. A systematic review of the cost-effectiveness of community and population interventions to reduce the modifiable risk factors for dementia
4. Abnormal information interaction in multilayer directed network based on cross-frequency integration of mild cognitive impairment and Alzheimer’s disease
5. Correction: A Web-Based Platform (CareVirtue) to Support Caregivers of People Living With Alzheimer Disease and Related Dementias: Mixed Methods Feasibility Study
6. Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study
7. Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
8. Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial
9. Exploring community knowledge, attitudes and perceptions of Alzheimer's Disease/Alzheimer's Disease‐Related Dementias and healthy ageing in Asian American, Native Hawaiian and Pacific Islanders
10. Features of the Development and Analysis of Impairments to Social Behavior and Cognitive Functions in Animals with Experimental Alzheimer’s Disease
11. Immunotherapies for Alzheimer’s Disease—A Review
12. Long Non-coding RNAs, Extracellular Vesicles and Inflammation in Alzheimer’s Disease
13. Monotherapy or complex treatment? Tactics of managing patients with Alzheimer’s disease and vascular dementia
14. Projected Ontario budget savings from reduced long-term care utilization due to a disease-modifying Alzheimer’s treatment
15. Relationship between adult subventricular neurogenesis and Alzheimer’s disease: Pathologic roles and therapeutic implications
16. Retrospective real-world pilot data on transcranial pulse stimulation in mild to severe Alzheimer's patients
17. Synthesis, Molecular Docking and ADME-TOX Studies of New Tacrine Analogs as Promising for Alzheimer's Disease Therapy
18. “An animated socialization without substance:” experiences of persons living with dementia through the COVID-19 pandemic

1. A Caregiver’s Guide to Communication Problems from Brain Injury or Disease edited by Barbara O’Connor Wells & Connie Porcaro, Johns Hopkins University Press, 2022, 256 pp.
2. A Role for PGC-1a in the Control of Abnormal Mitochondrial Dynamics in Alzheimer’s Disease
3. A Study of Dementia Prediction Models Based on Machine Learning with Survey Data of Community-Dwelling Elderly People in China
4. A Young Man with Cognitive Impairment and a Heart Condition
5. A glowing probe helps detect Alzheimer’s disease
6. Aducanumab for Alzheimer’s disease: Observations and opportunities
7. Aducanumab: A Novel Drug for Alzheimer's Disease; Future Challenges in Treatment
8. Alzheimer’s Disease and Inflammaging
9. Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort
10. Association Between Cognition, Health Related Quality of Life, and Costs in a Population at Risk for Cognitive Decline
11. Association Between Grip Strength and Cognitive Function in US Older Adults of NHANES 2011–2014
12. Association of COVID-19 with New-Onset Alzheimer’s Disease
13. Association of Cerebral Small Vessel Disease Burden with Neuropsychiatric Symptoms in Non-Demented Elderly: A Longitudinal Study
14. Associations Between Vascular Risk Factors and Perivascular Spaces in Adults with Intact Cognition, Mild Cognitive Impairment, and Dementia
15. Associations of Physical Activity with Alzheimer’s Disease Pathologies and Cognition: The CABLE Study
16. BBB-on-a-chip with Integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimer’s disease
17. Biomarkers for dementia in Latin American countries: Gaps and opportunities
18. Diagnostic Utility of Cerebrospinal Fluid α-Synuclein in Creutzfeldt-Jakob Disease: A Systematic Review and Meta-Analysis
19. Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System
20. Global Network Analysis of Alzheimer’s Disease with Minimum Spanning Trees
21. Immune-mediated diseases are associated with a higher incidence of dementia: a prospective cohort study of 375,894 individuals
22. Importance of Accounting for Regional Differences in Modifiable Risk Factors for Alzheimer’s Disease and Related Dementias: The Case for Tailored Interventions
23. Incidence and Outcomes of SARS-CoV-2 Infection in Older Adults Living with Dementia: A Population-Based Cohort Study
24. Inflammation Disrupts Cognitive Integrity via Plasma Neurofilament Light Chain Coupling Brain Networks in Alzheimer’s Disease
25. Interactive Effects of Pulse Pressure and Tau Imaging on Longitudinal Cognition
26. Lifestyle and Cognitive Decline in Community-Dwelling Stroke Survivors
27. Lipid Peroxidation as a Marker of Apathy and Executive Dysfunction in Patients at Risk for Vascular Cognitive Impairment
28. Lithium in drinking water and Alzheimer's dementia: Epidemiological Findings from National Data Base of Japan
29. Locus Coeruleus Degeneration Differs Between Frontotemporal Lobar Degeneration Subtypes
30. Measuring the Frailty Phenotype and its Association with Cognition in Mid-Life and Older Age
31. Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches
32. Multi-proteomic analysis of 5xFAD mice reveals new molecular signatures for early-stage Alzheimer’s disease
33. Neuropsychological and Neuroanatomical Features of Patients with Behavioral/Dysexecutive Variant Alzheimer’s Disease (AD): A Comparison to Behavioral Variant Frontotemporal Dementia and Amnestic AD Groups
34. Paired associative stimulation (PAS) and Alzheimer’s disease (AD)
35. Pathophysiological Association Between Diabetes Mellitus and Alzheimer's Disease
36. Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
37. Recent updates in the development of small molecules as potential clinical candidates for Alzheimer's disease: A review
38. Regional Disruption of White Matter Integrity and Network Connectivity Are Related to Cognition
39. Salivary Proteomics Reveals Significant Changes in Relation to Alzheimer’s Disease and Aging
40. Stakeholder Insights in Alzheimer’s Disease: Natural Language Processing of Social Media Conversations
41. Straight and Divergent Pathways to Cognitive State: Seven Decades of Follow-Up in the British 1946 Birth Cohort
42. The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
43. The Effectiveness of Community Aging Care Centers on Global Function for People Living with Dementia
44. The Effects on Gait of 4-Wheeled Walker Use in People with Alzheimer’s Disease Dementia and Gait Impairment: A Pilot Study
45. The Feasibility of Early Alzheimer’s Disease Diagnosis Using a Neural Network Hybrid Platform
46. The Role of Glymphatic System in Alzheimer’s and Parkinson’s Disease Pathogenesis
47. The effectiveness of intravenous sedation with midazolam for people with Alzheimer's disease requiring dental extraction
48. The multiple faces of extracellular vesicles released by microglia: Where are we 10 years after?
49. The present and future of minimally invasive methods for Alzheimer's disease diagnosis
50. Trace element concentration and cognitive dysfunction in elderly residents in Birjand
51. Triple Network Model-Based Analysis on Abnormal Core Brain Functional Network Dynamics in Different Stage of Amnestic Mild Cognitive Impairment
52. Undiagnosed Dementia Is Associated with Poor Physical Function in Older Adults
53. go4cognition: Combined Physiological and Cognitive Intervention in Mild Cognitive Impairment

1. Allergic diseases and risk of incident dementia and Alzheimer's disease
2. Association Between Low- and High-Value Medication and Hospital Referrals by General Practitioners in Patients Living with Dementia
3. Association between Subclinical Epileptiform Discharge and the Severity of Cognitive Decline in Alzheimer’s Disease: A Longitudinal Cohort Study
4. Association of late-life body mass index with the risk of Alzheimer disease: a 10-year nationwide population-based cohort study
5. CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies
6. Cognitive Heterogeneity and Risk of Progression in Data-Driven Subtle Cognitive Decline Phenotypes
7. Cognitive Impairments and Activities of Daily Living in the Alzheimer’s Disease Spectrum: The need to consider cognition and functional skills as separate related domains
8. Cognitive dispersion is elevated in amyloid-positive older adults and associated with regional hypoperfusion
9. Computer-aided early diagnosis of alzheimer's disease based on cost-sensitive and deep residual convolutional neural network
10. Exercise Benefits on Alzheimer’s Disease
11. Extra-virgin Avocado (Persea americana Mill.,Laucaceae) Oil Improves Cognitive Impairment in D-galactose-induced Alzheimer’s Disease Model on Ovariectomized Wistar Rat
12. Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
13. Home-Based Electronic Cognitive Therapy in Patients With Alzheimer Disease: Feasibility Randomized Controlled Trial
14. IL-1β and TNF-α play an important role in modulating the risk of periodontitis and Alzheimer’s disease
15. Impaired IL-23–dependent induction of IFN-γ underlies mycobacterial disease in patients with inherited TYK2 deficiency
16. Integrating multi-omics summary data using a Mendelian randomization framework
17. Linear Mixed Model Analysis of Polygenic Hazard Score on Verbal Memory Decline in Alzheimer’s Disease
18. Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals
19. Predictors of post-stroke cognitive impairment using acute structural MRI neuroimaging: A systematic review and meta-analysis
20. Schisandrin alleviates the cognitive impairment in rats with Alzheimer’s disease by altering the gut microbiota composition to modulate the levels of endogenous metabolites in the plasma, brain, and feces
21. Tea Consumption Is Associated with Reduced Cognitive Decline and Interacts with Iron Intake: A Population-Based Longitudinal Study on 4,820 Old Adults
22. The role of PKC/PKR in aging, Alzheimer's disease, and perioperative neurocognitive disorders
23. Understanding the Relationship Between Age-Related Hearing Loss and Alzheimer’s Disease: A Narrative Review

1. APOE ε4 influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal‐dominant Alzheimer's disease
2. Machine learning based on Optical Coherence Tomography images as a diagnostic tool for Alzheimer's disease
3. The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms

1. Aerobic Exercise Regulates Apoptosis through the PI3K/Akt/GSK-3β Signaling Pathway to Improve Cognitive Impairment in Alzheimer’s Disease Mice
2. Considering a Need for Dementia-Specific, Family-Centered Patient Navigation in Canada
3. Correction to: Regional optimum frequency analysis of resting-state fMRI data for early detection of Alzheimer’s disease biomarkers
4. Death induced by survival gene elimination (DISE) contributes to neurotoxicity in Alzheimer’s disease
5. Discovery of novel neuroprotective cinnamoyl-M30D hybrids targeting Alzheimer’s disease
6. Discovery of potent and selective dual cholinesterases and β-secretase inhibitors in pomegranate as a treatment for Alzheimer’s disease
7. Frontotemporal dementia associated with intrathecal antibodies against axon initial segments
8. Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer’s disease
9. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
10. Interaction between Alzheimer’s Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers
11. Venular amyloid accumulation in transgenic Fischer 344 Alzheimer’s disease rats
12. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease

1. A Alzheimer’s Disease Detection and Classification Using Customised Convolutional Neural Network
2. A Systematic Review on Machine Learning and Deep Learning Techniques in the Effective Diagnosis of Alzheimer’s Disease
3. A Systematic Study About EEG Signal Data and Computer Aided Models for the Diagnosis of Alzheimer's Disease
4. A novel deep learning approach for diagnosing Alzheimer's disease based on eye-tracking data
5. Association of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study
6. Associations Between Vascular Diseases and Alzheimer’s Disease or Related Dementias in a Large Cohort of Men and Women with Colorectal Cancer
7. Body mass index, genetic susceptibility, and Alzheimer's disease: a longitudinal study based on 475,813 participants from the UK Biobank
8. Diagnostic Values of Advanced Glycation End Products and Homocysteine in Patients with Alzheimer’s Disease and Sarcopenia
9. Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer’s Disease
10. Hierarchical Two-Stage Cost-Sensitive Clinical Decision Support System for Screening Prodromal Alzheimer’s Disease and Related Dementias
11. Hippocampal morphological atrophy and distinct patterns of structural covariance network in Alzheimer’s disease and mild cognitive impairment
12. Homozygous knockout of eEF2K alleviates cognitive deficits in APP/PS1 Alzheimer’s disease model mice independent of brain amyloid β pathology
13. Increased KV2.1 Channel Clustering Underlies the Reduction of Delayed Rectifier K+ Currents in Hippocampal Neurons of the Tg2576 Alzheimer’s Disease Mouse
14. Innate immune activation: Parallels in alcohol use disorder and Alzheimer’s disease
15. Integrating peripheral blood and brain transcriptomics to identify immunological features associated with Alzheimer’s disease in mild cognitive impairment patients
16. Investigating the temporal pattern of neuroimaging-based brain age estimation as a biomarker for Alzheimer's Disease related neurodegeneration
17. Is Aducanumab Treatment that Developed to Prevent Progression of Alzheimer's Disease Cost-Effective?
18. KL-FGF23-VD Axis in Improving Late-Onset Alzheimer’s Disease by Modulating IKK/NF-κB Signal Pathway
19. Membrane interaction to intercellular spread of pathology in Alzheimer’s disease
20. Mini-Mental State Examination and Montreal Cognitive Assessment as Tools for Following Cognitive Changes in Alzheimer’s Disease Neuroimaging Initiative Participants
21. New Drug Design Avenues Targeting Alzheimer’s Disease by Pharmacoinformatics-Aided Tools
22. Optimal Stimulation Sites and Networks for Deep Brain Stimulation of the Fornix in Alzheimer’s Disease
23. Predicting the Age of the Brain with Minimally Processed T₁-weighted MRI Data
24. Prevalence and Ascertainment of Dementia Cases in the Malmö Diet and Cancer Study
25. Self- and Other-Evaluation in Alzheimer’s Disease
26. Sex differences in early‐onset Alzheimer's disease
27. Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic Aβ Peptides
28. Statistical Evaluation of the Test Threshold for the Alzheimer’s Disease EEG Coherence Marker
29. Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer’s Disease
30. The Helico Maze Detects Early Impairment of Reference Memory at Three Months of Age in the 5XFAD Mouse Model of Alzheimer’s Disease
31. The Molecular Effects of Environmental Enrichment on Alzheimer’s Disease
32. Uncovering a tripartite landmark in posterior cingulate cortex
33. White matter integrity and key structures affected in Alzheimer's disease characterized by diffusion tensor imaging

1. A Retrospective Study of Progressive Gait Impairment in Alzheimer’s Disease
2. A feasibility study of a decision aid to support family carers of people with severe dementia or those towards the end-of-life
3. Acupuncture Treatment Modulate Regional Homogeneity of Dorsal Lateral Prefrontal Cortex in Patients with Amnesic Mild Cognitive Impairment
4. Advances in the study of the relationship between Alzheimer's disease and the gastrointestinal microbiome
5. Alzheimer’s Drug PBT2 Interacts with the Amyloid β 1–42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs
6. Assessment of the neuroprotective potential of d-cycloserine and l-serine in aluminum chloride-induced experimental models of Alzheimer’s disease: In vivo and in vitro studies
7. Association between inflammatory bowel disease and Alzheimer’s disease: multivariable and bidirectional Mendelian randomisation analyses
8. Association of rs2072446 in the NGFR gene with the risk of Alzheimer's disease and amyloid‐β deposition in the brain
9. Associations among Alzheimer disease, depressive disorder, and risk of end-stage kidney disease in elderly people
10. Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson’s disease
11. Curcumin Analogues as Novel Anti-Alzheimer's Candidates: Synthesis Development Strategy, In Vitro, Cell-Based and In Vivo Studies
12. Cytokine storm and neuropathological alterations in patients with neurological manifestations of COVID-19
13. Data-driven causal model discovery and personalized prediction in Alzheimer's disease
14. Decision letter for "Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study"
15. Design, synthesis, in silico and biological evaluations of novel polysubstituted pyrroles as selective acetylcholinesterase inhibitors against Alzheimer’s disease
16. Early impairment of cortical circuit plasticity and connectivity in the 5XFAD Alzheimer’s disease mouse model
17. Effects of rTMS treatment on global cognitive function in Alzheimer's disease: A systematic review and meta-analysis
18. Examination of Longitudinal Alterations in Alzheimer’s Disease-Related Neurogenesis in an APP/PS1 Transgenic Mouse Model, and the Effects of P33, a Putative Neuroprotective Agent Thereon
19. How context influences person-centred practice: a critical-creative case study examining the use of research evidence in occupational therapy with people living with dementia
20. Hyperglycemic Neurovasculature‐On‐A‐Chip to Study the Effect of SIRT1‐Targeted Therapy for the Type 3 Diabetes “Alzheimer's Disease”
21. Identification and Quantitation of Novel ABI3 Isoforms Relative to Alzheimer’s Disease Genetics and Neuropathology
22. Insights of Valacyclovir in Treatment of Alzheimer’s Disease: Computational Docking Studies and Scopolamine Rat Model
23. Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer’s disease (from the Nakayama Study)
24. NATURAL PRODUCT FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
25. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases
26. Neuroprotective effects of Morinda officinalis How.: Anti-inflammatory and antioxidant roles in Alzheimer’s disease
27. Novel Multipotent Amantadine–M30D Hybrids with Highly Selective Butyrylcholinesterase Inhibition and Neuroprotective Effects as Effective Anti-Alzheimer’s Agents
28. Perspectives of ozone induced neuropathology and memory decline in Alzheimer's disease: A systematic review of preclinical evidences
29. Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer’s Disease: A Narrative Review
30. Regulating microglial miR-155 transcriptional phenotype alleviates Alzheimer’s-induced retinal vasculopathy by limiting Clec7a/Galectin-3+ neurodegenerative microglia
31. Response to the letter titled “The conundrum of the AD continuum”
32. Sensitivity enhancement of magneto-optical Faraday effect immunoassay method based on biofunctionalized γ-Fe2O3@Au core-shell magneto-plasmonic nanoparticles for the blood detection of Alzheimer's disease
33. Sensitivity of memory subtests and learning slopes from the ADAS-Cog to distinguish along the continuum of the NIA-AA Research Framework for Alzheimer’s Disease
34. The conundrum of the AD continuum
35. The larval diving response (LDR): Validation of an automated, high-throughput, ecologically relevant measure of anxiety-related behavior in larval zebrafish (Danio rerio)
36. Validation of the Norma Latina Neuropsychological Assessment Battery in Patients with Alzheimer’s Disease in Mexico
37. Variations in Medicare Advantage Switching Rates among African American and Hispanic Medicare Beneficiaries with Alzheimer’s Disease and Related Dementias, by Sex and Dual Eligibility
38. What does heritability of Alzheimer’s disease represent?

1. A Hybrid Deep Learning model for predicting the early Alzheimer’s Disease stages using MRI
2. A quantitative meta-analysis of vitamin C in the pathophysiology of Alzheimer’s disease
3. A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer’s disease
4. Abnormal molecular signatures of inflammation, energy metabolism, and vesicle biology in human Huntington disease peripheral tissues
5. Aducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer’s disease
6. Advances in Antioxidant Nanomedicines for Imaging and Therapy of Alzheimer’s Disease
7. Alzheimer : vers un traitement précoce de la maladie ?
8. Association between Gut Microbiota with Mild Cognitive Impairment and Alzheimer’s Disease in a Thai Population
9. Author response for "Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study"
10. Causal effect of COVID‐19 on Alzheimer's disease: A Mendelian randomization study
11. Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease
12. Cognition-enhancing effect of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in the 5 × FAD transgenic mouse model of Alzheimer’s pathology
13. Cognitive Resilience in Brain Health and Dementia Research
14. Detection of Alzheimer’s Disease with Deep Learning Method
15. Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation
16. Effective connectivity in individuals with Alzheimer's disease and mild cognitive impairment: A systematic review
17. Exploring the inverse association of glioblastoma multiforme and Alzheimer’s disease via bioinformatics analysis
18. Global and local ancestry modulate APOE association with Alzheimer’s neuropathology and cognitive outcomes in an admixed sample
19. Homocysteine Modulates Brain Functional Connectivity in a Memory Retrieval Task
20. How best to capture the impact of complementary therapies in palliative care: A systematic review to identify and assess the appropriateness and validity of multi-domain tools
21. Identification of genetic loci shared between Alzheimer’s disease and hypertension
22. Impact of Alzheimer’s disease and related dementias on colorectal cancer screening utilization, knowledge, and associated health disparities
23. MACHINE LEARNING APPROACH FOR EARLY DETECTION OF ALZHEIMER'S DISEASE
24. On the reliability of deep learning-based classification for Alzheimer’s disease: Multi-cohorts, multi-vendors, multi-protocols, and head-to-head validation
25. Research trends and hotspots of exercise for Alzheimer’s disease: A bibliometric analysis
26. Scavenging Reactive Oxygen Species Decreases Amyloid-β Levels via Activation of PI3K/Akt/GLUT1 Pathway in N2a/APP695swe Cells
27. Towards Digital Therapy for Alzheimer’s Disease and Other Forms of Neurocognitive Disorder: the INFORMA Software Platform
28. Transformed domain convolutional neural network for Alzheimer's disease diagnosis using structural MRI

1. Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease
2. BBB-on-a-chip with Integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimer’s disease
3. Benefits of Gut Microbiota Reconstitution by Beta 1,3–1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases
4. CHRNA5 links chandelier cells to protection against amyloid pathology in human aging and Alzheimer's Disease
5. Cerebral Blood Flow Alterations and Obesity: A Systematic Review and Meta-Analysis
6. Diagnosis of Alzheimer’s, Parkinson’s disease and frontotemporal dementia using a generative adversarial deep convolutional neural network
7. Effects of Presenilin-1 Familial Alzheimer’s Disease Mutations on γ-Secretase Activation for Cleavage of Amyloid Precursor Protein
8. Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial
9. Effects of zinc and carnosine on aggregation kinetics of Amyloid-β40 peptide
10. Expression Changes in Mitochondrial Genes Affecting Mitochondrial Morphology, Transmembrane Potential, Fragmentation, Amyloidosis, and Neuronal Cell Death Found in Brains of Alzheimer’s Disease Patients
11. Fatty Acid-Binding Protein 3 is a Marker of Neurodegeneration and White Matter Hyperintensity Burden in Mexican American Older Adults
12. Frontostriatal and limbic contributions to cognitive decline in Parkinson's disease
13. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
14. High-resolution atlasing and segmentation of the subcortex: Review and perspective on challenges and opportunities created by machine learning
15. Ikos Test: New Tool for the Assessment of Semantic Knowledge in Early Alzheimer Disease
16. Impact of Cognitive Demand on Eye Movement Pattern in Patients with Alzheimer’s Disease
17. Incorporating Mitochondrial Gene Expression Changes Within a Testable Mathematical Model for Alzheimer’s Disease: Stress Response Modulation Predicts Potential Therapeutic Targets
18. Insulin-Related Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review
19. Iron in Alzheimer’s Disease: From Physiology to Disease Disabilities
20. Macular Microvascular Density as a Diagnostic Biomarker for Alzheimer’s Disease
21. Missing apolipoprotein E ɛ4 allele associated with nonamnestic Alzheimer’s disease in a Tunisian population
22. Neuroprotective effect of derris indica seed extract attenuates amyloid beta plaques induce Alzheimer’s in mice model
23. Neuroprotective properties of Ferulic acid in preclinical models of Alzheimer’s disease: A systematic literature review
24. PLCγ2 impacts microglia-related effectors revealing variants and pathways important in Alzheimer’s disease
25. Patchouli alcohol ameliorates the learning and memory impairments in an animal model of Alzheimer's disease via modulating SIRT1
26. Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
27. Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan
28. Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?
29. The Asparaginyl Endopeptidase Legumain: An Emerging Therapeutic Target and Potential Biomarker for Alzheimer’s Disease
30. The Effect of Ghrelin on Apoptosis, Necroptosis and Autophagy Programmed Cell Death Pathways in the Hippocampal Neurons of Amyloid-β 1–42-Induced Rat Model of Alzheimer’s Disease
31. The therapeutic efficacy of transcranial magnetic stimulation in managing Alzheimer’s disease: A systemic review and meta-analysis
32. Transdiagnostic connectome signatures from resting-state fMRI predict individual-level intellectual capacity
33. Truncated Tau caused by intron retention is enriched in Alzheimer’s disease cortex and exhibits altered biochemical properties
34. Validation of the Adapted German Versions of the Dementia Knowledge Assessment Tool 2, the Dementia Attitude Scale, and the Confidence in Dementia Scale for the General Population

1. Aurantiamide promotes M2 polarization of microglial cells to improve the cognitive ability of mice with Alzheimer's disease
2. Aβ plaques do not protect against HSV ‐1 infection in a mouse model of familial Alzheimer's disease, and HSV ‐1 does not induce Aβ pathology in a model of late onset Alzheimer's disease
3. Biomarcadores e Doença de Alzheimer: o que podemos aprender
4. Biomarker Genes Discovery of Alzheimer’s Disease by Multi-Omics-Based Gene Regulatory Network Construction of Microglia
5. Combination of NSAIDs with donepezil as multi-target directed ligands for the treatment of Alzheimer’s disease
6. Dementia-related genetic variants in an Italian population of early-onset Alzheimer’s disease
7. Distribution of cortical atrophy associated with cognitive decline in Alzheimer’s disease: a cross-sectional quantitative structure MRI study from PUMCH dementia cohort
8. Early-life stress and dietary fatty acids impact the brain lipid/oxylipin profile into adulthood, basally and in response to LPS
9. Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study
10. Globalizing Research toward Diverse Representation in Alzheimer's and Parkinson's Disease
11. Helicobacter pylori infection in the stomach induces neuroinflammation: the potential roles of bacterial outer membrane vesicles in an animal model of Alzheimer’s disease
12. Hemispheric lateralization, endothelial function, and arterial compliance in chronic post-stroke individuals: A cross-sectional exploratory study
13. Huntington’s disease age at motor onset is modified by the tandem hexamer repeat in TCERG1
14. Integrative Theory of Alzheimer’s and Parkinson’s Diseases
15. Multi-modality MRI for Alzheimer’s disease detection using deep learning
16. Predictors of Healthcare Utilization among Older Adults with Moderate to Severe Cognitive Limitations in Ghana: A Cross-Sectional Analysis of the WHO Study on Global Ageing and Adult Health (SAGE) Wave 1
17. Preparedness of the Brazilian health‐care system to provide access to a disease‐modifying Alzheimer's disease treatment
18. Promoting empowerment for people living with dementia in nursing homes: Development and feasibility evaluation of an empowerment program
19. Proteophenes – Amino Acid Functionalized Thiophene‐based Fluorescent Ligands for Visualization of Protein Deposits in Tissue Sections with Alzheimer's Disease Pathology
20. Retraction Note: Knockdown of long non‑coding RNA TUG1 depresses apoptosis of hippocampal neurons in Alzheimer’s disease by elevating microRNA‑15a and repressing ROCK1 expression
21. SARS-CoV-2 and vascular dysfunction: a growing role for pericytes
22. Synthesis, Neuroprotective Effect and Physicochemical Studies of Novel Peptide and Nootropic Analogues of Alzheimer Disease Drug
23. Tau seeding activity in various regions of down syndrome brain assessed by two novel assays
24. Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer’s disease

1. Are older adults susceptible to visual distraction when targets and distractors are spatially separated?
2. Different Trajectories of Depressive Symptoms in Alzheimer’s Disease Caregivers – 5-Year Follow-Up
3. Neuroprotective role of medicinal plant extracts evaluated in a scopolamine-induced rat model of Alzheimer's disease
4. Pathogenesis, therapeutic strategies and biomarker development based on “omics” analysis related to microglia in Alzheimer’s disease
5. Tear Biomarkers in Alzheimer’s and Parkinson’s Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review)
6. The Impairment of Blood-Brain Barrier in Alzheimer’s Disease: Challenges and Opportunities with Stem Cells

1. A population‐based meta‐analysis of circulating GFAP for cognition and dementia risk
2. A Review on Alzheimer’s disease and mesenchymal stem cell therapy
3. A multi-expert ensemble system for predicting Alzheimer transition using clinical features
4. Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
5. Cognitive Functioning of Unaffected First-degree Relatives of Individuals With Late-onset Alzheimer's Disease: A Systematic Literature Review and Meta-analysis
6. Design, Synthesis, and biological evaluation of pyrazolo-benzothiazole derivatives as a potential therapeutic agent for the treatment of Alzheimer’s disease
7. Ensemble learning using traditional machine learning and deep neural network for diagnosis of Alzheimer’s disease
8. Importance of Bmal1 in Alzheimer's disease and associated aging‐related diseases: Mechanisms and interventions
9. LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease
10. Longitudinal change in ATN biomarkers in cognitively normal individuals
11. Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
12. Neuroprotective and Antioxidant Role of Oxotremorine-M, a Non-selective Muscarinic Acetylcholine Receptors Agonist, in a Cellular Model of Alzheimer Disease
13. Static and dynamic functional connectivity variability of the anterior-posterior hippocampus with subjective cognitive decline
14. Two-Dimensional-Dwell-Time Analysis of Ion Channel Gating using High Performance Computing Clusters

1. APOE Genotype and Biological Sex Regulate Astroglial Interactions with Amyloid Plaques in Alzheimer’s Disease Mice
2. Altered levels of variant cholinesterase transcripts contribute to the imbalanced cholinergic signaling in Alzheimer’s and Parkinson’s disease
3. Assessment of Alzheimer's Disease Imaging Biomarkers in World Trade Center Responders with Cognitive Impairment at Midlife
4. Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
5. Cost-utility analysis of memantine in Alzheimer’s Disease in Brazil
6. Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease
7. Diminishing accelerated long-term forgetting in mild cognitive impairment: Study protocol for a prospective, double-blind, placebo-controlled, randomized controlled trial
8. Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease
9. Effect of acetylcholine deficiency on neural oscillation in a brainstem-thalamus-cortex neurocomputational model related with Alzheimer’s disease
10. Ever-expanding landscape: Alzheimer’s – new targets and new patents
11. FATORES QUE TORNAM O SEXO FEMININO MAIS PREDISPONENTE À DOENÇA DE ALZHEIMER
12. How do family carers and care-home staff manage refusals when assisting a person with advanced dementia with their personal care?
13. Hybrid Classification Algorithm for Early Prediction of Alzheimer’s Disease
14. Hypnosis for pain and anxiety management in cognitively impaired older adults undergoing scheduled lumbar punctures: a randomized controlled pilot study
15. LRP1 is a neuronal receptor for α-synuclein uptake and spread
16. Layer‐specific microstructural patterns of anterior hippocampus in Alzheimer's disease with ex vivo diffusion MRI at 14.1  T
17. MR GÖRÜNTÜLERİNDEN ALZHEİMER TESPİTİNDE BOYUT AZALTMA VE DERİN ÖĞRENME YAKLAŞIMLARININ KARŞILAŞTIRILMASI
18. Objectifying Subjective Cognitive Decline: The Prognostic Role of Alzheimer Biomarkers
19. Optimal anti-amyloid-beta therapy for Alzheimer’s disease via a personalized mathematical model
20. PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
21. Protective Effects of Flavonoids against Alzheimer’s Disease: Pathological Hypothesis, Potential Targets, and Structure–Activity Relationship
22. Sex differences in Alzheimer’s disease risk: are immune responses the key?
23. Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum
24. Synthetic analogs of 3-iodothyronamine (T1AM) prevent [beta]-amyloid neurotoxicity in an in vitro model of alzheimer's disease (AD)
25. The Polygenic Risk Score Knowledge Base offers a centralized online repository for calculating and contextualizing polygenic risk scores
26. The therapeutic prospects and challenges of human neural stem cells for the treatment of Alzheimer's Disease
27. The trend of disruption in the functional brain network topology of Alzheimer’s disease
28. Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease
29. Toxoplasma Gondii a risk factor for Alzheimer's disease infection, in Al-Diwaniyah Governorate, Iraq

1. In vivo neuroimaging evidence of hypothalamic alteration in Prader–Willi syndrome
2. A Computational Monte Carlo Simulation Strategy to Determine the Temporal Ordering of Abnormal Age Onset Among Biomarkers of Alzheimer's Disease
3. A Review of Oxylipins in Alzheimer’s Disease and Related Dementias (ADRD): Potential Therapeutic Targets for the Modulation of Vascular Tone and Inflammation
4. A privileged dual action Alzheimer's disease therapeutic platform targeting immunopathic and proteopathic mechanisms: (E)-3-styrylindoles as inhibitors of indoleamine 2,3-dioxygenase-mediated tryptophan metabolism and β-amyloid aggregation
5. Aberrant energy metabolism in Alzheimer’s disease
6. Alzheimer disease and the evolving treatment landscape
7. Alzheimer’s disease prediction using three machine learning methods
8. Author response: Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum
9. COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease
10. Combining visual rating scales to identify prodromal Alzheimer's disease and Alzheimer's disease dementia in a population from a low and middle-income country
11. Dental Care and Oral Health Maintenance among Alzheimer’s Disease Patients- A Narrative Review
12. Distinct volumetric features of cerebrospinal fluid distribution in idiopathic normal-pressure hydrocephalus and Alzheimer’s disease
13. Evaluating The Accuracy Of Medicare Risk Adjustment For Alzheimer’s Disease And Related Dementias
14. Exploring the key ferroptosis-related gene in the peripheral blood of patients with Alzheimer’s disease and its clinical significance
15. Genetic Causes of Alzheimer’s Disease and the Neuroprotective Role of Melatonin in its Management
16. Hypoglycaemia and the risk of dementia: a population-based cohort study using exposure density sampling
17. Identification of five potential predictive biomarkers for Alzheimer’s disease by integrating the unified test for molecular signatures and weighted gene co-expression network analysis
18. Improving risk indexes for Alzheimer’s disease and related dementias for use in midlife
19. Ketogenic diet prevents chronic sleep deprivation-induced Alzheimer’s disease by inhibiting iron dyshomeostasis and promoting repair via Sirt1/Nrf2 pathway
20. Medicinal importance and pharmacological activities of sciadopitysin in the medicine: Drug target for neuroprotection, myocardial infarction, Alzheimer’s disease, diabetes, and related complications
21. Multitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors
22. National Cohort Study of Homebound Persons Living With Dementia: Antibiotic Prescribing Trends and Opportunities for Antibiotic Stewardship
23. Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer’s disease
24. Neuroimaging Markers for Determining Former American Football Players at Risk for Alzheimer's Disease
25. OS02.5.A Alzheimer-type neuropathological changes in glioblastoma-adjacent cortex
26. Obstructive Sleep Apnea and Hypertension with Longitudinal Amyloid-β Burden and Cognitive Changes
27. Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Biomarker Proteins Reveals Stage-Specific Changes in Alzheimer’s Disease
28. Rationale and design of the “NEurodegeneration: Traumatic brain injury as Origin of the Neuropathology (NEwTON)” study: a prospective cohort study of individuals at risk for chronic traumatic encephalopathy
29. Reduced RNA adenosine-to-inosine editing in hippocampus vasculature associated with Alzheimer’s disease
30. Reduced white matter venous density on MRI is associated with neurodegeneration and cognitive impairment in the elderly
31. Role of Microglia and Astrocytes in Alzheimer’s Disease: From Neuroinflammation to Ca2+ Homeostasis Dysregulation
32. Shared genetic architecture between the two neurodegenerative diseases: Alzheimer’s disease and glaucoma
33. Statistical model for IC₅₀ determination of acetylcholinesterase enzyme for Alzheimer’s disease
34. Targeting Novel microRNAs in Developing Novel Alzheimer's Disease Treatments
35. Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease
36. The economic and societal burden of Alzheimer disease: managed care considerations
37. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
38. The reduction of astrocytic tau prevents amyloid-β-induced synaptotoxicity
39. Theta Band-Power Shapes Amyloid-Driven Longitudinal EEG Changes in Elderly Subjective Memory Complainers At-Risk for Alzheimer’s Disease
40. Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview
41. Vitis vinifera L. Flavones Regulate Hippocampal Neurons via Autophagy in APP/PS1 Alzheimer Model Mice

1. A Precise Computational Method for Hippocampus Segmentation from MRI of Brain to Assist Physicians in the Diagnosis of Alzheimer’s Disease
2. A Study on Voice Measures in Patients With Alzheimer's Disease
3. A case report of nonsurgical idiopathic normal pressure hydrocephalus differentiated from Alzheimer's dementia: Levetiracetam was effective in symptomatic epilepsy
4. A deep learning model for detection of Alzheimer's disease based on retinal photographs: a retrospective, multicentre case-control study
5. A genetically modified minipig model for Alzheimer’s disease with SORL1 haploinsufficiency
6. A shared cognitive and neural basis underpinning cognitive apathy and planning in behavioural-variant frontotemporal dementia and Alzheimer's disease
7. Aducanumab: A new hope in Alzheimer's disease
8. Aerobic Exercise Alleviates Defective Metaplasticity In A Mouse Model Of Alzheimer's Disease
9. Alltagszentrierte Projekte zur Alzheimer-Demenz mit "neurotechprize" ausgezeichnet
10. Alterations of sleep oscillations in Alzheimer's disease: A potential role for GABAergic neurons in the cortex, hippocampus, and thalamus
11. Alzheimer's Association launches ALZ‐NET: A long‐term data collection and sharing network for new treatments
12. Alzheimer's disease is associated with disruption in thiamin transport physiology: A potential role for neuroinflammation
13. Alzheimer's disease risk biomarkers: progress and challenges
14. Alzheimer’s disease diagnosis via multimodal feature fusion
15. Ameliorating Alzheimer’s-like Pathology by Minocycline via Inhibiting Cdk5/p25 Signaling
16. Amyloid fil rouge from invertebrate up to human ageing: A focus on Alzheimer disease
17. Anna, Alzheimer und ich
18. Artificial intelligence for detection of Alzheimer's disease: demonstration of real-world value is required to bridge the translational gap
19. Association between depression, gender and Alzheimer's neuropathology in older adults without dementia
20. Association of B cell profile and receptor repertoire with the progression of Alzheimer’s disease
21. Associations between primary care electrocardiography and non-Alzheimer dementia
22. Associations of cortical iron accumulation with cognition and cerebral atrophy in Alzheimer’s disease
23. Asymmetry of the pupillary light reflex during a cold pressor test
24. Automatic screening of mild cognitive impairment and Alzheimer’s disease by means of posterior-thresholding hesitation representation
25. Black-White variation in the relationship between early educational experiences and trajectories of cognitive function among US-born older adults
26. Blood mRNA Expression in Alzheimer's Disease and Dementia With Lewy Bodies
27. Blood-brain barrier Permeable nanoparticles for Alzheimer's disease treatment by selective mitophagy of microglia
28. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics
29. Caractérisation de la dysfonction mitochondriale dans les cellules immunitaires périphériques chez les patients Alzheimer
30. Caregivers of Adults Living With Alzheimer's Disease or Dementia in 2020: A Secondary Analysis
31. Cerebrospinal fluid sampling for research of Alzheimer’s disease and other neurodegenerative diseases when lumbar punctures are performed by anaesthetists
32. Choroid Plexus Volume and Permeability at Brain MRI within the Alzheimer Disease Clinical Spectrum
33. Circulating levels of vascular endothelial growth factor in patients with Alzheimer’s disease: a case-control study
34. Cognitive and neuroimaging correlates of financial exploitation vulnerability in older adults without dementia: Implications for early detection of Alzheimer’s disease
35. Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
36. Contributions of sex and genotype to exploratory behavior differences in an aged humanized APOE mouse model of late-onset Alzheimer's disease
37. Cost-Effectiveness of an Online Intervention for Caregivers of People Living With Dementia
38. Crossing borders in Alzheimer’s disease: A T cell’s perspective
39. Degradation-driven protein level oscillation in the yeast Saccharomyces cerevisiae
40. Depression in a Patient With Alzheimer Disease
41. Design and development of chitosan-insulin-transfersomes (Transfersulin) as effective intranasal nanovesicles for the treatment of Alzheimer’s disease: In vitro, in vivo, and ex vivo evaluations
42. Developing an integrated cognitive behavioral therapy and motivational interviewing intervention for African Americans with mild cognitive impairment: A pilot study.
43. Development of alumina-based hybrid composite coatings for high temperature erosive and corrosive environments
44. Development of an artificial intelligence‐based diagnostic model for Alzheimer's disease
45. Die Bedeutung des Darm-Mikrobioms für die Alzheimer-Demenz
46. Differentiation of Alzheimer conditions in brain MR images using bidimensional multiscale entropy-based texture analysis of lateral ventricles
47. Discovering epistasis interactions in Alzheimer’s disease using integrated framework of ensemble learning and multifactor dimensionality reduction (MDR)
48. Distinct brain lipid signatures in response to low-level PM2.5 exposure in a 3xTg-Alzheimer's disease mouse inhalation model
49. Divergent magnetic resonance imaging atrophy patterns in Alzheimer's disease and primary age-related tauopathy
50. Down-Syndrom und Alzheimer-Demenz
51. Dysphagia in Alzheimer’s disease: a systematic review
52. EEG coherence as a marker of functional connectivity disruption in Alzheimer's disease
53. Education in the Jim Crow South and Black-White inequities in allostatic load among older adults
54. Effect Of Treadmill Running On Gut Microbiota And Alzheimer’S Disease Neuropathology In Triple Transgenic Mice
55. Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer’s Disease: A Systematic review and Meta-analysis
56. Enhancing autophagy in Alzheimer's disease through drug repositioning
57. Error-prone protein synthesis recapitulates early symptoms of Alzheimer disease in aging mice
58. Estudio CORCOBIA: determinación de puntos de corte de biomarcadores de enfermedad de Alzheimer en LCR en una cohorte clínica
59. Exercise for the prevention of Alzheimer's disease: Multiple pathways to promote non-amyloidogenic AβPP processing
60. Exploring New Vista for Alzheimer's Disease Drug Targets
61. Exploring Plausible Therapeutic Targets for Alzheimer's Disease Using Multi-Omics Approach, Machine Learning and Docking
62. Exploring caregiving stressors and informal resources among Alzheimer's caregivers
63. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data
64. F30 A systematic review of the characteristics of pain assessment tools used with adults with the following neurodegenerative diseases: Huntington’s disease, parkinson’s disease, alzheimer’s disease and lewy bodies dementia
65. Facilitators and barriers for families caring for adults living with Alzheimer's dementia: A qualitative study
66. Factors associated with the 6-minute walk test performance in older adults with hyperkyphosis
67. Fasting-mimicking diet cycles reduce neuroinflammation to attenuate cognitive decline in Alzheimer’s models
68. Feature selection using efficient fusion of Fisher Score and greedy searching for Alzheimer’s classification
69. Fiscal consequences of Alzheimer's disease and informal care provision in the UK: A “government perspective” microsimulation
70. Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: A value of statistical life approach
71. Helping the Helpers – A research protocol for user-centered technology to aid caregiver management of medications for people with Alzheimer's disease and related dementias
72. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
73. Hypothesizing that the intranasal administration of streptozotocin would be a valid model of Alzheimer’s disease-like dementia
74. Identification and characterization of anthocyanins and non-anthocyanin phenolics from Australian native fruits and their antioxidant, antidiabetic, and anti-Alzheimer potential
75. Identification and validation of a gray matter volume network in Alzheimer's disease
76. Identification of potential therapeutic and diagnostic characteristics of Alzheimer disease by targeting the miR-132-3p/FOXO3a-PPM1F axis in APP/PS1 mice
77. Identification of risk genes for Alzheimer’s disease by gene embedding
78. Identifying the role of co-aggregation of Alzheimer’s amyloid-β with amorphous protein aggregates of non-amyloid proteins
79. Incidence, age at diagnosis and survival with dementia across ethnic groups in England: A longitudinal study using electronic health records
80. Indirubin-3′-monoxime-loaded PLGA-PEG nanoparticles for potential Alzheimer's disease treatment
81. Inflammasome activation in traumatic brain injury and Alzheimer's disease
82. Insulin and serine metabolism as sex-specific hallmarks of Alzheimer’s disease in the human hippocampus
83. Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)
84. Intermediate-length CGG repeat expansion in NOTCH2NLC is associated with pathologically confirmed Alzheimer's disease
85. Intermittent theta burst stimulation ameliorates cognitive impairment and hippocampal gliosis in the Streptozotocin-induced model of Alzheimer's disease
86. Intra-bloc tariffs and preferential margins in trade agreements
87. Investigating causal relations between heart failure and Alzheimer's disease: A two-sample Mendelian randomization study
88. Investigation of cognition, nutrition, independence and swallowing difficulty, relationship with quality of life, and effect levels in elderly people with Alzheimer’s disease living with their families
89. Isosteroidal alkaloids of Fritillaria taipaiensis and their implication to Alzheimer's disease: Isolation, structural elucidation and biological activity
90. Issue Information
91. Keep in ‘Mind’ Partnering with the Alzheimer’s Association to Expand Reach and Expertise
92. Kinetics and computational study of butyrylcholinesterase inhibition by methylrosmarinate: relevance to Alzheimer’s disease treatment
93. LP-05 A Novel Targeted Prussian Blue-Based Nanomaterial for Inhibiting Oxidative Stress and Aβ Aggregation of Alzheimer’s Disease
94. LP-28 Lead-exposure associated miRNAs in humans and Alzheimer’s disease: Potential biomarkers of the disease and disease processes
95. LP-61 Search for candidate miRNAs implicated in putative Adverse Outcome Pathway (AOP) relevant to sporadic Alzheimer’s disease
96. La « démentification subjective » comme effet de l’idéologie Alzheimer
97. Longitudinal association between nutritional status and behavioral and psychological symptoms of dementia in older women with mild cognitive impairment and early-stage Alzheimer's disease
98. Longitudinal cognitive change and duration of Alzheimer’s disease stages in relation to cognitive reserve
99. Loss of speech and functional impairment in Alzheimer's disease-related primary progressive aphasia: predictive factors of decline
100. Microbiota alteration and modulation in Alzheimer's disease by gerobiotics: The gut-health axis for a good mind
101. Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer’s disease
102. Mitochondrial function and Aβ in Alzheimer's disease postmortem brain
103. Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer’s disease
104. Mouse models of Alzheimer's disease for preclinical research
105. N-glycan branching enzymes involved in cancer, Alzheimer's disease and COPD and future perspectives
106. NO TITLE
107. Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease
108. Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias
109. Neural network on interval‐censored data with application to the prediction of Alzheimer's disease
110. Neuropathology of depression in non-demented older adults: A large postmortem study of 741 individuals
111. Neuroprotective, lifespan and memory enhancing potential, and molecular docking studies of natural compound from Curculigo orchioides: A study on Alzheimer's disease model of Appl-GAL4 Drosophila melanogaster
112. Neuropsychiatric symptoms and mortality among patients with mild cognitive impairment and dementia due to Alzheimer's disease
113. Novel 2-aminobenzohydrazide derivatives, design, synthesis, anti-Alzheimer evaluation, SAR studies and molecular docking analysis
114. ORAL MYIASIS IN ALZHEIMER'S PATIENT: A CASE REPORT
115. Obstructive sleep apnea and the risk of Alzheimer's disease and Parkinson disease: A Mendelian randomization study OSA, Alzheimer's disease and Parkinson disease
116. Parietal-hippocampal rTMS improves cognitive function in Alzheimer's disease and increases dynamic functional connectivity of default mode network
117. Particulate matter and Alzheimer’s disease: an intimate connection
118. Physicochemistry shapes bioactivity landscape of pan-ABC transporter modulators: Anchor point for innovative Alzheimer's disease therapeutics
119. Phytochemical Based Modulation of Endoplasmic Reticulum Stress in Alzheimer's Disease
120. Phytochemicals-based Therapeutics against Alzheimer's Disease: An Update
121. Pin1 and Alzheimer's Disease
122. Plasma-Biomarker zum Alzheimer-Demenz-Screening
123. Principal components from untargeted cerebrospinal fluid metabolomics associated with Alzheimer's disease biomarkers
124. Progression of socio-cognitive impairment from healthy aging to Alzheimer’s dementia: A systematic review and meta-analysis
125. Protective effect of Huangpu Tongqiao capsule against Alzheimer's disease through inhibiting the apoptosis pathway mediated by endoplasmic reticulum stress in vitro and in vivo
126. Protocol for topology-preserving smoothing of BOLD fMRI retinotopic maps of the human visual cortex
127. Psychedelics for Alzheimer's Disease Palliative Care
128. Public Awareness of Alzheimer’s Disease: A Cross-Sectional Study from Saudi Arabia
129. Pulsion et clinique de la déambulation dans un syndrome de type Alzheimer : une lecture lacanienne
130. Quantifying the impact of Pyramid Squeeze Attention mechanism and filtering approaches on Alzheimer's disease classification
131. Reading language of the eyes
132. Recent Advancements in Strategies for Abnormal Protein Clearance in Alzheimer's Disease
133. Retraction notice to “Osthole attenuates APP-induced Alzheimer's disease through up-regulating miRNA-101a-3p” [Life Sci. 225 (2019) 117–131]
134. Risk factors and a nomogram for frailty in Chinese older patients with Alzheimer's disease: A single-center cross-sectional study
135. SARS-CoV-2 Infection Increases the Gene Expression Profile for Alzheimer’s Disease Risk
136. Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: protocol for the ExPlas study
137. Self-efficacy in controlling upsetting thoughts, but not positive gains, mediates the effects of benefit-finding group intervention for Alzheimer family caregivers.
138. Semantic processing and neurobiology in Alzheimer's disease and Mild Cognitive Impairment
139. Severe tauopathy and axonopathy in the medulla oblongata in Alzheimer’s disease implicate the changes in autonomic nervous function
140. Should we lower or raise levels of amyloid-β in the brains of Alzheimer patients?
141. Sodium propionate improves cognitive and memory function in mouse models of Alzheimer's disease
142. Staging of Alzheimer’s disease: past, present, and future perspectives
143. Structural and functional connectivity abnormalities of the default mode network in patients with Alzheimer's disease and mild cognitive impairment within two independent datasets
144. Structure-Based Drug Design of Novel Piperazine Containing Hydrazone Derivatives as Potent Alzheimer Inhibitors: Molecular Docking and Drug Kinetics Evaluation
145. TCT-45 Cholinesterase Inhibitors Reduce Mortality in Patients With Myocardial Infarction and Alzheimer´s disease
146. TH-227. Structural and functional connectivity changes in patients with Alzheimer’s disease after six months of repetitive transcranial magnetic stimulation over precuneus
147. TH-228. Machine learning classification of Alzheimer’s Disease respect to physiological aging by means of graph theory EEG biomarkers
148. TH-230. Mechanistic understanding of Alzheimer’s disease through hybrid brain models: from mesoscale to macroscale, and design of personalized stimulation protocols
149. TH-231. Network-level permutation entropy of resting-state MEG recordings: A novel biomarker for early-stage Alzheimer’s disease?
150. TU-143. Decreased frontal gamma activity in Alzheimer’s disease patients
151. TU-145. Short and long-term clinical and resting-state EEG results of Transcranial Pulse Stimulation in Alzheimer’s Disease
152. TU-148. A systematic model-based approach to parameter selection for a transcranial direct current stimulation intervention in Alzheimer’s disease
153. TU-149. Brain stimulation via MRT-tracked TPS (transcranial pulse stimulation) – a new method for ameliorating deficits in patients with Alzheimer’s disease
154. TU-150. Neuronavigated magnetic stimulation combined with cognitive training for Alzheimer’s patients: an EEG graph study
155. TU-190. Principal component analysis of auditory ERPs discriminates mild cognitive impairment and Alzheimer’s disease from normal aging
156. TU-192. Alteration of gamma oscillations correlates with cortical tau deposition in Alzheimer’s disease
157. TU-193. Decrease of delta responses during cognitive paradigm in Parkinson’s dementia and lewy body dementia is more severe than Alzheimer’s disease
158. Targeting gut microbiota to alleviate neuroinflammation in Alzheimer’s disease
159. Temporal and Sex-Linked Protein Expression Dynamics in a Familial Model of Alzheimer’s Disease
160. Tensorizing GAN With High-Order Pooling for Alzheimer’s Disease Assessment
161. The Blood–Cerebrospinal Fluid Barrier May Play a Role in Alzheimer Disease Pathogenesis
162. The CX3CL1 intracellular domain exhibits neuroprotection via insulin receptor/ insulin like growth factor receptor signaling
163. The Therapeutic Potential of Restoring Gamma Oscillations in Alzheimer’s Disease
164. The basal forebrain volume reduction detected by MRI does not necessarily link with the cholinergic neuronal loss in the Alzheimer's disease mouse model
165. The future of stem cell therapies of Alzheimer’s disease
166. The promising role of natural products in Alzheimer's disease
167. The road to precision medicine: Eliminating the “One Size Fits All” approach in Alzheimer’s disease
168. The shared genetic architecture of modifiable risk for Alzheimer's disease: a genomic structural equation modelling study
169. Toward inflammation-free therapeutics in Alzheimer’s disease
170. Trained immunity in viral infections, Alzheimer's disease and multiple sclerosis: A convergence in type I interferon signalling and IFNβ-1a
171. Transfer learning for cognitive reserve quantification
172. Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid PET
173. Warburg-like metabolic transformation underlies neuronal degeneration in sporadic Alzheimer’s disease
174. Weißbuch „Volkskrankheit Alzheimer“ präsentiert
175. Z-scan optical method complements the Thioflavin T assay for investigation of anti-Alzheimer's impact of polyphenols
176. “Please Don't Forget Us”: A Descriptive Qualitative Study of Caregivers of Older Adults With Alzheimer's Disease and Related Dementias During the COVID-19 Pandemic

1. A Study of Gene Expression in the Brains of COVID-19, Alzheimer’s Disease, and Vascular Dementia Patients
2. Alzheimer Disease MRI Preprocessed Images: A Machine Intelligent Based Approach for Classification and Analysis
3. Alzheimer’s Disease as a Disease of Evolutionary Mismatch, with a Focus on Reproductive Life History
4. Associations of Peak-Width Skeletonized Mean Diffusivity and Post-Stroke Cognition
5. Caring Experience of Spouse Caregivers of Persons with Alzheimer's Disease: A Qualitative Study
6. Combined Metabolic Activators Improves Cognitive Functions in Alzheimer’s Disease Patients
7. Contribution of hyperglycemia-induced changes in microglia to Alzheimer’s disease pathology
8. Detection of Parkinson’s Disease in Alzheimer’s Patients Utilizing Brain Imaging
9. Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia
10. Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta‐analysis
11. Effects of a Ketogenic and Low Fat Diet on the Human Metabolome, Microbiome and Food-ome in Adults at Risk for Alzheimer’s Disease
12. Electroencephalographic hallmarks of Alzheimer’s disease
13. Evaluation of the state of pharmaceutical supply of patients with dementia with Alzheimer disease in Ukraine in accordance with international recommendations
14. Exploring the Paradox of COVID-19 in Neurological Complications with Emphasis on Parkinson’s and Alzheimer’s Disease
15. Functionality, the capacity to make decisions and awareness in patients suffering from Alzheimer’s disease
16. Global, regional, and national trends of dementia incidence and risk factors, 1990–2019: A Global Burden of Disease study
17. Gut Microbiome and Mycobiome Alterations in an In Vivo Model of Alzheimer’s Disease
18. Herpes Simplex Virus Infection Increases Beta-Amyloid Production and Induces the Development of Alzheimer’s Disease
19. Machine learning algorithms for the diagnosis of Alzheimer and Parkinson disease
20. Multi-Features Fusion in Multi-plane MRI Images for Alzheimer’s Disease Classification
21. Physical activity measurement in older adults: Wearables versus self-report
22. Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
23. RNA hypomethylation and unchanged DNA methylation levels in the cortex of ApoE4 carriers and Alzheimer’s disease subjects
24. Screening for preclinical Alzheimer’s disease: Deriving optimal policies using a partially observable Markov model
25. Severity Classification of Alzheimer Dementia Based on MRI Images Using Deep Neural Network
26. The Effects of Reminiscence Training on Cognitive Function in Elderly with Dementia of the Alzheimer Type: A Systematic Review
27. The PTPIP51 coiled-coil domain is important in VAPB binding, formation of ER-mitochondria contacts and IP3 receptor delivery of Ca2+ to mitochondria
28. The effect of treadmill endurance exercise and PDE5 inhibitor on pathologic features and cognitive function in the mouse model of Alzheimer’s disease
29. The emerging neuroprotective roles of exerkines in Alzheimer’s disease
30. The molecular and functional changes of Neural stem cells in Alzheimer’s disease: Can they be reinvigorated to conduct Neurogenesis
31. “It Encourages Family Discussion”: A Mixed-Methods Examination of the This Is Us Alzheimer’s Disease & Caregiving Storyline

1. A Multimodal Neuroimaging and Neuropsychological Study of Visual Hallucinations in Alzheimer’s Disease
2. A “multi-omics” analysis of blood–brain barrier and synaptic dysfunction in APOE4 mice
3. Alzheimer’s Disease Polygenic Risk Score Is Not Associated With Cognitive Decline Among Older Adults With Type 2 Diabetes
4. Assessment Tools to Evaluate Motor Function in People with Dementia: A Systematic Review
5. Association Between High Serum Tetrahydrofolate and Low Cognitive Functions in the United States: A Cross-Sectional Study
6. Association of Carotid Intima Media Thickening with Future Brain Region Specific Amyloid-β Burden
7. Brain disorder prediction with dynamic multivariate spatio-temporal features: Application to Alzheimer’s disease and autism spectrum disorder
8. Bridging Integrator 1 (BIN1, rs6733839) and Sex Are Moderators of Vascular Health Predictions of Memory Aging Trajectories
9. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
10. Cerebrospinal Fluid Synaptosomal-Associated Protein 25 Levels in Patients with Alzheimer’s Disease: A Meta-Analysis
11. Comparative Analysis of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach
12. Complement 3 Is a Potential Biomarker for Cerebral Amyloid Angiopathy
13. Correction: Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy
14. Correlation Between Plasma Oligomeric Amyloid-β and Performance on the Language Neutral Visual Cognitive Assessment Test in a Southeast Asian Population
15. Costs of Persons with Dementia Living in Nursing Homes in The Netherlands
16. Design, Synthesis, and Biological Evaluation of Notopterol Derivatives as Triple Inhibitors of AChE/BACE1/GSK3β for the Treatment of Alzheimer’s Disease
17. Diabetes, Hypertension, and the Risk of Dementia
18. Differential Diagnosis among Alzheimer's Disease, Mild Cognitive Impairment, and Normal Subjects Using Resting-State fMRI Data Extracted from Multi-Subject Dictionary Learning Atlas: A Deep Learning-Based Study
19. Difficulties with Activities of Daily Living and Receipt of Care Among Older Adults with Cognitive Impairment: Differences Between Those Living Alone and Those Living with Others
20. Does Loss of Integrity of the Cingulum Bundle Link Amyloid-β Accumulation and Neurodegeneration in Alzheimer’s Disease?
21. Dysphagia Profiles Among Inpatients with Dementia Referred for Swallow Evaluation
22. Early Identification of Different Behavioral Phenotypes in the Behavioral Variant of Frontotemporal Dementia with the Aid of the Mini-Frontal Behavioral Inventory (mini-FBI)
23. Effects of a 6-Month Multifaceted Diet and Exercise Intervention on Cognition in Older Adults at Risk of Cognitive Decline: The PONDER Double-Blind, Placebo-Controlled Randomized Trial
24. Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology
25. Establishing an Autopsy-Based Cerebrospinal Fluid Biomarker Signature in Alzheimer Disease Patients
26. IL-37 expression reduces acute and chronic neuroinflammation and rescues cognitive impairment in an Alzheimer’s disease mouse model
27. Impact of hyperactive neuropsychiatric symptoms on brain morphology in mild cognitive impairment and Alzheimer’s disease
28. Incidental Finding: Urine Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP) and Serum Vitamin D25
29. Integrated analysis and identification of hub genes as novel biomarkers for Alzheimer’s disease
30. Joint Computational/Cell-Based Approach for Screening Inhibitors of Tau Oligomerization: A Proof-of-Concept Study
31. Long-Term Depression-Inducing Low Frequency Stimulation Enhances p-Tau181 and p-Tau217 in an Age-Dependent Manner in Live Rats
32. Neuroimaging associations with spatial navigation impairment in Alzheimer’s disease continuum: A narrative review
33. Olfactory Bulb Integrity in Frontotemporal Dementia and Alzheimer’s Disease
34. Oral microbiome and serological analyses on association of Alzheimer's disease and periodontitis
35. Osteoarthritis and APOE4 Interact to Influence Memory Decline in Non-Demented Older People
36. Parkinson’s Disease rs117896735 Variant Regulates INPP5F Expression in Brain Tissues and Increases Risk of Alzheimer’s Disease
37. Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
38. Pharmacological importance of Bacopa monnieri on Neurological disease (Alzheimer’s Disease) and Diabetic neuropathy - A Concise Review
39. Plasma biomarkers and their correlation in adult children of parents with Alzheimer’s disease
40. Polygenic Risk Scores in Alzheimer’s Disease Genetics: Methodology, Applications, Inclusion, and Diversity
41. Population Attributable Fractions for Modifiable Risk Factors of Incident Dementia in Cognitively Normal and Mild Cognitively Impaired Older Adults: Data from Two Cohort Studies
42. Processing of Facial Expressions of Emotions and Pain in Alzheimer’s Disease
43. Rational design of molecular rotor-based fluorescent probes with bi-aromatic rings for efficient in vivo detection of amyloid-β plaques in Alzheimer's disease
44. Reduced Hippocampal and Anterior Cingulate Expression of Antioxidant Enzymes and Membrane Progesterone Receptors in Alzheimer’s Disease with Depression
45. Resilience and resistance to Alzheimer’s disease-associated neuropathological substrates in centenarians: an age-continuous perspective
46. Rich-Club Connectivity of the Structural Covariance Network Relates to Memory Processes in Mild Cognitive Impairment and Alzheimer’s Disease
47. Risk of Dementia in Cancer Survivors: A Meta-Analysis of Population-Based Cohort Studies
48. SORLA mediates endocytic uptake of proIAPP and protects against islet amyloid deposition
49. Screening for Cognitive Impairment with the Quick Memory Check: Validation of a Caregiver Administered Cognitive Screen
50. Selenoprotein P Concentrations in the Cerebrospinal Fluid and Serum of Individuals Affected by Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment and Alzheimer’s Dementia
51. Soluble TREM2 mediates earliest amyloid-associated p-tau increases and cerebral glucose hypermetabolism in Alzheimer’s disease
52. Subjective Cognitive Decline: Is a Resilient Personality Protective Against Progression to Objective Cognitive Impairment? Findings from Two Community-Based Cohort Studies
53. Systemic Injection of Aged Blood Plasma in Adult C57BL/6 Mice Induces Neurophysiological Impairments in the Hippocampal CA1
54. Tau and amyloid biomarkers modify the degree to which cognitive reserve and brain reserve predict cognitive decline
55. The Neuroanatomic Correlates of Olfactory Identification Impairment in Healthy Older Adults and in Persons with Mild Cognitive Impairment
56. The Pictorial Screening Memory Test (P-MIS) for Adults with Moderate Intellectual Disability and Alzheimer’s Disease

1. Alzheimer’s: What You Can Do: Part 1 of 2
2. A Comparative study of Posterior cingulate metabolism in Patients with Mild Cognitive Impairment due to Parkinson’s Disease or to Alzheimer’s Disease
3. A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer’s disease mouse model
4. A low dimensional cognitive-network space in Alzheimer’s disease and frontotemporal dementia
5. A modified 3D EfficientNet for the classification of Alzheimer's disease using structural magnetic resonance images
6. Alzheimer Hastasının Gordon un Fonksiyonel Sağlık Örüntüleri Modeli ne Göre İncelenmesi: Olgu Sunumu
7. Alzheimer’s Disease Severity Is Associated with an Imbalance in Serum Levels of Enzymes Regulating Plasmin Synthesis
8. Alzheimer’s: What You Can Do: Part 2 of 2
9. Biogen’s Aduhelm controversy as a case study for accelerated approval biomarkers in Alzheimer’s and related diseases
10. Cellular transcriptional alterations of peripheral blood in Alzheimer’s disease
11. Circular RNAs in Alzheimer’s Disease: A New Perspective of Diagnostic and Therapeutic Targets
12. Computational Modeling of New Drugs for the Treatment of Alzheimer’s Disease (AD) using Functional Correlations and Artificial Intelligence (AI)
13. Development of quantitative and continuous measure for severity degree of Alzheimer’s disease evaluated from MRI images of 761 human brains
14. Differential microRNA expression analyses across two brain regions in Alzheimer’s disease
15. Difficulties experienced by caregivers of patients with Alzheimer's Disease in relation to dietary care: integrative review
16. Dysfunctional Glymphatic System with Disrupted Aquaporin 4 Expression Pattern on Astrocytes Causes Bacterial Product Accumulation in the CSF during Pneumococcal Meningitis
17. Evidence for the Existence of a Bacterial Etiology for Alzheimer’s Disease and for a Temporal-Spatial Development of a Pathogenic Microbiome in the Brain
18. Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s disease
19. Exposure of metal toxicity in Alzheimer’s disease: An extensive review
20. Genetic Evidence for Protective Effects of Angiotensin-Converting Enzyme Against Alzheimer Disease But Not Other Neurodegenerative Diseases in European Populations
21. Higher performance for women than men in MRI-based Alzheimer’s disease detection
22. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-amyloid Immunotherapy: A Meta-analysis
23. Neural network process simulations support a distributed memory system and aid design of a novel computer adaptive digital memory test for preclinical and prodromal Alzheimer’s disease.
24. Neuropathologic validation of the Alzheimer’s Questionnaire
25. Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross‐Sectional Tau Positron Emission Tomography
26. Overload and Emotional Wellbeing in a Sample of Spanish Caregivers of Alzheimer’s Patients during COVID-19 pandemic
27. Polygenic risk of type 2 diabetes is associated with Vascular Dementia but not with Alzheimer's Disease: a Prospective Cohort Study
28. Progression of Alzheimer's disease parallels unusual structural plasticity of human dentate granule cells
29. Protein arginine methyltransferase 4 modulates nitric oxide synthase uncoupling and cerebral blood flow in Alzheimer's disease

1. Altered retinal cerebral vessel oscillation frequencies in Alzheimer's disease compatible with impaired amyloid clearance
2. Flavonoids as Promising Neuroprotectants and Their Therapeutic Potential against Alzheimer’s Disease
3. Head-to-Head Comparison of Different Blood Collecting Tubes for Quantification of Alzheimer’s Disease Biomarkers in Plasma
4. Influence of genetic and cardiometabolic risk factors in Alzheimer’s disease
5. Reducing variations in multi-center Alzheimer’s disease classification with convolutional adversarial autoencoder
6. The influence of Latino cultural values on the perceived caregiver role of family members with Alzheimer’s disease and related dementias

1. A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease
2. Andrographolide Attenuates Short-Term Spatial and Recognition Memory Impairment and Neuroinflammation Induced by a Streptozotocin Rat Model of Alzheimer’s Disease
3. Carthamus tinctorius L.: A natural neuroprotective source for anti-Alzheimer's disease drugs
4. Controversial Effects of Diverse Types of Toxoplasma gondii on the Anxiety-like Behavior and Cognitive Impairments in the Animal Model of Alzheimer's Disease
5. Discovering epistasis interactions in Alzheimer's disease using deep learning model
6. Effects of Different Lipopolysaccharide Doses on Short- and Long-Term Spatial Memory and Hippocampus Morphology in an Experimental Alzheimer’s Disease Model
7. Modifiable Innate Biology within the Gut–Brain Axis for Alzheimer’s Disease
8. Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study
9. Plasma Lipidomics Approach in Early and Specific Alzheimer’s Disease Diagnosis
10. TRPV1 Modulator Ameliorates Alzheimer-Like Amyloid-β Neuropathology via Akt/Gsk3β-Mediated Nrf2 Activation in the Neuro-2a/APP Cell Model
11. To donate, or not to donate, that is the question: Latino insights into brain donation
12. Unifying framework for cognitive training interventions in brain aging

1. A MUSICOTERAPIA COMO INTERVENÇÃO NA REABILITAÇÃO NEUROPSICOLÓGICA DE PACIENTES COM A DOENÇA DE ALZHEIMER
2. A network pharmacology approach to identify the mechanisms and molecular targets of curcumin against Alzheimer disease
3. A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer’s disease
4. Altered membrane properties but unchanged intrinsic excitability and spontaneous postsynaptic currents in an aged APPswe/PS1dE9 model of Alzheimer’s disease
5. Alzheimer’s Disease: The Case for a Paradigm Shift
6. Alzheimer’s target still viable but untested
7. Application of Micro-Western Array for Identifying Different Serum Protein Expression Profile among Healthy Control, Alzheimer’s Disease Patients and Patients’ Adult Children
8. Calpain Inhibitor Calpeptin Improves Alzheimer’s Disease–Like Cognitive Impairments and Pathologies in a Diabetes Mellitus Rat Model
9. Commentary on Phosphodiesterase 5 Inhibitor Mirodenafil Ameliorates Alzheimer-Like Pathology and Symptoms by Multimodal Actions
10. Crosstalk between acetylation and the tyrosination/detyrosination cycle of α-tubulin in Alzheimer’s disease
11. Focal-type, but not Diffuse-type, Amyloid Beta Plaques are Correlated with Alzheimer’s Neuropathology, Cognitive Dysfunction, and Neuroinflammation in the Human Hippocampus
12. Impact of the COVID-19 Pandemic on Latino Families with Alzheimer’s Disease and Related Dementias: Qualitative Interviews with Family Caregivers and Primary Care Providers (Preprint)
13. In vivo imaging of tau deposition in Alzheimer’s disease using both [18F]-THK5317 and [18F]-S16: A pilot human study
14. Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
15. International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease
16. MUSICOTERAPIA NO TRATAMENTO DO ALZHEIMER
17. News story miscasts Alzheimer’s science
18. Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease
19. Pharmacological activation of the C5a receptor leads to stimulation of the β-adrenergic receptor and alleviates cognitive impairment in a murine model of familial Alzheimer’s disease
20. Phosphorus metabolism in the brain of cognitively normal midlife individuals at risk for Alzheimer's disease
21. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-Analysis
22. Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer’s disease
23. Role of Aβ in Alzheimer’s-related synaptic dysfunction
24. Targeted Mitochondrial Epigenetics: A New Direction in Alzheimer’s Disease Treatment
25. Targeted brain delivery of RVG29‐modified rifampicin‐loaded nanoparticles for Alzheimer's disease treatment and diagnosis
26. Task-dependent learning and memory deficits in the TgF344-AD rat model of Alzheimer’s disease: three key timepoints through middle-age in females
27. The Potential of Small Molecules to Modulate the Mitochondria–Endoplasmic Reticulum Interplay in Alzheimer’s Disease
28. The mechanisms of ferroptosis and its role in alzheimer’s disease

1. A Novel Coupling Model of Physiological Degradation and Emotional State for Prediction of Alzheimer’s Disease Progression
2. A new classification network for diagnosing Alzheimer's disease in class-imbalance MRI datasets
3. AVE 0991 suppresses neuroinflammation of Alzheimer's disease by enhancing autophagy in astrocytes
4. An integrative machine-learning meta-analysis of high-throughput omics data identifies age-specific hallmarks of Alzheimer’s disease
5. Biomarkers of Alzheimer syndrome and related dementias: A&D author's guide
6. Chiral Nanoparticles Force Neural Stem Cell Differentiation to Alleviate Alzheimer's Disease
7. Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer’s disease
8. Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study
9. Comprehensive analysis reveals a 5-gene signature and immune cell infiltration in Alzheimer’s disease with qPCR validation
10. Cu ²⁺ ‐Chelatable and ROS‐Scavenging MXenzyme as NIR‐II‐Triggered Blood–Brain Barrier‐Crossing Nanocatalyst against Alzheimer's Disease
11. Deep Counterfactual-Guided MRI Feature Representation and Quantitatively Interpretable Alzheimer’s Disease Prediction
12. Differential Vulnerability of Hippocampal Subfields in Primary Age-Related Tauopathy and Chronic Traumatic Encephalopathy
13. Disfluency patterns in Alzheimer’s disease and frontotemporal lobar degeneration
14. Effect of White Matter Hyperintensities on Daily Function via Depressive Symptoms: A Longitudinal Study in Patients With Dementia Including Alzheimer’s Disease and Subcortical Ischemic Vascular Dementia
15. Evaluation of Transfer Learning Methods for Detecting Alzheimer’s Disease with Brain MRI
16. Extending the Bioavailability of Hydrophilic Antioxidants for Metal Ion Detoxification via Crystallization with Polysaccharide Dopamine
17. Impaired sharp-wave ripple coordination between the medial entorhinal cortex and hippocampal CA1 of knock-in model of Alzheimer’s disease
18. In Alzheimer-prone brain regions, metabolism and risk-gene expression are strongly correlated
19. Influência do resveratrol no tratamento da doença de Alzheimer: uma revisão da literatura
20. Lack of bidirectional association between age‐related macular degeneration and Alzheimer's disease: A Mendelian randomization study
21. Levetiracetam alleviates cognitive decline in Alzheimer’s disease animal model by ameliorating the dysfunction of the neuronal network
22. Lithium Cholesterol Sulfate: A Novel and Potential Drug for Treating Alzheimer’s Disease and Autism Spectrum Disorder
23. Microglial Activation and Connectivity in Alzheimer Disease and Aging
24. Multimodality Imaging in Primary Progressive Aphasia
25. Musical Bridges to Memory
26. Neuronal cell death mechanisms in Alzheimer’s disease: An insight
27. New Myrtenal–Adamantane Conjugates Alleviate Alzheimer’s-Type Dementia in Rat Model
28. O PAPEL DA RESISTÊNCIA À INSULINA NOS MECANISMOS NATURAIS DE DEFESA DO INDIVÍDUO COM DOENÇA DE ALZHEIMER
29. Optical Redox Imaging of Ex Vivo Hippocampal Tissue Reveals Age-Dependent Alterations in the 5XFAD Mouse Model of Alzheimer’s Disease
30. Protocol: the complexity of informal caregiving for Alzheimer's disease and related dementias in rural South Africa
31. Regional optimum frequency analysis of resting-state fMRI data for early detection of Alzheimer’s disease biomarkers
32. Role of NLRP3 Inflammasome and Its Inhibitors as Emerging Therapeutic Drug Candidate for Alzheimer’s Disease: a Review of Mechanism of Activation, Regulation, and Inhibition

1. CYLD variants identified in Alzheimer's disease and frontotemporal dementia patients
2. A Metabologenomic approach reveals alterations in the gut microbiota of a mouse model of Alzheimer’s disease
3. A comparison of the composition and functions of the oral and gut microbiotas in Alzheimer’s patients
4. ALZHEİMER HASTALIĞI İLE PERİODONTAL HASTALIKLAR ARASINDA BİR İLİŞKİ OLABİLİR Mİ?
5. Alzheimer’s disease classification based on graph kernel SVMs constructed with 3D texture features extracted from MR images
6. Application of PEG-modified Copper-cysteamine in photodynamic therapy for Alzheimer's disease
7. Associations of sensory and motor function with blood-based biomarkers of neurodegeneration and Alzheimer's disease in midlife
8. Atypical Alzheimer’s disease phenotypes with normal or borderline PET biomarker profiles
9. Bio-guided isolation of anti-Alzheimer’s compounds from Phyllanthus niruri and role of niruriflavone in the reversal of aluminum chloride-induced neurobehavioral and biochemical changes in an animal model
10. Convolutional neural networks to predict brain tumor grades and Alzheimer’s disease with MR spectroscopic imaging data
11. Current advances in our understanding of circular RNA (circRNA) in Alzheimer’s disease (AD); the potential utilization of synthetic circRNAs as a therapeutic strategy in the clinical management of AD
12. Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer’s disease in Aotearoa, New Zealand
13. Effects of Acute Sepsis on Cellular Dynamics and Amyloid Formation in a Mouse Model of Alzheimer’s Disease
14. Evaluating the performance of Bayesian and frequentist approaches for longitudinal modeling: application to Alzheimer’s disease
15. Exploring Social Cognition Tests to Differentiate Frontotemporal Dementia from Depression
16. Exploring the role of non-coding RNAs as potential candidate biomarkers in the cross-talk between diabetes mellitus and Alzheimer’s disease
17. How segmentation methods affect hippocampal radiomic feature accuracy in Alzheimer’s disease analysis?
18. Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study
19. Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer’s disease
20. Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2
21. Multi-class Recognition of Alzheimer’s and Parkinson’s diseases using Bag of Deep reduced Features (BoDrF) with Improved Chaotic Multi Verse Harris Hawks Optimization (CMVHHO) and Random Forest (RF) based classification for early diagnosis
22. Parental Education and Delirium Risk after Surgery in Older Adults
23. Pathogenesis and Personalized Interventions for Pharmacological Treatment-Resistant Neuropsychiatric Symptoms in Alzheimer’s Disease
24. Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies
25. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease
26. Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume
27. RESVERATROL AND ITS ANALOGS: NATURAL AMPK AGONISTS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
28. Resetting the circadian clock of Alzheimer’s mice via GLP-1 injection combined with time-restricted feeding
29. Yuan-Zhi decoction in the treatment of Alzheimer’s disease: An integrated approach based on chemical profiling, network pharmacology, molecular docking and experimental evaluation

1. A Methodical and Performance-based Investigation of Alzheimer Disease Detection on Magnetic Resonance and Multimodal Images
2. An Alzheimer’s disease patient-derived olfactory cell model identifies gene expression changes associated with cognition
3. Anodal and cathodal transcranial direct current stimulations of prefrontal cortex in a rodent model of Alzheimer’s disease
4. Autolysosomal acidification failure as a primary driver of Alzheimer disease pathogenesis
5. Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders
6. Combined structure and ligand-based design of dual BACE-1/GSK-3β inhibitors for Alzheimer’s disease
7. Common Variants Near ZIC1 and ZIC4 in Autopsy‐Confirmed Multiple System Atrophy
8. Comparative Bioavailability study of a Novel Multi-day Patch Formulation of Rivastigmine (twice weekly) with Exelon® Transdermal Patch (daily). A randomized clinical trial
9. Discovery of promising cholinesterase inhibitors for Alzheimer's disease treatment through DFT, docking, and molecular dynamics studies of eugenol derivatives
10. Distinct microglia alternative splicing in Alzheimer's disease
11. Dysfunctional Glucose Metabolism in Alzheimer’s Disease Onset and Potential Pharmacological Interventions
12. Evidence for the reliability and validity of a Spanish translation of the Medication Management Ability Assessment administered via tele-assessment
13. Impact of Endocannabinoid Mediated Glial Cells on Cognitive Function in Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Animal Studies
14. Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease
15. Network pharmacology identify intersection genes of quercetin and Alzheimer’s disease as potential therapeutic targets
16. Network synchronization deficits caused by dementia and Alzheimer’s disease serve as topographical biomarkers: a pilot study
17. Novel Phenothiazine/Donepezil-like Hybrids Endowed with Antioxidant Activity for a Multi-Target Approach to the Therapy of Alzheimer’s Disease
18. Preemptive Diagnosis of Alzheimer’s Disease in the Eastern Province of Saudi Arabia Using Computational Intelligence Techniques
19. Reactive astrocyte biomarkers mirror Alzheimer disease pathology
20. SSRI-associated apathy in Alzheimer's disease: a case series
21. The role of oxidative stress in the development of Alzheimer's disease
22. Therapeutic insights elaborating the potential of retinoids in Alzheimer’s disease
23. Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease

1. A systems biology-based identification and in vivo functional screening of Alzheimer’s disease risk genes reveals modulators of memory function
2. Alzheimer’s disease–implicated protein tau puts the squeeze on microtubules
3. Biological determinants of blood‐based cytokines in the Alzheimer's disease clinical continuum
4. CD34⁺ progenitor cells as diagnostic and therapeutic targets in Alzheimer’s disease
5. CRISPR/Cas9 screen in human iPSC‐derived cortical neurons identifies NEK6 as a novel disease modifier of C9orf72 poly(PR) toxicity
6. CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer’s disease
7. Classification of cognitively normal controls, mild cognitive impairment and Alzheimer’s disease using transfer learning approach
8. Decision letter for "Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study"
9. Decision letter for "White matter integrity and key structures affected in Alzheimer’s disease characterized by diffusion tensor imaging"
10. Development and validation of immune-based biomarkers and deep learning models for Alzheimer’s disease
11. Divalent 2-(4-Hydroxyphenyl)benzothiazole Bifunctional Chelators for 64Cu PET Imaging in Alzheimer’s Disease
12. Endosomal trafficking and related genetic underpinnings as a hub in Alzheimer's disease
13. Hiperlipidemia: um fator de risco para o desenvolvimento da doença de alzheimer
14. Identification of genetic molecular markers and immune infiltration characteristics of Alzheimer's disease through weighted gene co-expression network analysis
15. Lysosomal exocytosis releases pathogenic α-synuclein species from neurons in synucleinopathy models
16. Making pre-screening for Alzheimer's disease (AD) and Postoperative delirium among post-acute COVID-19 syndrome - (PACS) a national priority: The Deep Neuro Study
17. Mendelian Randomization Identified CHRNE as a Potential Drug Target for Alzheimer’s disease
18. Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease
19. Non-coding RNAs in Alzheimer’s disease: perspectives from omics studies
20. O uso de Cannabis sativa no tratamento de Alzheimer
21. Predicting Dementia Severity by Merging Anatomical and Diffusion MRI with Deep 3D Convolutional Neural Networks
22. Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer’s disease
23. Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer’s disease
24. TMEM16F may be a new therapeutic target for Alzheimer’s disease
25. Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint
26. Undergraduate nursing students’ knowledge of and attitudes toward people with alzheimer’s disease
27. Unveiling Trail Making Test: visual and manual trajectories indexing multiple executive processes
28. Virtual screening and molecular dynamics study of natural products against Rab10 for the treatment of Alzheimer’s disease
29. White matter hyperintensities in former American football players

1. A Mathematical Investigation of Sex Differences in Alzheimer’s Disease
2. An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer’s Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model
3. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment
4. Development and In Vitro-Ex Vivo Evaluation of Novel Polymeric Nasal Donepezil Films for Potential Use in Alzheimer’s Disease Using Experimental Design
5. Endoplasmic reticulum stress induces Alzheimer disease‐like phenotypes in the neuron derived from the induced pluripotent stem cell with D678H mutation on amyloid precursor protein
6. Observational and genetic studies of C‐reactive protein levels and risk of Alzheimer's disease
7. Pre-symptomatic reduction of individuality in the App^NL-F knock-in model of Alzheimer’s disease
8. Serotonin 5-HT6 Receptor Ligands and Butyrylcholinesterase Inhibitors Displaying Antioxidant Activity—Design, Synthesis and Biological Evaluation of Multifunctional Agents against Alzheimer’s Disease
9. The effect of different SARS‐CoV‐2 variants
10. The effect of different SARS‐CoV‐2 variants: Reply
11. Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer’s Disease
12. “C‐reactive protein levels and risk of dementia”: Subgroup analyses in Mendelian randomization are likely to be misleading

1. AD-EHS: Alzheimer's disease severity detection using efficient hybrid image segmentation
2. Comparing Medial Temporal Atrophy Between Early-Onset Semantic Dementia and Early-Onset Alzheimer's Disease Using Voxel-Based Morphometry: A Multicenter MRI Study
3. Deficient Novelty Detection and Encoding in Early Alzheimer’s Disease: An ERP Study
4. Diagnosing Alzheimer’s Disease Specifically and Sensitively With pLG72 and Cystine/Glutamate Antiporter SLC7A11 AS Blood Biomarkers
5. Doença de alzheimer: atividade anticolinesterásica das plantas alimentícias não convencionais (PANC) uma revisão integrativa narrativa
6. Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading
7. Hippocampal glutathione depletion with enhanced iron level in patients with mild cognitive impairment and Alzheimer’s disease compared with healthy elderly participants
8. Impact of Alzheimer’s Disease on Caregivers in the United States
9. Multiple drugs
10. Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics
11. Saffron as a promising therapy for diabetes and Alzheimer's disease: mechanistic insights
12. Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease
13. Senescence Markers in Peripheral Blood Mononuclear Cells in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease

1. 2,4-Diacetylphloroglucinol Reduces Beta-Amyloid Production and Secretion by Regulating ADAM10 and Intracellular Trafficking in Cellular and Animal Models of Alzheimer’s Disease
2. Association of Enlarged Perivascular Spaces With Amyloid Burden and Cognitive Decline in Alzheimer Disease Continuum
3. Associations of genetic liability for Alzheimer’s disease with cognition and eye movements in a large, population-based cohort study
4. Augmenting neurogenesis rescues memory impairments in Alzheimer’s disease by restoring the memory-storing neurons
5. Cell-associated Transcriptional Alterations in the Retinal of Alzheimer’s Disease
6. Design, synthesis and biological evaluation of novel coumarin derivatives as multifunctional ligands for the treatment of Alzheimer's disease
7. Designing the next-generation clinical care pathway for Alzheimer’s disease
8. Driving Ability Evaluation and Rehabilitation for People With Alzheimer’s Disease and Related Dementias
9. Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer’s disease: a study protocol for a multicenter randomized controlled trial
10. Exercise to Improve Postural Stability in Older Adults with Alzheimer’s Disease: A Systematic Review of Randomized Control Trials
11. Factores que influyen en la sobrecarga de cuidadores informales de pacientes con Trastorno Neurocognitivo debido a enfermedad de Alzheimer
12. HDL-like-Mediated Cell Cholesterol Trafficking in the Central Nervous System and Alzheimer’s Disease Pathogenesis
13. Identification of endoplasmic reticulum stress-associated genes and subtypes for prediction of Alzheimer’s disease based on interpretable machine learning
14. Impact of behavioral and psychological symptoms of Alzheimer’s disease on caregiver outcomes
15. Industrial air pollutant emissions and mortality from Alzheimer's disease in Canada
16. Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I-UDSNB 1.0): development and normative data
17. Memórias, Materialidades e Narrativas na Doença de Alzheimer
18. Neuroprotective activity of selenium nanoparticles against the effect of amino acid enantiomers in Alzheimer’s disease
19. Pharmacological characterization of the α_2A-adrenergic receptor inhibiting rat hippocampal CA3 epileptiform activity: comparison of ligand efficacy and potency
20. Promoting successful participation of people living with Alzheimer's disease and related dementias in pain-related neuroimaging research studies
21. Providing a Purposeful and Stimulating Volunteer Opportunity for Older Adults With Mild Cognitive Impairment
22. Source recognition discriminability impairment in Huntington’s versus Alzheimer’s disease: Evidence from the CVLT-3
23. Substituent Orchestration in Dimethylquinoxaline Derivatives: A Tool for Fishing Out Appropriate CDK5 Inhibitors as Potential Therapeutics for Alzheimer's
24. The effect of bacterial composition shifts in the oral microbiota on Alzheimer's disease
25. VGG-C Transform Model with Batch Normalization to Predict Alzheimer’s Disease through MRI Dataset

1. Aqp4 stop codon readthrough facilitates amyloid-β clearance from the brain
2. A Case of Atypical Alzheimer Disease With Clinical Manifestation That Straddled the Boundary Between Primary Progressive Aphasia and Posterior Cortical Atrophy
3. A circular RNA blood panel that differentiates Alzheimer’s disease from other dementia types
4. Accelerated aging-related transcriptome alterations in neurovascular unit cells in the brain of Alzheimer’s disease
5. Characterizing Plasma Biomarkers of Alzheimer's in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort
6. Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer’s disease
7. Deep learning facilitates fully automated brain image registration of optoacoustic tomography and magnetic resonance imaging
8. Dual-Ligand Near-Infrared Luminescent Lanthanide-Based Metal–Organic Framework Coupled with In Vivo Microdialysis for Highly Sensitive Ratiometric Detection of Zn²⁺ in a Mouse Model of Alzheimer’s Disease
9. Exploring Early Physical Examination Diagnostic Biomarkers for Alzheimer’s Disease Based on Least Absolute Shrinkage and Selection Operator
10. In Vitro Modeling of the Blood–Brain Barrier for the Study of Physiological Conditions and Alzheimer’s Disease
11. Mechanism of Zhinao Capsule in Treating Alzheimer’s Disease Based on Network Pharmacology Analysis and Molecular Docking Validation
12. Plasma Biomarkers of Alzheimer’s Disease Are Associated with Physical Functioning Outcomes Among Cognitively Normal Adults in the Multiethnic HABS-HD Cohort
13. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals
14. Potential of hsa-miR200a-3p and hsa-miR502-3p as blood-based biomarker for Alzheimer's disease
15. Potential utility of plasma p-tau and NfL as surrogate biomarkers for preventive clinical trials
16. Presenilin and Alzheimer’s disease interactions with aging, exercise and high-fat diet: A systematic review
17. Recent insights into viral infections as a trigger and accelerator in alzheimer's disease
18. Review for "Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study"
19. Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer’s disease
20. Single-Cell Transcriptional Profiling and Gene Regulatory Network Modeling in Tg2576 Mice Reveal Gender-Dependent Molecular Features Preceding Alzheimer-Like Pathologies
21. Striatal tau burden is increased in APOE-e4+ mild cognitive impairment
22. Supplemental Material for Neural Network Process Simulations Support a Distributed Memory System and Aid Design of a Novel Computer Adaptive Digital Memory Test for Preclinical and Prodromal Alzheimer’s Disease
23. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
24. The multi-domain exercise intervention for memory and brain function in late middle-aged and older adults at risk for Alzheimer's disease: A protocol for Western–Eastern Brain Fitness Integration Training trial

1. A-100 A Mini-Meta Analysis on Alzheimer’s Disease and Aggression/Agitation Behaviors
2. A-103 Predicting Time to Loss of Independent Living in Alzheimer’s Clinical Syndrome
3. A-104 The Effect of Apathy on Semantic Category Fluency Performance in Alzheimer’s Disease Patients with MCI
4. A-207 Spatial Working Memory in Periadolescent Children: Preliminary Findings from the PRANK Study and Implications for Alzheimer’s Disease & Down Syndrome
5. A-214 A Novel Computerized Cognitive Test for the Detection of MCI and its Association with Neurodegeneration in Alzheimer’s Disease Prone Brain Regions
6. A-5 Accelerated Parietal Cortex Thinning in Middle Aged Adults at Genetic Risk for Alzheimer’s Disease
7. Advances in Research and Treatment on Patients with Alzheimer's disease Induced by Sleep disorders
8. Altered dynamic intrinsic brain activity of the default mode network in Alzheimer’s disease: A resting-state fMRI study
9. Alzheimer’s Amyloid-β Accelerates Cell Senescence and Suppresses the SIRT1/NRF2 Pathway in Human Microglial Cells
10. Alzheimer’s: Alleged image manipulation in seminal paper casts doubt on leading hypothesis of disease
11. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer’s disease
12. Aß Pathology and Neuron–Glia Interactions: A Synaptocentric View
13. Bioactivity of hamamelitannin, flavokawain A, and triacetyl resveratrol as natural compounds: Molecular docking study, anticolon cancer, and anti‐Alzheimer potentials
14. Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
15. C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer’s disease
16. Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer's disease: A current update on molecular mechanisms and combination therapy
17. Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis
18. Energy crisis links to autophagy and ferroptosis in Alzheimer’s disease: current evidence and future avenues
19. Inside Alzheimer's Disease Diagnosis
20. Neuroprotective Effects of Phytochemicals against Aluminum Chloride-Induced Alzheimer’s Disease through ApoE4/LRP1, Wnt3/β-Catenin/GSK3β, and TLR4/NLRP3 Pathways with Physical and Mental Activities in a Rat Model
21. New, Fully Implantable Device for Selective Clearance of CSF-Target Molecules: Proof of Concept in a Murine Model of Alzheimer’s Disease
22. Novel melatonin-trientine conjugate as potential therapeutic agents for Alzheimer’s disease
23. Prediction and Classification of Alzheimer’s Disease using Deep Learning
24. Rational Design, Synthesis of Fluorescence Probes for Quantitative Detection of Amyloid-β in Alzheimer’s Disease Based on Rhodamine-Metal Complex
25. Relation of CDC42 , Th1, Th2, and Th17 cells with cognitive function decline in Alzheimer's disease
26. Research advances in the study of sleep disorders, circadian rhythm disturbances and Alzheimer’s disease
27. Saúde do idoso acamado com Alzheimer durante a pandemia da COVID-19: revisão integrativa
28. Scalable Bayesian functional GWAS method accounting for multivariate quantitative functional annotations with applications to studying Alzheimer’s disease
29. Sex differences in patterns of associative memory-related activation in individuals at risk of Alzheimer's disease
30. Spatio-Temporal Dynamics of Entropy in EEGS during Music Stimulation of Alzheimer’s Disease Patients with Different Degrees of Dementia
31. Synthesis, biological evaluation, and molecular docking study of novel 1,2,4-substituted triazoles as inhibitors of alzheimer’s disease
32. The Gut Microbiota Dysbiosis as a Trigger of Inflammation-Driving Pathogensis of Alzheimer’s Disease
33. The Risk and The Prevention of Alzheimer's Disease and Its Challenges Within These Thirty Years
34. The influence of Alzheimer’s disease stigma on pain assessment in older persons
35. Theoretical insights into chelated metal complexes of herbacetin for the application in Alzheimer’s disease
36. Utilizing Electronic Medical Records Identifies Similarities and Differences in Alzheimer’s Disease Comorbidities Between Racialized Populations
37. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease

1. 3-Hydroxyacyl-CoA and Alcohol Dehydrogenase Activities of Mitochondrial Type 10 17β-Hydroxysteroid Dehydrogenase in Neurodegeneration Study
2. A Comparison of Operational Definitions for Mild Cognitive Impairment
3. A Novel Explainability Approach for Technology-Driven Translational Research on Brain Aging
4. A Validation Study of the Hong Kong Brief Cognitive Test for Screening Patients with Mild Cognitive Impairment and Alzheimer’s Disease
5. Acetylated Tau Protein: A New Piece in the Puzzle between Brain Ischemia and Alzheimer’s Disease
6. Altered Gene Expression in Excitatory Neurons is Associated with Alzheimer’s Disease and Its Higher Incidence in Women
7. An Elicitation Study to Understand Black, Hispanic, and Male Older Adults’ Willingness to Participate in Alzheimer’s Disease-Focused Research Registries
8. Assessment of the Causal Effect of IgG N-Glycosylation Level on Risk of Dementia: A 2-Sample Mendelian Randomization Study
9. Association Between Metformin and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Clinical Observational Studies
10. Association of Depressive Symptoms and Cognition in Older Adults Without Dementia Across Different Biomarker Profiles
11. B Lymphocytes in Alzheimer’s Disease—A Comprehensive Review
12. Clinical Progression of Baseline Risk States for Mild Cognitive Impairment
13. Cognitive training for elderly patients with early Alzheimer’s disease in the Qinghai-Tibet Plateau: A pilot study
14. Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer’s Disease
15. Combined targeting of pathways regulating synaptic formation and autophagy attenuates Alzheimer’s disease pathology in mice
16. Contribution of Memory Tests to Early Identification of Conversion from Amnestic Mild Cognitive Impairment to Dementia
17. Contributions of Caregiver Management Styles to the Discrepancy Between Reported and Observed Task Performance in People with Dementia
18. Convolutional Neural Networks to Classify Alzheimer’s Disease Severity Based on SPECT Images: A Comparative Study (Preprint)
19. Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
20. Efficacy and Moderators of Virtual Reality for Cognitive Training in People with Dementia and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis
21. Elevated Levels of Naturally-Occurring Autoantibodies Against the Extracellular Domain of p75NTR Aggravate the Pathology of Alzheimer’s Disease
22. Endosomal-Lysosomal and Autophagy Pathway in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
23. Evoked Cortical Depolarizations Before and After the Amyloid Plaque Accumulation: Voltage Imaging Study
24. Exercise Training for Mild Cognitive Impairment Adults Older Than 60: A Systematic Review and Meta-Analysis
25. Facets of Personality and Risk of Cognitive Impairment: Longitudinal Findings in a Rural Community from Sardinia
26. Frontal Atrophy and Executive Dysfunction Relate to Complex Numbers Impairment in Progressive Supranuclear Palsy
27. Head holder and cranial window design for sequential magnetic resonance imaging and optical imaging in awake mice
28. Implications of Liver Enzymes in the Pathogenesis of Alzheimer’s Disease
29. Intestinal Flora Balance Therapy Based on Probiotic Support Improves Cognitive Function and Symptoms in Patients with Alzheimer’s Disease: A Systematic Review and Meta-analysis
30. Low Xanthophylls, Retinol, Lycopene, and Tocopherols in Grey and White Matter of Brains with Alzheimer’s Disease
31. Modeling the early stages of Alzheimer’s disease by administering intracerebroventricular injections of human native Aβ oligomers to rats
32. Organized Registration for the Assessment of Dementia by the Nationwide General Consortium Toward Effective Treatment (ORANGE) Registry: Current Status and Perspectives of Mild Cognitive Impairment
33. Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice
34. Perpectivas atuais da terapia antiamiloide para a Doença de Alzheimer
35. Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
36. Polygenic Scores of Alzheimer’s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden
37. Precision Medicine Approach to Alzheimer’s Disease: Successful Pilot Project
38. Prediction of Alzheimer’s Using Random Forest with Radiomic Features
39. Primary and Secondary Care Related Quality Indicators for Dementia Care Among Australian Aged Care Users: National Trends, Risk Factors, and Variation
40. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
41. Redox Active α-Lipoic Acid Differentially Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer and Its Control Cells
42. Regulation of the Human IL-10RB Gene Expression by Sp8 and Sp9
43. Self-perspective Versus Caregiver-perspective on Cognitive Impairment at Different Stages of the Alzheimer’s Continuum
44. The Effects of Normal Aging, Subjective Cognitive Decline, Mild Cognitive Impairment, or Alzheimer’s Disease on Visual Search
45. The Tryptophan Catabolite or Kynurenine Pathway in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
46. The Use of Digital Technology to Assess Cognitive Function in Tunisian Adults
47. The use of artificial neural networks to diagnose Alzheimer’s disease from brain images
48. Understanding the Quality of Life Impacts of Providing Informal Care to People with Dementia: A Systematic Review of Qualitative Studies
49. Upregulated Blood miR-150-5p in Alzheimer’s Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid-β, and Cerebral Atrophy
50. Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer’s Disease in Nordic Populations
51. Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease

1. N-Benzyl Benzamide Derivatives as Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer’s Disease
2. A DOENÇA DE ALZHEIMER E ALTERAÇÕES DO PLEXO CORÓIDE
3. A importância da musicoterapia no tratamento e prognóstico da demência na doença de Alzheimer em pacientes idosos
4. A review of stem cell therapy: An emerging treatment for dementia in Alzheimer's and Parkinson's disease
5. Adult-Onset Deficiency of Mitochondrial Complex III in a Mouse Model of Alzheimer’s Disease Decreases Amyloid Beta Plaque Formation
6. Alzheimer’s Disease and Melatonin/Testosterone/Estrogens: Neurophysiological and Neuroendocrinological Routing of Longevity
7. Association between Human Blood Metabolome and the Risk of Alzheimer's Disease
8. Cases with familial diffuse leukoencephalopathy
9. Circadian dysfunction and Alzheimer's disease – An updated review
10. Create a Device for Identifying the Location of Alzheimer's Patients
11. Dementia with Lewy Bodies and Alzheimer's Disease Sometimes Coexist
12. Dietary choline intake is necessary to prevent systems-wide organ pathology and reduce Alzheimer’s disease hallmarks
13. Differential diagnosis of amnestic dementia patients based on an FDG‐PET signature of autopsy‐confirmed LATE‐NC
14. ER stress and UPR in Alzheimer’s disease: mechanisms, pathogenesis, treatments
15. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer’s disease
16. Impact of alcohol-induced intestinal microbiota dysbiosis in a rodent model of Alzheimer’s disease
17. L-Fucose is a candidate monosaccharide neuromodulator and mitigates Alzheimer’s synaptic deficits
18. Merck enters pact for Alzheimer’s drugs
19. Multifunctionality of Clausena harmandiana Extract and Its Active Constituents against Alzheimer’s Disease
20. Patient Outcomes After Delirium Screening and Incident Alzheimer’s Disease or Related Dementias in Skilled Nursing Facilities
21. Pharmacological Role of Heterocyclic Compounds in the Treatment of Alzheimer’s Disease: A Review
22. Prevalence and Association of Basal Ganglia Calcifications and Depressive Symptoms in Patients With Mild Cognitive Impairment or Dementia
23. Reply to the letter titled, "Dementia with Lewy Bodies and Alzheimer's Disease Sometimes Coexist"
24. Sex differences in risk factors that predict progression from mild cognitive impairment to Alzheimer’s dementia
25. Sirtuins promote brain homeostasis, preventing Alzheimer’s disease through targeting neuroinflammation
26. Structural Scaffolds as Anti- Alzheimer Agents
27. The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease
28. Time-restricted feeding rescues circadian disruption-aggravated progression of Alzheimer's disease in diabetic mice
29. What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?

1. Aaptamine – a dual acetyl – and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent
2. Affiliation Correction: Web-Based Platform (CareVirtue) to Support Caregivers of People Living With Alzheimer Disease and Related Dementias: Mixed Methods Feasibility Study. (Preprint)
3. Epidermal Growth Factor Receptor Kinase Inhibitor Ameliorates β-Amyloid Oligomer-Induced Alzheimer Disease in Swiss Albino Mice
4. Merck, Ceverance collaborate to treat Alzheimer’s
5. Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease
6. Unveiling the anti-Alzheimer, antioxidant, anti-inflammatory, antiviral Therapeutic Functionality of Polysaccharides extracted from Opuntia ficus peels

1. Author response for "White matter integrity and key structures affected in Alzheimer’s disease characterized by diffusion tensor imaging"
2. FAK-Mediated Signaling Controls Amyloid Beta Overload, Learning and Memory Deficits in a Mouse Model of Alzheimer’s Disease
3. Modulation of Inflammatory Mediators and Microglial Activation Through Physical Exercise in Alzheimer’s and Parkinson's Diseases
4. Perspectives and challenges in patient stratification in Alzheimer’s disease
5. Progressive Vascular Abnormalities in the Aging 3xTg-AD Mouse Model of Alzheimer’s Disease
6. Regression‐based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49–79 and comparison with published norms
7. Tau positron emission tomography in preclinical Alzheimer’s disease
8. The potential use of O6-benzylg uanine, and O6-methylguanine for the treatment of alzheimer’s disease, and t. brucei group trypanosomes infections
9. Wine-related flavonols for therapeutic use in Alzheimer’s disease, an in-silico investigation

1. 041 Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis
2. 049 Hippocampal place cell dysfunction in an APP knock-in mouse model of Alzheimer’s disease
3. 052 SKYLINE study design efficacy and safety of gantenerumab in participants at-risk for Alzheimer’s disease
4. A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
5. All roads lead to heterogeneity: The complex involvement of astrocytes and microglia in the pathogenesis of Alzheimer’s disease
6. Alzheimer Cafék online tevékenysége a koronavírus járvány kitörése előtti és utáni fél évben I.
7. Alzheimer Cafék online tevékenysége a koronavírus járvány kitörése előtti és utáni fél évben II.
8. Alzheimer’s Disease Prediction Using Attention Mechanism with Dual-Phase 18F-Florbetaben Images
9. An integrated intervention of computerized cognitive training and physical exercise in virtual reality for people with Alzheimer's disease: The jDome study protocol
10. Autophagy Balances Neuroinflammation in Alzheimer’s Disease
11. Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis
12. Can a serious game-based cognitive training attenuate cognitive decline related to Alzheimer’s disease? Protocol for a randomized controlled trial
13. Circ_0003611 regulates apoptosis and oxidative stress injury of Alzheimer’s disease via miR-383-5p/KIF1B axis
14. Comparison of Functional Connectivity Analysis Methods in Alzheimer’s Disease
15. Comparison of brain microstructure alterations on diffusion kurtosis imaging among Alzheimer’s disease, mild cognitive impairment, and cognitively normal individuals
16. Cortical waste clearance in normal and restricted sleep with potential runaway tau buildup in Alzheimer’s disease
17. Differential Gene Expression in Sporadic and Genetic Forms of Alzheimer’s Disease and Frontotemporal Dementia in Brain Tissue and Lymphoblastoid Cell Lines
18. Diverse Roles of Ceramide in the Progression and Pathogenesis of Alzheimer’s Disease
19. Erratum zu: Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit
20. Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome
21. Fine‐mapping and replication of EWAS loci harboring putative epigenetic alterations associated with AD neuropathology in a large collection of human brain tissue samples
22. Identification and Experimental Validation of Marker Genes between Diabetes and Alzheimer’s Disease
23. Machine Learning-Based Multimodel Computing for Medical Imaging for Classification and Detection of Alzheimer Disease
24. Microglia Impairs Proliferation and Induces Senescence In-Vitro in NGF Releasing Cells Used in Encapsulated Cell Biodelivery for Alzheimer’s Disease Therapy
25. Microglia activation linking amyloid-β drive tau spatial propagation in Alzheimer's disease
26. Multimodal magnetic resonance imaging reveals distinct sensitivity of hippocampal subfields in asymptomatic stage of Alzheimer’s disease
27. Natural remedies for Alzheimer’s disease: A systematic review of randomized controlled trials
28. Nicotinic receptor components of amyloid beta 42 proteome regulation in human neural cells
29. ORP5 and ORP8 orchestrate lipid droplet biogenesis and maintenance at ER–mitochondria contact sites
30. Palliative Care in Advanced Alzheimer’s Disease Dementia: Evaluation of the Answers Given by Caregivers and Physicians to the Accuracy of Surprise Question, as a Prognostic Tool
31. Pimavanserin for the Treatment of Alzheimer’s Disease Psychosis: An Evaluation of the Clinical Importance of Efficacy Results
32. Primate brain pattern-based automated Alzheimer's disease detection model using EEG signals
33. Residual reserve index modifies the effect of amyloid pathology on fluorodeoxyglucose metabolism: Implications for efficiency and capacity in cognitive reserve
34. Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer’s Disease
35. Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
36. The Relationship between Oxidative Stress and Subjective Sleep Quality in People with Coronary Artery Disease

1. A Fast and Robust Strategy to Remove Variant-Level Artifacts in Alzheimer Disease Sequencing Project Data
2. A molecular dynamic approach to a hypothesis on the dynamical behavior of Rosuvastatin on Alzheimer's disease amyloid beta-peptide interactions in the atomic structures
3. A multi-target directed ligands strategy for the treatment of Alzheimer's disease: Dimethyl fumarate plus Tranilast modified Dithiocarbate as AChE inhibitor and Nrf2 activator
4. Aberrant splicing of PSEN2, but not PSEN1, in individuals with sporadic Alzheimer’s disease
5. Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice
6. An MRI-based deep learning approach for accurate detection of Alzheimer’s disease
7. An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
8. Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer’s Disease
9. Decoding the underlying neural activity of neurodegeneration in Alzheimer’s Disease
10. Deep learning of MRI contrast enhancement for mapping cerebral blood volume from single-modal non-contrast scans of aging and Alzheimer's disease brains
11. Deep learning prediction of chemical-induced dose-dependent and context-specific multiplex phenotype responses and its application to personalized alzheimer’s disease drug repurposing
12. Dietary Fiber Modulates the Release of Gut Bacterial Products Preventing Cognitive Decline in an Alzheimer’s Mouse Model
13. Family Typology and 6-Year All-Cause Mortality Among U.S. Chinese Older Adults
14. GRK5 deficiency in the hippocampus leads to Alzheimer’s Disease-like phenotypes via the abnormal microglia alterations
15. Improving Our Understanding of Driving Changes in Preclinical and Early Symptomatic Alzheimer’s Disease: The Role of Naturalistic Driving Studies
16. Individualized diagnosis of preclinical Alzheimer’s Disease using deep neural networks
17. Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer disease
18. Microglia associations with brain pericytes and the vasculature are reduced in Alzheimer’s disease
19. MoCA 7.1: Multicenter Validation of the First Italian Version of Montreal Cognitive Assessment
20. Normalized Theta but Increased Gamma Activity after Acetylcholinesterase Inhibitor Treatment in Alzheimer’s Disease: Preliminary qEEG Study
21. Penalized decomposition using residuals (PeDecURe) for feature extraction in the presence of nuisance variables
22. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
23. QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics
24. Stage-independent biomarkers for Alzheimer’s disease from the living retina: an animal study
25. Targeting NLRP3-Mediated Neuroinflammation in Alzheimer’s Disease Treatment
26. The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease
27. The causes and consequences of Alzheimer’s disease: phenome-wide evidence from Mendelian randomization
28. The genetic and environmental etiology of blood-based biomarkers related to risk of Alzheimer’s Disease in a population-based sample of early old-age men
29. The role of neutrophils in the dysfunction of central nervous system barriers
30. Triiodothyronine Treatment reverses Depression-Like Behavior in a triple-transgenic animal model of Alzheimer’s Disease
31. Zinc finger protein 33B demonstrates sex-interaction with atopy-related markers in childhood asthma

1. A multidimensional ODE-based model of Alzheimer's disease progression
2. An effective convolutional neural network-based stacked long short-term memory approach for automated Alzheimer’s disease prediction
3. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
4. Calcium inhibits penetration of Alzheimer's Aβ ₁ – ₄₂ monomers into the membrane
5. Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study
6. Design and Evaluation of Solid Lipid Microparticles of Curcumin for the Treatment of Alzheimer’s Disease
7. Diagnosis of Alzheimer's disease using structure highlighting key slice stacking and transfer learning
8. Dual PET-fMRI reveals a link between neuroinflammation, amyloid binding and compensatory task-related brain activity in Alzheimer’s disease
9. EAAT2 as a therapeutic research target in Alzheimer's disease: A systematic review
10. Early Changes in Transcriptomic Profiles in Synaptodendrosomes Reveal Aberrant Synaptic Functions in Alzheimer’s Disease
11. Effect of cognitive reserve on amnestic mild cognitive impairment due to Alzheimer’s disease defined by fluorodeoxyglucose-positron emission tomography
12. Evaluating Racial/Ethnic Equity in Planning-Related U.S. Health Impact Assessments Involving Parks and Greenspaces
13. Genetic variant rs11136000 upregulates clusterin expression and reduces Alzheimer’s disease risk
14. Genome‐wide profiling of circulatory microRNAs associated with cognition and dementia
15. Hierarchical multi-class Alzheimer’s disease diagnostic framework using imaging and clinical features
16. Identification of influential probe types in epigenetic predictions of human traits: implications for microarray design
17. MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer’s Disease
18. Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study
19. Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders
20. Primitive detection of Alzheimer’s disease using neuroimaging: A progression model for Alzheimer’s disease: Their applications, benefits, and drawbacks
21. Protective effect of apolipoprotein E epsilon 3 on sporadic Alzheimer’s disease in the Chinese population: a meta-analysis
22. Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
23. Using genetic analysis to understand the relationship of cognitive traits with peptic ulcer and Alzheimer’s disease

1. 1-L Transcription in Alzheimer’s Disease
2. 2-Mercaptobenzimidazole clubbed hydrazone for Alzheimer’s therapy: In vitro, kinetic, in silico, and in vivo potentials
3. A CAD System for Alzheimer’s Disease Classification Using Neuroimaging MRI 2D Slices
4. Alzheimer’s Disease: Molecular Biology, Pathophysiology and Biomarkers
5. An explainable self-attention deep neural network for detecting mild cognitive impairment using multi-input digital drawing tasks
6. Analysis of ROQUIN, Tristetraprolin (TTP), and BDNF/miR-16/TTP regulatory axis in late onset Alzheimer’s disease
7. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer’s Disease?
8. Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer’s disease
9. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease
10. Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer’s disease: A systematic review and network meta-analysis
11. Detection of Alzheimer’s Dementia by Using Signal Decomposition and Machine Learning Methods
12. Downregulating PTBP1 Fails to Convert Astrocytes into Hippocampal Neurons and to Alleviate Symptoms in Alzheimer's Mouse Models
13. Faculty Opinions recommendation of Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation.
14. Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology
15. GC-CNNnet: Diagnosis of Alzheimer’s Disease with PET Images Using Genetic and Convolutional Neural Network
16. Histopathological Analysis of Cerebral Microvasculature Pathology with Alzheimer’s Disease Neuropathological Changes: An Autopsy Study
17. Induction of A Disintegrin and Metalloproteinase with Thrombospondin motifs 1 by a rare variant or cognitive activities reduces hippocampal amyloid-β and consequent Alzheimer’s disease risk
18. Melatonin Ameliorates the Progression of Alzheimer’s Disease by Inducing TFEB Nuclear Translocation, Promoting Mitophagy, and Regulating NLRP3 Inflammasome Activity
19. Neuropharmacology in Alzheimer and Huntington Disease
20. Novel 3-aminobenzofuran derivatives as multifunctional agents for the treatment of Alzheimer’s disease
21. On Extracting Digitized Spiral Dynamics’ Representations: A Study on Transfer Learning for Early Alzheimer’s Detection
22. Racial/ethnic disparities in the enrollment of Medication Therapy Management programs among Medicare beneficiaries with Alzheimer’s disease and related dementias
23. Recent advances of small molecule JNK3 inhibitors for Alzheimer’s disease
24. Simultaneous Sensing of H₂S and ATP with a Two-Photon Fluorescent Probe in Alzheimer’s Disease: toward Understanding Why H₂S Regulates Glutamate-Induced ATP Dysregulation
25. To My Husband With Alzheimer Disease
26. Treatment with IgM ‐enriched intravenous immunoglobulins enhances clearance of stroke‐associated bacterial lung infection

1. A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice
2. Alzheimer's disease medication use and adherence patterns by race and ethnicity
3. Anti-Inflammatory Activity of 4-(4-(Heptyloxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one via Repression of MAPK/NF-κB Signaling Pathways in β-Amyloid-Induced Alzheimer’s Disease Models
4. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia: a Cochrane Review
5. Contribution of blood-brain barrier-related blood-borne factors for Alzheimer’s disease vs. vascular dementia diagnosis: A pilot study
6. Corpora amylacea are associated with tau burden and cognitive status in Alzheimer’s disease
7. Diagnose Alzheimer's disease by combining 3D discrete wavelet transform and 3D moment invariants
8. Dimethyl Itaconate Reduces Cognitive Impairment and Neuroinflammation in APPswe/PS1ΔE9 Transgenic Mouse Model of Alzheimer’s Disease
9. Exosomal MicroRNAs modulate the cognitive function in fasudil treated APPswe/PSEN1dE9 transgenic (APP/PS1) mice model of Alzheimer's disease
10. Exploration of combined physical activity and music for patients with Alzheimer’s disease: A systematic review
11. Extracellular vesicles and Alzheimer’s disease in the novel era of Precision Medicine: implications for disease progression, diagnosis and treatment
12. Forest Biomass as a Promising Source of Bioactive Essential Oil and Phenolic Compounds for Alzheimer’s Disease Therapy
13. Impact of constipation on progression of Alzheimer's disease: A retrospective study
14. Multiomics profiling of human plasma and CSF reveals ATN derived networks and highlights causal links in Alzheimer’s disease
15. Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta‐analysis
16. Nomograms of human hippocampal volume shifted by polygenic scores
17. Prediction of Alzheimer’s Disease by a Novel Image-Based Representation of Gene Expression
18. Seed-induced Aβ deposits in the corpus callosum disrupt white matter integrity in a mouse model of Alzheimer’s disease
19. Serine ether glycerophospholipids: Decrements in the frontal cortex associated with mild cognitive impairment and Alzheimer’s disease
20. Structural Analysis and Conformational Dynamics of Short Helical Hyperphosphorylated Segments of Tau Protein (Sequence 254–290) in Alzheimer’s Disease: A Molecular Dynamics Simulation Study
21. Synaptosome microRNAs regulate synapse functions in Alzheimer’s disease
22. Textural features reflecting local activity of the hippocampus improve the diagnosis of Alzheimer’s disease and amnestic mild cognitive impairment: A radiomics study based on functional magnetic resonance imaging
23. The challenges of anti-tau therapeutics in Alzheimer disease
24. The cognitive performance in the Phototest is predictor of biological markers of Alzheimer's disease

1. AT[N]-net
2. Alzheimer's genetic risk effects on cerebral blood flow across the lifespan are proximal to gene expression
3. Deep learning-based alzheimer disease detection techniques
4. Multitargeting the Action of 5-HT6 Serotonin Receptor Ligands by Additional Modulation of Kinases in the Search for a New Therapy for Alzheimer’s Disease: Can It Work from a Molecular Point of View?
5. Neuronal network-based biomimetic chip for long-term detection of olfactory dysfunction model in early-stage Alzheimer's disease
6. Plasma exchange: An effective method to eliminate neurotoxic lipophilic chemicals from blood
7. Using Alzheimer's disease blood tests to accelerate clinical trial enrollment
8. circAβ RNA drives the formation and deposition of β-amyloid plaques in the sporadic Alzheimer’s disease

1. Advances in polysaccharides of natural source of the anti-Alzheimer's disease effect and mechanism
2. Combined ligand-based and structure-based design of PDE 9A inhibitors against Alzheimer’s disease
3. Ethnic Differences in Attitudes and Preventive Behaviors Related to Alzheimer’s Disease in the Israeli Survey of Aging
4. Life-space, frailty, and health-related quality of life
5. Multi-ancestry meta-analysis and fine-mapping in Alzheimer’s Disease
6. Role of micronutrients in Alzheimer's disease: Review of available evidence

1. A diagnostic index based on pseudo-continuous arterial spin labeling and T1-mapping improves efficacy in discriminating Alzheimer’s disease from normal cognition
2. Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
3. Assessing the Influence of Salvia Triloba on Memory Deficit Caused by Sleep Deprivation in the context of Oxidative Stress
4. Ayurvedic Herbal Therapies: A Review of Treatment and Management of Dementia.
5. Brain aging, Alzheimer's disease, and the role of stem cells in primate comparative studies
6. Decision letter for "Oral microbiome and serological analyses on association of Alzheimer's disease and periodontitis"
7. Dendrimers: A Neuroprotective Lead in Alzheimer Disease: A Review on its Synthetic approach and Applications
8. Detecting Primary Progressive Aphasia Atrophy Patterns: A Comparison of Visual Assessment and Quantitative Neuroimaging Techniques
9. Development of Iron Nanoparticles (FeNPs) Using Biomass of Enterobacter: Its Characterization, Antimicrobial, Anti-Alzheimer’s, and Enzyme Inhibition Potential
10. Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease
11. Discovery and validation of dominantly inherited Alzheimer’s disease mutations in populations from Latin America
12. Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP
13. Effects of Selenium Supplementation in Patients with Mild Cognitive Impairment or Alzheimer’s Disease: A Systematic Review and Meta-Analysis
14. Effects of an essential amino acid mixture on behavioral and psychological symptoms of dementia and executive function in patients with Alzheimer's disease: A double‐blind, randomized, placebo‐controlled exploratory clinical trial
15. Elevated plasma zonulin and CAF22 are correlated with sarcopenia and functional dependency at various stages of Alzheimer’s diseases
16. Endophenotypic effects of the SORL1 variant rs2298813 on regional brain volume in patients with late-onset Alzheimer’s disease
17. Exendin-4 alleviates β-Amyloid peptide toxicity via DAF-16 in a Caenorhabditis elegans model of Alzheimer's disease
18. Global cognitive trajectory patterns in Alzheimer’s disease – CORRIGENDUM
19. Human microRNA-4433 (hsa-miR-4443) Targets 18 Genes to be a Risk Factor of Neurodegenerative Diseases
20. Investigating the power of eyes open resting state EEG for assisting in dementia diagnosis
21. Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?
22. Kaempferol as a potential neuroprotector in Alzheimer's disease
23. Lithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice Model of Alzheimer’s Disease
24. Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome
25. Metalloenzymes for the Potent Treatment of Alzheimer’s Disease and Parkinson’s Disease: A Review
26. Mild behavioral impairment: an early sign and predictor of Alzheimer's disease dementia
27. Moxifloxacin Disrupts and Attenuates Aβ42 Fibril and Oligomer Formation: Plausibly Repositioning an Antibiotic as Therapeutic against Alzheimer’s Disease
28. Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer’s disease
29. Predictive Model Uses MRI to More Accurately Diagnose Alzheimer's
30. Psychiatric and Psychosocial Characteristics of a Cohort of Spanish Individuals Attending Genetic Counseling Due to Risk for Genetically Conditioned Dementia
31. Quantitative susceptibility mapping as an imaging biomarker for Alzheimer’s disease: The expectations and limitations
32. Ratings of the reasons for and against the disclosure of an Alzheimer’s disease diagnosis: has anything changed in the past 20 years?
33. Rodent model preclinical assessment of PEGylated block copolymer targeting cognition and oxidative stress insults of Alzheimer’s disease
34. Salivary Testosterone and Cortisol Levels in Tunisian Elderly Male Patients With Mild Alzheimer’s Disease. Implications of Musical Therapy And/Or Physical Rehabilitation
35. Serine racemase expression differentiates aging from Alzheimer’s brain
36. Structural Correlates of Overt Sentence Reading in Mild Cognitive Impairment and Mild-to-Moderate Alzheimer’s Disease
37. Temporal Cortical Thickness and Cognitive Associations among Typical and Atypical Phenotypes of Alzheimer’s Disease
38. Ten-Year Trends in Sales of Alzheimer Disease Drugs in France Compared With Sales in Germany, Spain, and the UK
39. The effect of chronic stress and its preconditioning on spatial memory as well as hippocampal LRP1 and RAGE expression in a streptozotocin-induced rat model of Alzheimer’s disease
40. The protective effects of dietary polyphenols on Alzheimer's disease
41. The survey for memory, attention, and reaction time (SMART): Preliminary normative online panel data and user attitudes for a brief web-based cognitive performance measure
42. Validation of the Alzheimer’s disease-resemblance atrophy index in classifying and predicting progression in Alzheimer’s disease
43. What Biological Factors, Social Determinants, and Psychological and Behavioral Symptoms of Patients with Mild Alzheimer’s Disease Correlate with Caregiver Estimations of Financial Capacity? Bringing Biases Against Older Women Into Focus
44. What are the Risk Factors for Alzheimer's Disease?
45. Why is Alzheimer’s Disease More Prevalent in the Hispanic Community?

1. A Web-Based Platform (CareVirtue) to Support Caregivers of People Living With Alzheimer Disease and Related Dementias: Mixed Methods Feasibility Study
2. ASPECTOS CONSIDERADOS PELO ENFERMEIRO NO CUIDADO AO BINÔMIO DEMENCIADO(A)/CUIDADOR(A) NO MANEJO DO ALZHEIMER: UMA REVISÃO INTEGRATIVA
3. Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan
4. Alzheimer’s Disease and the Neurobiology of Long-Term Memory Formation
5. Association between serum total bilirubin and Alzheimer's disease: A bidirectional Mendelian randomization study
6. Autocorrection if→of function words in reading aloud: A novel marker of Alzheimer’s risk.
7. Combination of Dexamethasone and Tofacitinib Reduces Xenogeneic MSC-Induced Immune Responses in a Mouse Model of Alzheimer’s Disease
8. Design and Development of Benzothiazole-Based Fluorescent Probes for Selective Detection of Aβ Aggregates in Alzheimer’s Disease
9. Design synthesis and In vitro evaluation of Tacrine- Flavone hybrids as Multifunctional Cholinesterase inhibitors for Alzheimer’s disease
10. Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer’s Disease
11. Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase‐1A (DYRK1A), A Master Regulatory Protein Involved in Down Syndrome Brain Alterations and Mental Disability, A Key Contributor to Neurodegenerative Disorders of Alzheimer's Disease and A Potential Therapeutic Target
12. Effects of Combining Biofactors on Bioenergetic Parameters, Aβ Levels and Survival in Alzheimer Model Organisms
13. Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer’s disease: Current trends and future perspectives
14. Genetic Variant for Alzheimer's Disease May Increase Risk of Chronic Traumatic Encephalopathy After Repetitive Head Impact
15. High consumption of whole grain foods decreases the risk of dementia and Alzheimer's disease: Framingham Offspring Cohort (Preprint)
16. Identification of molecular signatures associated with sleep disorder and Alzheimer’s disease
17. Integrated comparative metabolomics and network pharmacology approach to uncover the key active ingredients of Polygonati rhizoma and their therapeutic potential for the treatment of Alzheimer’s disease
18. Integrating transcriptome and chemical analyses to reveal the anti-Alzheimer’s disease components in Verbena officinalis Linn
19. Linnaeite Mineral for NIR Light-Triggered Disruption of Alzheimer’s Pore-Forming Aβ Oligomers
20. Novel (p-tolyl)-3(2H)-pyridazinone derivatives containing substituted-1,2,3-triazole moiety as new anti-Alzheimer agents: Synthesis, in vitro and in silico assays
21. Predicting real world spatial disorientation in Alzheimer’s disease patients using virtual reality navigation tests
22. Retinal Vascular Physiology Biomarkers in a 5XFAD Mouse Model of Alzheimer’s Disease
23. Seeing the Woods for the Trees? Applying Diagnostic Criteria for Dementia with Lewy Bodies to Patients Presenting with Posterior Cortical Atrophy
24. Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies
25. Testing the link between isoaspartate and Alzheimer's disease etiology
26. Therapeutic effect and mechanism of Anemarrhenae Rhizoma on Alzheimer’s disease based on multi-platform metabolomics analyses
27. β Bursting in the Retrosplenial Cortex Is a Neurophysiological Correlate of Environmental Novelty Which Is Disrupted in a Mouse Model of Alzheimer's Disease

1. A Study to assess the effectiveness of Structured Teaching Programme on knowledge regarding Alzheimer disease among the family member of elderly person in selected area at Udaipur city
2. APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants
3. Adiponectin, the adiponectin paradox, and Alzheimer’s Disease: Is this association biologically plausible?
4. Alzheimer's and Parkinson's disease therapies in the clinic
5. Anticholinesterase agents for Alzheimer's Disease treatment: an updated overview.
6. Cognitive resilience depends on white matter connectivity: The Maastricht Study
7. Cornuside Is a Potential Agent against Alzheimer’s Disease via Orchestration of Reactive Astrocytes
8. Cumulative loneliness and subsequent memory function and rate of decline among adults aged ≥50 in the United States, 1996 to 2016
9. Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach
10. Epigenetic regulation of synaptic disorder in Alzheimer’s disease
11. Genistein attenuates memory impairment in Alzheimer's disease via ERS-mediated apoptotic pathway in vivo and in vitro
12. Gut microbiota may be involved in Alzheimer’s disease pathology by dysregulating pyrimidine metabolism in APP/PS1 mice
13. Hybrid Nature-Inspired Algorithm for Feature Selection in Alzheimer Detection Using Brain MRI Images
14. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
15. Linking glycosphingolipids to Alzheimer’s amyloid-ß: extracellular vesicles and functional plant materials
16. Lipolysis-Stimulated Lipoprotein Receptor Acts as Sensor to Regulate ApoE Release in Astrocytes
17. Metformin and Dementia Risk: A Systematic Review with Respect to Time Related Biases
18. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
19. Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain
20. Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
21. Polygenic risk score analysis identifies deleterious protein-coding variants in novel immune pathway genes ATP8B4, FCGR1A, and LILRB1 that associate with Alzheimer’s disease.
22. Publisher Correction: Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes
23. Review for "Oral microbiome and serological analyses on association of Alzheimer's disease and periodontitis"
24. Sleep Movements and Respiratory Coupling as a Biobehavioral Marker for Early Alzheimer’s Disease in Independently Dwelling Adults
25. Targeting microglial autophagic degradation of the NLRP3 inflammasome for identification of thonningianin A in Alzheimer’s disease
26. Tau–FG-nucleoporin98 interaction and impaired nucleocytoplasmic transport in Alzheimer’s disease
27. Transcranial Electromagnetic Treatment Stops Alzheimer’s Disease Cognitive Decline over a 2½-Year Period: A Pilot Study
28. Versatile Dicyanomethylene-Based Fluorescent Probes for the Detection of β-Amyloid in Alzheimer’s Disease: A Theoretical Perspective

1. Alteration of Gut Microbiota in Alzheimer’s Disease and Their Relation to the Cognitive Impairment
2. Alzheimer’s Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment
3. Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer’s Disease Prior to Overt Global Amyloid Positivity
4. Anti-Tau Antibody Semorinemab Fails to Slow Alzheimer Disease
5. Association Between Estimated Pulse Wave Velocity and Cognitive Performance in Older Black and White Adults in NHANES
6. Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals
7. Automated Early Detection of Alzheimer’s Disease by Capturing Impairments in Multiple Cognitive Domains with Multiple Drawing Tasks
8. Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria
9. Characterization of Early Alzheimer’s Disease-Like Pathological Alterations in Non-Human Primates with Aging: A Pilot Study
10. Cognitive Decline Risk Stratification in People with Late-Onset Epilepsy of Unknown Etiology: An Electroencephalographic Connectivity and Graph Theory Pilot Study
11. Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms
12. DAPI (4’,6-diamidino-2-phenylindole) Stains Compact Amyloid Plaques
13. Development of a system to analyze oral frailty associated with Alzheimer's disease using a mouse model
14. Diet Patterns, the Gut Microbiome, and Alzheimer’s Disease
15. Dietary Methylglyoxal Exposure Induces Alzheimer’s Disease by Promoting Amyloid β Accumulation and Disrupting Autophagy in Caenorhabditis elegans
16. Differential Diagnosis Between Alzheimer’s Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid-β Imaging?
17. Differing Methodologies Are Required to Estimate Prevalence of Dementia: Single Study Types Are No Longer Reliable
18. Does APOE ɛ4 Status Change How 24-Hour Time-Use Composition Is Associated with Cognitive Function? An Exploratory Analysis Among Middle-to-Older Adults
19. Early Prediction of a Pre-Symptomatic Neurodegeneration Disorder by Measuring Macrophage Inhibitory Factor Level in Diabetic Patients
20. Efficacy and Safety of Chinese Herbal Medicines Combined with Chemical Drugs for Alzheimer's Disease: A Systematic Review and Meta-Analysis
21. Elevated Plasma Orexin-A Levels in Prodromal Dementia with Lewy Bodies
22. Functional Neurophysiological Biomarkers of Early-Stage Alzheimer’s Disease: A Perspective of Network Hyperexcitability in Disease Progression
23. Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease
24. Increased Financial Altruism is Associated with Alzheimer’s Disease Neurocognitive Profile in Older Adults
25. Informal Caregivers’ Attitude Toward Dementia: The Impact of Dementia Knowledge, Confidence in Dementia Care, and the Behavioral and Psychological Symptoms of the Person with Dementia. A Cross-Sectional Study
26. Is dietary choline intake related to dementia and Alzheimer's disease risks? Results from the Framingham Heart Study
27. Low Serum Insulin-like Growth Factor-I Is Associated with Decline in Hippocampal Volume in Stable Mild Cognitive Impairment but not in Alzheimer’s Disease
28. Multi-task longitudinal forecasting with missing values on Alzheimer’s disease
29. Natural Pattern of Cognitive Aging
30. Non-Modifiable Factors as Moderators of the Relationship Between Physical Activity and Brain Volume: A Cross-Sectional UK Biobank Study
31. Noninvasive Antemortem Detection of Retinal Prions by a Fluorescent Tracer
32. Nonobese Male Patients with Alzheimer’s Disease Are Vulnerable to Decrease in Plasma Leptin
33. PILRA polymorphism modifies the effect of APOE4 and GM17 on Alzheimer’s disease risk
34. Pharmacologic Stabilization of Retromer Rescues Endosomal Pathology Induced by Defects in the Alzheimer’s gene SORL1
35. Posterior pole analysis and ganglion cell layer measurements in Alzheimer’s disease
36. Poststroke cognitive impairment: a longitudinal follow-up and pre/poststroke mini-mental state examination comparison
37. Potential Involvement of Varicella Zoster Virus in Alzheimer’s Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1
38. Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults
39. Prevalence of Depressive Symptoms in a Memory Clinic Cohort: A Retrospective Study
40. Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer’s Disease APP/PS1 Mouse Model
41. Putting participants and study partners FIRST when clinical trials end early
42. Quantitative Assessment of Cortical Excitability in Alzheimer’s Dementia and Its Association with Clinical Symptoms: A Systematic Review and Meta-Analyses
43. Recommendations for Preclinical Testing of Treatments Against Alzheimer’s Disease-Related Epileptiform Spikes in Transgenic Rodent Models
44. Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer’s Disease
45. Regulatory Effect of Adipose-Derived Mesenchymal Stem Cells and/ or Acitretin on Adam10 Gene in Alzheimer's Disease Rat Model
46. Releasing the Butterfly: A Love Affair in Four Acts by Max Sherman, 2020, 280 pp.
47. Review for "Oral microbiome and serological analyses on association of Alzheimer's disease and periodontitis"
48. Risk of Alzheimer’s Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching
49. Screening of active ingredients in Kaixin Powder for Alzheimer’s disease based on molecular docking
50. Selective disruption of Drp1-independent mitophagy and mitolysosome trafficking by an Alzheimer’s disease relevant tau modification in a novel Caenorhabditis elegans model
51. Self-reported sleepiness associates with greater brain and cortical volume and lower prevalence of ischemic covert brain infarcts in a community sample
52. Sleep duration, genetic susceptibility, and Alzheimer's disease: a longitudinal UK Biobank-based study
53. Survey of Different Techniques to Detect Alzheimer’s Disease
54. Synthetic PPAR Agonist DTMB Alleviates Alzheimer’s Disease Pathology by Inhibition of Chronic Microglial Inflammation in 5xFAD Mice
55. TREM2 Deficiency Disrupts Network Oscillations Leading to Epileptic Activity and Aggravates Amyloid-β-Related Hippocampal Pathophysiology in Mice
56. The Associations of Cerebrospinal Fluid Ferritin with Neurodegeneration and Neuroinflammation Along the Alzheimer’s Disease Continuum
57. The Dark Side of Alzheimer’s Disease: Neglected Physiological Biomarkers of Brain Hyperexcitability and Abnormal Consciousness Level
58. Therapeutic Effects and Metabolic Spectrum of Traditional Chinese Medicine Hengqing II Prescription on Alzheimer’s Disease
59. Traumatic Brain Injury and Risk of Alzheimer’s Disease and Related Dementias in the Population
60. Vestibular therapy to reduce falls in people with Alzheimer’s disease: study protocol for a pilot randomized controlled trial

1. A Morphology-Driven Method for Measuring Technology Complementarity: Empirical Study Involving Alzheimer's Disease
2. A Novel Segment White Matter Hyperintensities Approach for Detecting Alzheimer
3. A modified residual network for detection and classification of Alzheimer’s disease
4. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies
5. Aduhelm for Alzheimer’s: Questions Remain About Cost, Clinical Effectiveness
6. An accurate Alzheimer's disease detection using a developed convolutional neural network model
7. BSCI-12 BREAST TO BRAIN METASTASIS IS EXACERBATED WITH CHEMOTHERAPY THROUGH BLOOD-CEREBRAL SPINAL FLUID-BARRIER AND INDUCES ALZHEIMER’S-LIKE PATHOLOGY
8. Chr21 protein–protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer’s disease
9. Circulating oxysterols in Alzheimer’s disease: a systematic review and meta-analysis
10. Deep transfer learning–based fully automated detection and classification of Alzheimer’s disease on brain MRI
11. ENCSR010OLA
12. ENCSR015QSB
13. ENCSR067CHU
14. ENCSR153PPA
15. ENCSR367JOT
16. ENCSR426AVN
17. ENCSR456UAR
18. ENCSR493UZT
19. ENCSR630MSF
20. ENCSR650DHI
21. ENCSR897QAH
22. ENCSR988ILZ
23. Early Mitochondrial Defects in the 5xFAD mouse model of Alzheimer’s Disease
24. Engaging Caregivers to use an Evidence-Based Intervention for Medicaid Beneficiaries with Alzheimer’s Disease: A Pilot Study
25. FDA Clears First In Vitro Assay to Improve Alzheimer’s Diagnosis
26. Facilitating Treatment Initiation in Early-Stage Alzheimer Disease
27. Identification of Biomarkers Related to M2 Macrophage Infiltration in Alzheimer’s Disease
28. Identifying genetic markers enriched by brain imaging endophenotypes in Alzheimer’s disease
29. Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
30. Integrated Analysis of Cortex Single-Cell Transcriptome and Serum Proteome Reveals the Novel Biomarkers in Alzheimer’s Disease
31. Kidney Function Impacts Plasma Alzheimer’s Biomarkers in a Cognitively Normal Multi- Ethnic Cohort
32. MCU-knockdown in hippocampal neurons improves memory performance in the APP/PS1/tau transgenic mouse model of Alzheimer’s disease
33. MicroRNAs in Learning and Memory and Their Impact on Alzheimer’s Disease
34. Multi-scale discriminative regions analysis in FDG-PET imaging for early diagnosis of Alzheimer’s disease
35. Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments
36. Patient with Corticobasal Syndrome Showing Disease-Associated Biomarkers of Dementia with Lewy Bodies: A Treviso Dementia (TREDEM) Registry Case Report
37. Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts
38. Raman Spectroscopy Techniques for the Investigation and Diagnosis of Alzheimer's Disease
39. SVR-based Multimodal Active Subspace Analysis for the Brain using Neuroimaging Data
40. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease
41. Semi-quantitative Assessment of Alzheimer's-like Pathology in Two Aged Polar Bears (Ursus maritimus)
42. Synthesis, vibrational spectra, Hirshfeld surface analysis, DFT calculations, and in silico ADMET study of 3-(2-chloroethyl)-2,6-bis(4-fluorophenyl)piperidin-4-one: A potent anti-Alzheimer agent
43. The Effect of Stilbene Glycosides on the Hippocampal Neurons and N-methyl D-aspartate Receptor Subtype 2B Receptors in Alzheimer’s Disease Rats
44. The Role of Resveratrol in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review
45. Three-round learning strategy based on 3D Deep Convolutional GANs for Alzheimer’s disease staging
46. Timely Diagnosis of Alzheimer Disease
47. Timeseries biomarkers clustering for Alzheimer’s Disease progression
48. Treatment of Alzheimer’s disease by promoting the aggregation of small β-amyloid peptides
49. Ultra-high-resolution time-frequency analysis of EEG to characterise brain functional connectivity with the application in Alzheimer’s disease
50. Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials
51. What to Know About the Alzheimer Drug Aducanumab (Aduhelm)
52. “Left Behind and Ignored”: Increasing Awareness and Accessibility of Resources for Alzheimer’s Disease and Related Dementias in the Deaf Community

1. 3D convolutional neural networks with hybrid attention mechanism for early diagnosis of Alzheimer’s disease
2. In Silico Studies to Develop New GSK3β Inhibitors Effective in the Alzheimer's Disease
3. A Multi-Stream Convolutional Neural Network for Classification of Progressive MCI in Alzheimer’s Disease Using Structural MRI Images
4. A comparison of end-of-life care patterns between older patients with both cancer and Alzheimer's disease and related dementias versus those with only cancer
5. A computational study of metal ions interaction with amyloid-β 1–42 peptide structure in hyperpyrexia: Implications for Alzheimer disease
6. A finer-grained linguistic profile of Alzheimer's disease and Mild Cognitive Impairment
7. A multi-target theranostic nano-composite against Alzheimer's disease fabricated by conjugating carbon dots and triple-functionalized human serum albumin
8. A phenome-wide association and Mendelian randomization study for Alzheimer’ disease: a prospective cohort study of 502,493 participants from UK Biobank
9. APOE ε4 and Alzheimer's disease diagnosis associated differences in L-carnitine, GBB, TMAO and acylcarnitines in blood and brain.
10. Abnormal Functional Connectivity of Thalamic Subdivisions in Alzheimer’s Disease: A Functional Magnetic Resonance Imaging Study
11. Adherence to the Mediterranean diet and incident frailty: Results from a longitudinal study
12. Alzheimer's disease amyloid-β pathology in the lens of the eye
13. Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress
14. Alzheimer: Neustart mit veränderten Vorzeichen
15. Alzheimer’s Disease: Effects on brain circuits and synapses
16. Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead
17. An Insight into the Role of Artificial Intelligence in the Early Diagnosis of Alzheimer’s Disease
18. Anti-Alzheimer’s Activity of Methanolic Tender Green Pod Extract of Cyamopsis Tetragonoloba (L.) Taub. on Scopolamine Induced Amnesia in Mice
19. Association Plasma Aβ42 Levels with Alzheimer’s Disease and Its Influencing Factors in Chinese Elderly Population
20. Association between obstructive sleep apnea and Alzheimer's disease-related blood and cerebrospinal fluid biomarkers: A meta-analysis
21. Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer’s disease
22. Astrocytic urea cycle detoxifies Aβ-derived ammonia while impairing memory in Alzheimer’s disease
23. Automated quantification of brain connectivity in Alzheimer's disease using ClusterMetric
24. Azo-based multifunctional molecules and their copper(II) complexes as potential inhibitors against Alzheimer’s disease: XRD/Hirshfeld analysis/DFT/molecular docking/cytotoxicity
25. Bifunctional super-hydrophilic mesoporous nanocomposite: a novel nanoprobe for investigation of glycosylation and phosphorylation in Alzheimer's disease
26. Blood pressure, antihypertensive drugs, and incident frailty: The Multidomain Alzheimer Preventive Trial (MAPT)
27. CD33 isoforms in microglia and Alzheimer's disease: Friend and foe
28. COVID-19 and first manic episodes: a systematic review
29. Carbamate-based N-Substituted tryptamine derivatives as novel pleiotropic molecules for Alzheimer's disease
30. Cathepsin B-A Neuronal Death Mediator in Alzheimer’s Disease Leading to Neurodegeneration
31. Causal effects of circulating cytokine concentrations on risk of Alzheimer’s disease and cognitive function
32. Chlorpyrifos oxon crosslinking of amyloid beta 42 peptides is a new route for generation of self-aggregating amyloidogenic oligomers that promote Alzheimer's disease
33. Clinically important natural products for Alzheimer's disease
34. Cognitive Impairment in Alzheimer’s and Metabolic Diseases: A Catecholaminergic Hypothesis
35. Computational prediction of potential drug-like compounds from Cannabis sativa leaf extracts targeted towards Alzheimer therapy
36. Connectome-based biophysics models of Alzheimer’s disease diagnosis and prognosis
37. Correlations between sleep disturbance and brain structures associated with neurodegeneration in the National Alzheimer's Coordinating Center Uniform Data Set
38. Cortical excitability and plasticity in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis of transcranial magnetic stimulation studies
39. Current trends in blood biomarker detection and imaging for Alzheimer’s disease
40. Current understanding of AD pathophysiology and impact of amyloid beta–targeted treatments on biomarkers and clinical endpoints
41. DMTHB ameliorates memory impairment in Alzheimer's disease mice through regulation of neuroinflammation
42. Deciphering the noxious relationship between oxidative stress and the unfolded protein response in Alzheimer-like neuropathology
43. Decreased levels of cytokines implicate altered immune response in plasma of moderate-stage Alzheimer’s disease patients
44. Deep brain stimulation of fornix for memory improvement in Alzheimer’s disease: A critical review
45. Deep learning for Alzheimer's disease diagnosis: A survey
46. Dioscin alleviates Alzheimer's disease through regulating RAGE/NOX4 mediated oxidative stress and inflammation
47. Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease
48. Drug reposition-based design, synthesis, and biological evaluation of dual inhibitors of acetylcholinesterase and β-Secretase for treatment of Alzheimer's disease
49. Effect of APOE ε4 allele and redox signature in circulating extracellular vesicles in cognitively impaired patients converted to Alzheimer's disease
50. Effects of DDT on Amyloid Precursor Protein Levels and Amyloid Beta Pathology: Mechanistic Links to Alzheimer’s Disease Risk
51. Effects of Eph/ephrin signalling and human Alzheimer's disease-associated EphA1 on behaviour and neurophysiology
52. Effects of interventions on cerebral perfusion in the Alzheimer's disease spectrum: A systematic review
53. Efficient self-attention mechanism and structural distilling model for Alzheimer’s disease diagnosis
54. End-of-Life Costs of Cancer Patients With Alzheimer's Disease and Related Dementias in the U.S.
55. Erhöhtes Alzheimer-Risiko ein Jahr nach COVID-19-Infektion?
56. Establishment of SIAISi021-A, an induced pluripotent stem cell (iPSC) line from a 71-year-old Chinese Han male with Alzheimer’s Disease (AD) having two copies of APOE4/4 allele
57. Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer’s disease
58. Experiences of Active Everyday Life Among Persons with Prodromal Alzheimer’s Disease: A Qualitative Study
59. Experimental modelling of Alzheimer's disease for therapeutic screening
60. FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer’s disease expressing APOE4
61. Ferulic acid and vinpocetine intake improves memory function by enhancing insulin sensitivity and reducing neuroinflammation and oxidative stress in type 2 diabetic animals with induced Alzheimer's disease
62. Focus on the controversial Role of 24-hydroxycholesterol in Alzheimer's disease
63. Genetics of the human microglia regulome refines Alzheimer’s disease risk loci
64. Glucocorticoids, synaptic plasticity and Alzheimer's disease
65. Greater intake of the MEDI diet is associated with better cognitive trajectory in older adults with type 2 diabetes
66. Histone deacetylase-6 modulates Tau function in Alzheimer's disease
67. How neurons die in Alzheimer's disease: Implications for neuroinflammation
68. Impaired type I interferon signaling activity implicated in the peripheral blood transcriptome of preclinical Alzheimer's disease
69. Integration of Network Pharmacology and Molecular Docking Technology Reveals the Mechanism of the Therapeutic Effect of Xixin Decoction on Alzheimer's Disease
70. Intravenous treatment with a molecular chaperone designed against β-amyloid toxicity improves Alzheimer’s disease pathology in mouse models
71. Invited Perspective: Long-Lasting Legacy of Banned Contaminants in Alzheimer’s Disease Etiology—Convergence of Epidemiological and Toxicological Findings
72. Issue Information
73. Ketogenic Diet: A Promising Neuroprotective Composition for Managing Alzheimer’s Diseases and its Pathological Mechanisms
74. Lipids as Early and Minimally Invasive Biomarkers for Alzheimer’s Disease
75. Lipoprotein metabolism in Alzheimer’s disease: CSF and plasma HDL characterization in an Italian cohort
76. London Cabbies Help Drive Alzheimer's Research
77. Long non-coding RNA MALAT1 protects against Aβ1–42 induced toxicity by regulating the expression of receptor tyrosine kinase EPHA2 via quenching miR-200a/26a/26b in Alzheimer's disease
78. Low-rank sparse feature selection with incomplete labels for Alzheimer's disease progression prediction
79. Mass spectrometry-based ganglioside profiling provides potential insights into Alzheimer's disease development
80. Methodology and preliminary data on feasibility of a neurofeedback protocol to improve visual attention to letters in mild Alzheimer's disease
81. Microbiota-gut-brain axis in the Alzheimer's disease pathology - an overview
82. Multi-factor combined biomarker screening strategy to rapidly diagnose Alzheimer's disease and evaluate drug effect based on a rat model
83. NO TITLE
84. Natural Product-based Nanomedicine: Recent Advances and Issues for the Treatment of Alzheimer's Disease
85. Necroptosis in Alzheimer’s disease: Potential therapeutic target
86. Neuron-astrocyte transmitophagy is altered in Alzheimer's disease
87. Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer's disease
88. New insights into the role and mechanisms of ginsenoside Rg1 in the management of Alzheimer’s disease
89. Nontoxic silicene photothermal agents with high near-infrared absorption for disassembly of Alzheimer’s amyloid‑β fibrils
90. Novel aryl(4-phenylpiperazin-1-yl)methanethione derivatives as new anti-Alzheimer agents: Design, synthesis, in vitro and in silico assays
91. Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's disease
92. Peripheral apoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function
93. Phytochemical Compounds Loaded to Nanocarriers as Potential Therapeutic Substances for Alzheimer’s Disease-Could They be Effective?
94. Pinpointing the locus of GABAergic vulnerability in Alzheimer’s disease
95. Population-Based Prevalence of Infarctions on 3D Fluid-Attenuated Inversion Recovery (FLAIR) Imaging
96. Post-modified porous hollow nanospheres incorporating multiple strategies for comprehensive phosphoproteomics analysis of serum of Alzheimer's disease
97. Potential Roles of α-amylase in Alzheimer’s Disease: Biomarker and Drug Target
98. Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease
99. Proteomic Markers and Early Prediction of Alzheimer’s Disease
100. Proximity-based labeling reveals DNA damage–induced phosphorylation of fused in sarcoma (FUS) causes distinct changes in the FUS protein interactome
101. RNA induces unique tau strains and stabilizes Alzheimer’s disease seeds
102. Recent Update on the Alzheimer's Disease Progression, Diagnosis and Treatment Approaches
103. Regulation of phase I and phase II neurosteroid enzymes in the hippocampus of an Alzheimer’s disease rat model: A focus on sulphotransferases and UDP-glucuronosyltransferases
104. Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults
105. Resources for Enhancing Alzheimer's Caregiver Health in Vietnam (REACH VN): Exploratory Analyses of Outcomes of a Cluster Randomized Controlled Trial to Test the Feasibility and Preliminary Efficacy of a Family Dementia Caregiver Intervention in Vietnam
106. Risk factors for apathy in Alzheimer’s disease: A systematic review of longitudinal evidence
107. Screening Traditional Chinese Medicine Combination for Co-Treatment of Alzheimer's Disease and Major Depressive Disorder by Network Pharmacology
108. Signal pathways in the treatment of Alzheimer’s disease with traditional Chinese medicine
109. Spontaneous and induced adaptive immune responses in Alzheimer’s disease: new insights into old observations
110. Statin use and risk of dementia and Alzheimer’s disease: A meta-analysis of observational studies
111. Stem cells from human exfoliated deciduous teeth relieves Alzheimer’s disease symptoms in SAMP8 mice by up-regulating the PPARγ pathway
112. Strategic Approaches to Target the Enzymes using Natural Compounds for the Management of Alzheimer’s Disease: A Review
113. Structural Activity Relationship based Medicinal Perspectives of Pyrimidine Derivatives as Anti-Alzheimer’s Agents: A Comprehensive Review
114. Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease
115. Study protocol: computerised cognitive testing in a cohort of people with frontotemporal dementia
116. TR-GAN: Multi-Session Future MRI Prediction With Temporal Recurrent Generative Adversarial Network
117. Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease
118. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
119. The CORCOBIA study: Cut-off points of Alzheimer’s disease CSF biomarkers in a clinical cohort
120. The association of enlarged perivascular space with microglia-related inflammation and Alzheimer's pathology in cognitively normal elderly
121. The default mode network, depression and Alzheimer’s disease
122. The use of seaweed-derived phytosterols to defeat Alzheimer's Disease
123. Therapeutic nanotechnologies for Alzheimer’s disease: A critical analysis of recent trends and findings
124. Trans-urocanic acid facilitates spatial memory, implications for Alzheimer's disease
125. Trisomy 21 and aberrant redox homeostasis: a synergistic path to Alzheimer disease
126. Using the urea cycle to shift astrocytes from harmful to helpful in Alzheimer’s disease
127. VGF Expression by Monocytes in Patients with Alzheimer’s Disease and Vascular Dementia
128. Variants in the Niemann-pick type C genes are not associated with Alzheimer's disease: a large case-control study in the Chinese population
129. Vesicles of yeast cell wall-sitagliptin to alleviate neuroinflammation in Alzheimer's disease
130. When a trophic process turns toxic: Alzheimer’s disease as an aberrant recapitulation of a developmental mechanism
131. miRNA sensing hydrogels capable of self-signal amplification for early diagnosis of Alzheimer's disease

1. A Review on: Alzheimer’s disease and mechanistic insights of bioactive compounds in its treatment
2. Chronic AMPK Activation Reduces the Expression and Alters Distribution of Synaptic Proteins in Neuronal SH-SY5Y Cells
3. Deep Learning Framework for Predicting Alzheimer's Disease using Multi-omics Data
4. Detection of Alzheimer’s Disease from MRI scan using Machine Learning An Implementation Paper
5. Diagnosis of Alzheimer’s Disease using Machine Learning Algorithms
6. Genetic evidence that the causal association of educational attainment with reduced risk of Alzheimer's disease is driven by intelligence
7. Genetic inhibition of PDK1 robustly reduces plaque deposition and ameliorates gliosis in the 5×FAD mouse model of Alzheimer's disease
8. Novel Exopolysaccharide from Marine Bacillus subtilis with Broad Potential Biological Activities: Insights into Antioxidant, Anti-Inflammatory, Cytotoxicity, and Anti-Alzheimer Activity
9. Prediction of Alzheimer\'s Disease Using CNN
10. Targeting Oxidative Stress Mechanisms to Treat Alzheimer’s and Parkinson’s Disease: A Critical Review
11. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
12. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
13. The Mechanistic Pathways of Periodontal Pathogens Entering the Brain: The Potential Role of Treponema denticola in Tracing Alzheimer’s Disease Pathology
14. The Relationship between the Aberrant Long Non-Coding RNA-Mediated Competitive Endogenous RNA Network and Alzheimer’s Disease Pathogenesis
15. p38α‐MAPK‐deficient myeloid cells ameliorate symptoms and pathology of APP ‐transgenic Alzheimer's disease mice

1. A Preliminary Assessment of the Nutraceutical Potential of Acai Berry (Euterpe sp.) as a Potential Natural Treatment for Alzheimer’s Disease
2. ANTI-INFLAMATÓRIOS NÃO ESTEROIDAIS (AINES) COMO ALTERNATIVA FARMACOLÓGICA PARA TRATAMENTO DA DOENÇA DE ALZHEIMER
3. Aging the brain: multi-region methylation principal component based clock in the context of Alzheimer’s disease
4. Characterization of norbelladine synthase and noroxomaritidine/norcraugsodine reductase reveals a novel catalytic route for the biosynthesis of Amaryllidaceae alkaloids including the Alzheimer’s drug galanthamine
5. Covariance-based vs. correlation-based functional connectivity dissociates healthy aging from Alzheimer disease
6. DeepPVC: prediction of a partial volume-corrected map for brain positron emission tomography studies via a deep convolutional neural network
7. Delineating biosynthesis of Huperzine A, A plant-derived medicine for the treatment of Alzheimer's disease
8. Features of pharmacodynamics of cholinoblockers and cholinomimetics in Alzheimer’s patients
9. Food regimen to treat heart disease, Alzheimer’s disease and amyotrophic lateral sclerosis
10. New Insights into the Molecular Interplay between Human Herpesviruses and Alzheimer’s Disease—A Narrative Review
11. Plants, Plants, and More Plants: Plant-Derived Nutrients and Their Protective Roles in Cognitive Function, Alzheimer’s Disease, and Other Dementias
12. Whole genome analysis in APOE4 homozygotes identifies the DAB1-RELN pathway in Alzheimer's disease pathogenesis

1. Adeno-associated virus (AAV) 9-mediated gene delivery of Nurr1 and Foxa2 ameliorates symptoms and pathologies of Alzheimer disease model mice by suppressing neuro-inflammation and glial pathology
2. Alzheimer’s disease: Prevention Strategy
3. Amyloid beta peptides (Aβ) from Alzheimer’s disease neuronal secretome induce endothelial activation in a human cerebral microvessel model
4. Associations of multiple visual rating scales based on structural magnetic resonance imaging with disease severity and cerebrospinal fluid biomarkers in patients with Alzheimer’s disease
5. Clinical impact of whole-genome sequencing in patients with early-onset dementia
6. Early increase of cerebrospinal fluid 14-3-3ζ protein in the alzheimer's disease continuum
7. Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
8. Functional neuronal circuitry and oscillatory dynamics in human brain organoids
9. HTLML: Hybrid AI Based Model for Detection of Alzheimer’s Disease
10. Hesperidin Improves Memory Function by Enhancing Neurogenesis in a Mouse Model of Alzheimer’s Disease
11. Identification of diagnostic signatures associated with immune infiltration in Alzheimer’s disease by integrating bioinformatic analysis and machine-learning strategies
12. Identifying the regional substrates predictive of Alzheimer's disease progression through a convolutional neural network model and occlusion
13. Molecular Docking Studies of Interaction Curcumin against Beta-secretase 1, Amyloid A4 Protein, Gamma-secretase and Glycogen Synthase Kinase-3β as Target Therapy for Alzheimer Disease
14. Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer’s disease in a multigenerational Colombian Family
15. Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden
16. New Imaging Modality of COVID-19 Pneumonia Developed on the Basis of Alzheimer’s Disease Research
17. Oxygen Tissue Levels as an Effectively Modifiable Factor in Alzheimer’s Disease Improvement
18. Psychological well-being and cognitive aging in Black, Native American, and White Alzheimer’s Disease Research Center participants
19. Repetitive Transcranial Magnetic Stimulation Decreases Serum Amyloid-β and Increases Ectodomain of p75 Neurotrophin Receptor in Patients with Alzheimer’s Disease
20. The effect of socioeconomic status on mortality among Alzheimer’s disease patients: A nationwide population-based cohort study in Korea
21. The gesture imitation test in dementia with Lewy bodies and Alzheimer's disease dementia
22. Trail Making Test Error Analysis in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Dementia With and Without Depression
23. α‐Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α‐Synuclein in the Context of Co‐Pathology and Non‐LBD Diagnoses

1. Accelerated vascular aging: Ethnic differences in basilar artery length and diameter, and its association with cardiovascular risk factors and cerebral small vessel disease
2. Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review
3. Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
4. Development and validation of the care challenge scale in family caregivers of people with Alzheimer's disease
5. Distribution and inter-regional relationship of amyloid-beta plaque deposition in a 5xFAD mouse model of Alzheimer’s disease
6. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
7. Dynamic modeling of practice effects across the healthy aging-Alzheimer’s disease continuum
8. FISIOTERAPIA NA PREVENÇÃO DE QUEDAS EM IDOSOS COM ALZHEIMER: REVIÃO INTEGRATIVA
9. Fluorosulfate-containing pyrazole heterocycles as selective BuChE inhibitors: structure-activity relationship and biological evaluation for the treatment of Alzheimer’s disease
10. Frequency distribution of the hereditary Alzheimer’s disease-related genes seems to fit Poisson distribution, why?
11. GH deficiency confers protective advantages against Alzheimer’s disease through rescued miRNA expression profile in APP/PS1 mice
12. Identification and immunological characterization of cuproptosis-related molecular clusters in Alzheimer's disease
13. Inflammatory bowel disease: A potential pathogenic factor of Alzheimer's disease
14. Parameter Combination Optimization in Three-Dimensional Convolutional Neural Networks and Transfer Learning for Detecting Alzheimer’s Disease from Magnetic Resonance Images
15. Qual o melhor Instrumento para avaliar a Qualidade de Vida de portadores de Doença de Alzheimer? Uma revisão sistemática
16. Quality of dietary fat and risk of Alzheimer’s disease and dementia in adults aged ≥50 years: a systematic review
17. Rapid olfactory decline during aging predicts dementia and GMV loss in AD brain regions
18. Regional white matter hyperintensities in posterior cortical atrophy and logopenic progressive aphasia
19. Review on the roles of specific cell-derived exosomes in Alzheimer's disease
20. Risk association between midlife lipid and glucose levels and future Alzheimer's disease
21. Supplemental Material for Autocorrection if→of Function Words in Reading Aloud: A Novel Marker of Alzheimer’s Risk
22. Synthesis and Evaluation of 1,3-Dimethylbarbituric Acid Based Enamine Derivatives as Anti-Alzheimer Agent
23. The Role of Vitamin D in Alzheimer’s Disease: A Transcriptional Regulator of Amyloidopathy and Gliopathy
24. Transplantation of fecal microbiota from APP/PS1 mice and Alzheimer’s disease patients enhanced endoplasmic reticulum stress in the cerebral cortex of wild-type mice
25. Using a two-sample mendelian randomization analysis to explore the relationship between physical activity and Alzheimer’s disease
26. Virtual screening of lead compounds for the treatment of Alzheimer’s disease based on multi-target strategy

1. A CORRELAÇÃO ENTRE OS NUTRIENTES E A EVOLUÇÃO E O PROGNOSTICO DA DOENÇA DE ALZHEIMER
2. APPLICATION AND EXPERIMENTATION OF ARTISTIC-MUSIC LANGUAGE AS ALTERNATIVE THERAPEUTIC PROCEDURE FOR INDIVIDUALS DIAGNOSED WITH ALZHEIMER'S PATHOLOGICAL CONDITION
3. An Activity‐Based Fluorescent Probe for Imaging Fluctuations of Peroxynitrite (ONOO ⁻ ) in the Alzheimer's Disease Brain
4. An Activity‐Based Fluorescent Probe for Imaging Fluctuations of Peroxynitrite (ONOO ⁻ ) in the Alzheimer's Disease Brain
5. Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease
6. Corpus callosum anatomical changes in Alzheimer patients and the effect of acetylcholinesterase inhibitors on corpus callosum morphometry
7. Decision letter for "A review of stem cell therapy: An emerging treatment for dementia in Alzheimer's and Parkinson's disease"
8. Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways
9. Effects of Aducanumab on treating Alzheimer’s disease: targets and clinical trials
10. Evaluation of CB₂R expression and pyridine-based radiotracers in brains from a mouse model of Alzheimer’s disease
11. Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study
12. Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease
13. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases
14. Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses
15. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
16. Photodynamic Alzheimer’s disease therapy: From molecular catalysis to photo-nanomedicine
17. Temporal Belonging: Loss of Time and Fragile Attempts to Belong with Alzheimer’s Disease
18. Web-Based Protein Interactions Calculator Identifies Likely Proteome Coevolution with Alzheimer’s Disease-Associated Proteins
19. [18F]ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer’s disease pathology in APP/PS1 mice

1. A Review on Treatment of Alzheimer's Disease in Traditional Medicine Vs. Modern Science
2. A novel method for identification of candidate genes for Alzheimer’s disease using network topology measure and intelligent based deep learning models
3. A robust framework to investigate the reliability and stability of explainable artificial intelligence markers of Mild Cognitive Impairment and Alzheimer’s Disease
4. Alzheimer’s Disease Risk Factors: APOE ε4 Allele and Traumatic Brain Injuries
5. Amyloid precursor protein (APP) and amyloid β (Aβ) interact with cell adhesion molecules: Implications in Alzheimer’s disease and normal physiology
6. Boron Nitride Nanoparticles Loaded with a Boron-Based Hybrid as a Promising Drug Carrier System for Alzheimer’s Disease Treatment
7. Chronic-Antibiotics Induced Gut Microbiota Dysbiosis Rescues Memory Impairment and Reduces β-Amyloid Aggregation in a Preclinical Alzheimer’s Disease Model
8. Decision letter for "Structural synaptic signatures of Alzheimer’s Disease and Dementia with Lewy Bodies in the male brain"
9. Dulaglutide Alleviates Alzheimer's Disease by Regulating Microglial Polarization and Neurogenic Activity
10. Individualized Prospective Prediction of Opioid Use Disorder
11. Krüppel-like factor 5 accelerates the pathogenesis of Alzheimer’s disease via BACE1-mediated APP processing
12. Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews
13. Physiology of Glymphatic Solute Transport and Waste Clearance from the Brain
14. Prediction of Stage of Alzheimer's Disease DenseNet Deep Learning Model
15. Prospective biomarkers of Alzheimer’s disease: A systematic review and meta-analysis
16. Quantitative susceptibility mapping demonstrates different patterns of iron overload in subtypes of early-onset Alzheimer’s disease

1. A consolidated review on stem cell therapy for treatment and management of Alzheimer's disease
2. A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing
3. Aging Effect, Reproducibility, and Test–Retest Reliability of a New Cerebral Amyloid Angiopathy MRI Severity Marker—Cerebrovascular Reactivity to Visual Stimulation
4. Alzheimer-Compound Identification Based on Data Fusion and forgeNet_SVM
5. Amyloid Fibril Formation of Arctic Amyloid-β 1–42 Peptide is Efficiently Inhibited by the BRICHOS Domain
6. An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD
7. Analysis of family stigma and socioeconomic factors impact among caregivers of patients with early- and late-onset Alzheimer's disease and frontotemporal dementia
8. Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy
9. Author response: IL-37 expression reduces acute and chronic neuroinflammation and rescues cognitive impairment in an Alzheimer’s disease mouse model
10. Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study
11. Critical appraisal on mitochondrial dysfunction in Alzheimer’s disease
12. Decision letter for "Calcium Inhibits Penetration of Alzheimer's Aβ _1‐42 Monomers into the Membrane"
13. Decreased visual acuity is related to thinner cortex in cognitively normal adults: cross-sectional, single-center cohort study
14. EEG coherence as a marker of Alzheimer’s disease
15. Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease
16. Early β-amyloid accumulation and hypoconnectivity in the default mode network are related to its disengagement from global brain activity
17. Effect of Chronic Cadmium Exposure on Brain and Liver Transporters and Drug-Metabolizing Enzymes in Male and Female Mice Genetically Predisposed to Alzheimer’s Disease
18. End-to-End Deep Learning Architectures Using 3D Neuroimaging Biomarkers for Early Alzheimer’s Diagnosis
19. Goal-directed action is transiently impaired in an hAPP-J20 mouse model of Alzheimer’s disease, and in aging male mice regardless of genotype
20. Is Alzheimer's disease an infectious neurological disease? A review of the literature
21. Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve
22. Multiparameter phenotypic screening for endogenous TFEB and TFE3 translocation identifies novel chemical series modulating lysosome function
23. Myelin and Physical Activity in Older Adults With Cerebral Small Vessel Disease and Mild Cognitive Impairment
24. Neurovascular dysfunction in GRN-associated frontotemporal dementia identified by single-nucleus RNA sequencing of human cerebral cortex
25. Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer and coronary disease pathways
26. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis
27. Polygenic resilience scores capture protective genetic effects for Alzheimer’s disease
28. Study on the effect of extreme learning machine and its variants in differentiating Alzheimer conditions from selective regions of brain MR images
29. Temporal Cortex Microarray Analysis Revealed Impaired Ribosomal Biogenesis and Hyperactivity of the Glutamatergic System: An Early Signature of Asymptomatic Alzheimer's Disease
30. YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer’s disease and frontotemporal lobar degeneration

1. Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease
2. Depletion of glutathione induced apoptosis and oxidative stress via the activation of TRPM2 channels in the microglia cells with Alzheimer’ disease model
3. Human Palatine Tonsils Are Linked to Alzheimer’s Disease through Function of Reservoir of Amyloid Beta Protein Associated with Bacterial Infection
4. Hyper Parameters Tuning ResNet-50 for Alzheimer’s Disease Classification on Neuroimaging Data
5. Systems Genetic Identification of Mitochondrion-Associated Alzheimer’s Disease Genes and Implications for Disease Risk Prediction
6. The Monkey Head Mushroom and Memory Enhancement in Alzheimer’s Disease
7. The Western Australia Olfactory Memory Test: Reliability and Validity in a Sample of Older Adults
8. The beneficial effect of Pluchea lanceolata on aluminum chloride-induced Alzheimer's disease in rats
9. Therapeutic Effect of Erythropoietin on Alzheimer’s Disease by Activating the Serotonin Pathway

1. Adenosine receptor signalling in Alzheimer’s disease
2. Blood‐based bioenergetic profiling reveals differences in mitochondrial function associated with cognitive performance and Alzheimer's disease
3. Feasibility, usability and clinical value of intensive longitudinal diary assessments in older persons with cognitive impairment and depressive symptoms
4. Frontal grey matter microstructure is associated with sleep slow waves characteristics in late midlife
5. Intervenciones de enfermería en salud familiar en familias con ancianos con Alzheimer: revisión integrativa
6. Neighborhood segregation and cognitive change: Multi‐Ethnic Study of Atherosclerosis
7. Novel mathematical model based on cellular automata for study of Alzheimer’s disease progress
8. Regional distribution and maturation of tau pathology among phenotypic variants of Alzheimer’s disease
9. Sex-specific effects of microglial activation on Alzheimer’s disease proteinopathy in older adults
10. Surface Functionalisation of Dental Implants with a Composite Coating of Alendronate and Hydrolysed Collagen: DFT and EIS Studies
11. Thermal cycling-hyperthermia ameliorates cognitive impairment of intracerebroventricular Aβ_25-35-induced Alzheimer’s disease in C57BL/6 mice

1. 3D bioengineered neural tissue generated from patient-derived iPSCs develops time-dependent phenotypes and transcriptional features of Alzheimer’s disease
2. A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer’s Disease Mice Models
3. Alzheimer’s disease and epilepsy: The top 100 cited papers
4. Assessing the Association Between Lead Pollution and Risk of Alzheimer’s Disease by Integrating Multigenomics
5. Blood levels of circulating methionine components in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis
6. Brain And Ocular Nutrition Conference 2022, Lecture Abstracts 27–29 July 2022, Downing College, Cambridge University, UK
7. CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
8. Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer’s Disease and Other Neurodegenerative Diseases
9. Classification of Alzheimer’s Disease Using Dual-Phase 18F-Florbetaben Image with Rank-Based Feature Selection and Machine Learning
10. Double‐negative T cells mediate M1 polarization of microglial cells via TNF‐α‐NLRP3 to aggravate neuroinflammation and cognitive impairment in Alzheimer's disease mice
11. Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer’s Disease
12. Empowering interventions for people living with dementia: A European survey
13. Epigenetic Peripheral Biomarkers for Early Diagnosis of Alzheimer’s Disease
14. Feelings of loneliness and isolation: Social brain and social cognition in the elderly and Alzheimer's disease
15. Grey matter changes on brain MRI in subjective cognitive decline: a systematic review
16. Integrating Zebrafish Model to Screen Active Ingredients and Network Pharmacology Methods to Explore the Mechanism of Lavandula angustifolia Therapy for Alzheimer's Disease
17. Jatamansinol from Nardostachys jatamansi Ameliorates Tau-Induced Neurotoxicity in Drosophila Alzheimer’s Disease Model
18. Mechanistic multiscale modelling of energy metabolism in human astrocytes indicates morphological effects in Alzheimer’s Disease
19. Mendelian randomization confirms the role of Y-chromosome loss in Alzheimer’s Disease etiopathogenesis in males
20. Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study
21. Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer’s Disease
22. PSEN1 c.1292C<A Variant and Early-Onset Alzheimer’s Disease: A Scoping Review
23. Potential Diagnostic Applications of Multi-Delay Arterial Spin Labeling in Early Alzheimer’s Disease: The Chinese Imaging, Biomarkers, and Lifestyle Study
24. Preclinical Alzheimer’s disease biomarkers accurately predict cognitive and neuropathological outcomes
25. Psychological Resilience in Adolescence as a function of Genetic Risk for Major Depressive Disorder and Alzheimer’s Disease
26. Real-Time Detection and Visualization of Amyloid-β Aggregates Induced by Hydrogen Peroxide in Cell and Mouse Models of Alzheimer’s Disease
27. Research backing experimental Alzheimer’s drug was first target of suspicion
28. Research backing experimental Alzheimer’s drug was first target of suspicion
29. Seed-induced Aβ deposition alters neuronal function and impairs olfaction in a mouse model of Alzheimer’s disease
30. Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline
31. Spiritual Therapeutic Robot for Elderly With Early Alzheimer’s Disease: A Design Guide Based on Gender
32. Structural Connectivity in Down Syndrome and Alzheimer’s Disease
33. Synergistic photobiomodulation with 808-nm and 1064-nm lasers to reduce the β-amyloid neurotoxicity in the in vitro Alzheimer's disease models
34. The clinical correlation between Alzheimer's disease and epilepsy
35. The effect of dietary fat consumption on Alzheimer’s disease pathogenesis in mouse models
36. The effects of exercise programs on cognition, activities of daily living, and neuropsychiatric symptoms in community-dwelling people with dementia—a systematic review
37. Therapeutic Potential of Different Natural Products for the Treatment of Alzheimer’s Disease
38. Vitamin D intake and cognitive decline in Blacks and Whites: The role of diet and supplements
39.  Hormone Replacement Therapy is associated with improved cognition and larger brain volumes in at risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort

1. A systematic review on adherence to continuous positive airway pressure (CPAP) treatment for obstructive sleep apnoea (OSA) in individuals with mild cognitive impairment and Alzheimer's disease dementia
2. Altered sleep behavior in a genetic mouse model of Alzheimer’s disease following anesthetic exposure
3. Alzheimer’s Disease Risk Variant rs3865444 in the CD33 Gene: A Possible Role in Susceptibility to Multiple Sclerosis
4. Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome
5. Association of Being Accompanied at Medical Consultation and Having Memory Complaints With Cognitive Impairment in Elderly Brazilian Outpatients
6. Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease
7. Diabetes-associated cognitive decline in mice with genetic predisposition to Alzheimer's disease, not in wild type
8. Disentangling the effects of Alzheimer’s and small vessel disease on white matter fibre tracts
9. ENCSR384DBJ
10. Episodic Memory in Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer’s Disease Dementia (ADD): Using the “Doors and People” Tool to Differentiate between Early aMCI—Late aMCI—Mild ADD Diagnostic Groups
11. Examining the Role of Aging Perceptions in Subjective Cognitive Decline
12. Harmonizing the preclinical Alzheimer cognitive composite for multicohort studies.
13. If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
14. Naringin prevents the reduction of the number of neurons and the volume of CA1 in a Scopolamine-Induced animal model of Alzheimer's disease (AD): A stereological study
15. Non-invasive sleep-measuring devices for the prevention of Alzheimer’s disease: a systematic review of validity studies
16. Non-parametric actigraphy-derived measures differ in dementia with Lewy bodies compared to Alzheimer’s dementia: a feasibility study
17. Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort
18. Possible fabrications in Alzheimer’s research, and bad news for life on Enceladus
19. Potential fabrication in research images threatens key theory of Alzheimer’s disease
20. Therapeutic effects of total saikosaponins from Radix bupleuri against Alzheimer’s disease

1. Alzheimer’s Detection with Speech Using Singular Spectrum Analysis Trend Extraction Method
2. Alzheimer’s Disease: Risk Tests and the Medical Record
3. Alzheimer’s disease: Early-Stage Prediction and Classification using Multi-Model Technique
4. Anesthesia promotes acute expression of genes related to Alzheimer’s disease and latent tau aggregation in transgenic mouse models of tauopathy
5. Causal feature selection using a knowledge graph combining structured knowledge from the biomedical literature and ontologies: a use case studying depression as a risk factor for Alzheimer’s disease
6. Convolution Neural Networks for the Automatic Segmentation of 18F-FDG PET Brain as an Aid to Alzheimer’s Disease Diagnosis
7. Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer’s disease
8. Early Diagnosis of Alzheimer's disease using Electrochemical-based Nanobiosensors for miRNA Detection
9. Geriatricians’ Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer’s Disease: A Qualitative Study
10. IOT Based Smart Safety Wearable for Small Fry and Alzheimer’s Patients
11. Immunohistochemical Demonstration of the pGlu79 α-Synuclein Fragment in Alzheimer’s Disease and Its Tg2576 Mouse Model
12. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts
13. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
14. Selective Detection of Misfolded Tau From Postmortem Alzheimer’s Disease Brains
15. Signatures for Viral Infection and Inflammation in the Proximal Olfactory System in Familial Alzheimer’s Disease
16. Sistema personalizado de dosificación (SPD), más allá del blíster: presentación de un caso clínico en un paciente con enfermedad de Alzheimer
17. Stem Cell-based Therapies as a Promising Approach in Alzheimer's Disease
18. Thalamo-hippocampal pathway regulates incidental memory capacity in mice
19. Total and regional fat‐to‐muscle mass ratio and risks of incident all‐cause dementia, Alzheimer's disease, and vascular dementia
20. miR-143-3p Inhibits Aberrant Tau Phosphorylation and Amyloidogenic Processing of APP by Directly Targeting DAPK1 in Alzheimer’s Disease

1. A Comparison of Well-Being of Carers of People with Dementia and Their Ability to Manage Before and During the COVID-19 Pandemic: Findings from the IDEAL Study
2. A Novel Panel of Plasma Proteins Predicts Progression in Prodromal Alzheimer’s Disease
3. Additions to Alpha-Sheet Based Hypotheses for the Cause of Alzheimer’s Disease
4. Alterations in Retinal Signaling Across Age and Sex in 3xTg Alzheimer’s Disease Mice
5. Alzheimer's disease and AD‐related dementias‐Microbiome‐gut brain nexus (NIH)
6. Alzheimer’s Disease at a Crossroad: Time to Part from Amyloid to More Promising Aspects—Atherosclerosis for a Start
7. Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years
8. Antiamyloid therapy of Alzheimer’s disease: origins, current state and prospects of development
9. Assessment of Current Practices Across Alzheimer's Disease Research Centers Biorepositories
10. Association Between Cerebral Microbleeds and Circulating Levels of Mid-Regional Pro-Adrenomedullin
11. Association of vitamin D receptor gene haplotypes with late‑onset Alzheimer's disease in a Southeastern European Caucasian population
12. Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer’s Disease
13. Biological and Disease Hallmarks of Alzheimer’s Disease Defined by Alzheimer’s Disease Genes
14. Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation
15. Blood BMP6 Associated with Cognitive Performance and Alzheimer’s Disease Diagnosis: A Longitudinal Study of Elders
16. Brain MRI Biomarkers to Predict Cognitive Decline in Older People with Alzheimer’s Disease
17. COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences
18. Cognitive Stimulation Program Presented Through New Technologies in a Group of People with Moderate Cognitive Impairment
19. Cognitive, Functional, and Emotional Changes During the COVID-19 Pandemic in Greek Patients with Neurocognitive Disorders
20. Convergent and divergent oscillatory aberrations during visuospatial processing in HIV-related cognitive impairment and Alzheimer’s disease
21. DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes
22. Daily Physical Activity Patterns as a Window on Cognitive Diagnosis in the Baltimore Longitudinal Study of Aging (BLSA)
23. Demonstration of Clinical Meaningfulness of the Integrated Alzheimer’s Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes
24. Distinct Patterns Link the BDNF Val66Met Polymorphism to Alzheimer’s Disease Pathology
25. Early Detection of Alzheimer’s Disease With Nonlinear Features of EEG Signal and MRI Images by Convolutional Neural Network
26. Effects of Tianeptine Treatment on Depression and Cognitive Function in Patients with Alzheimer’s Disease: A 12-Month Retrospective Observational Study
27. Enhanced Long Short Term Memory for Early Alzheimer's Disease Prediction
28. Erratum to: Relation of Literacy and Music Literacy to Dementia in Older Black and White Brazilians
29. Exploring links between 2‐oxoglutarate‐dependent oxygenases and Alzheimer's disease
30. GA-MADRID: design and validation of a machine learning tool for the diagnosis of Alzheimer’s disease and frontotemporal dementia using genetic algorithms
31. Genome-Wide Association Study of Incident Dementia in a Community-Based Sample of Older Subjects
32. Immunogenomics Parameters for Patient Stratification in Alzheimer’s Disease
33. In Individuals With Subjective Cognitive Decline, Age, Memory and Speed Scores at Baseline Predict Progression to Cognitive Impairment
34. Intestinal Microflora Changes in Patients with Mild Alzheimer’s Disease in a Chinese Cohort
35. Is There a Connection between the Metabolism of Copper, Sulfur, and Molybdenum in Alzheimer’s Disease? New Insights on Disease Etiology
36. Ischemic Stroke and Dietary Vitamin B12 Deficiency in Old-Aged Females: Impaired Motor Function, Increased Ischemic Damage Size, and Changed Metabolite Profiles in Brain and Cecum Tissue
37. Janina Krell-Roesch, PhD, and Yonas E. Geda, MD recipients of the 2022 Alzheimer Award
38. Mapping the Genetic-Imaging-Clinical Pathway with Applications to Alzheimer’s Disease
39. Metabolic Reprogramming of Microglia Enhances Proinflammatory Cytokine Release through EphA2/p38 MAPK Pathway in Alzheimer’s Disease
40. MicroRNA-650 regulates the pathogenesis of Alzheimer’s Disease through targeting Cyclin-Dependent Kinase 5
41. Muramyl Dipeptide Administration Delays Alzheimer’s Disease Physiopathology via NOD2 Receptors
42. Nanoparticles-based anti-aging treatment of Alzheimer’s disease
43. Neighborhood Social Cohesion and Dementia-Related Stigma Among Mothers of Adolescents in the Pre- and Current COVID-19 Period: An Observational Study Using Population-Based Cohort Data
44. Neural Networks in Autosomal Dominant Alzheimer’s Disease: Insights From Functional Magnetic Resonance Imaging Studies
45. Novel Alzheimer risk factor IQ motif containing protein K is abundantly expressed in the brain and is markedly increased in patients with Alzheimer’s disease
46. Olfactory Function and Markers of Brain Pathology in Non-Demented Individuals with Autosomal Dominant Alzheimer’s Disease
47. Ovarian steroid hormones: A long overlooked but critical contributor to brain aging and Alzheimer’s disease
48. Pattern of Altered Magnetization Transfer Rate in Alzheimer’s Disease
49. Pelargonidin and Berry Intake Association with Alzheimer’s Disease Neuropathology: A Community-Based Study
50. Peripheral Inflammatory Biomarkers of Alzheimer’s Disease
51. Platelet-Derived Amyloid-β Protein Precursor as a Biomarker of Alzheimer’s Disease
52. Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort
53. Prospective Evaluation of an Amide-Based Zinc Scaffold as an Anti-Alzheimer Agent: In Vitro, In Vivo, and Computational Studies
54. Relative quantification of sulfenic acids in plasma proteins using differential labelling and mass spectrometry coupled with 473 nm photo-dissociation analysis: A multiplexed approach applied to an Alzheimer's disease cohort
55. Secular Trends in Dementia Free Cognitive Function in Older Adults: A Systematic Review
56. Sex-Differential Associations Between Body Mass Index and the Incidence of Dementia
57. Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer’s Disease
58. Subclinical Hypothyroidism and Cognitive Impairment
59. Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease
60. Testing Visual Binding by the TMA-93 in People Aged 75 and Over
61. The Diagnostic Patterns of Referring Physicians and Hospital Expert Psychiatrists Regarding Particular Frontotemporal Lobar Degeneration Clinical and Neuropathological Subtypes
62. The Impact of Agitation in Dementia on Caregivers: A Real-World Survey
63. The Relationship Between Prior Cancer Diagnosis and All-Cause Dementia Progression Among US Adults
64. Training with Odors Impacts Hippocampal Thickness in Patients with Mild Cognitive Impairment
65. X-ray multiscale 3D neuroimaging to quantify cellular aging and neurodegeneration postmortem in a model of Alzheimer’s disease
66. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease

1. A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer’s disease and gastrointestinal tract disorders
2. Acid-sensing ion channel 1a: a novel target in Alzheimer’s disease?
3. Aerobic Training with Naringin Supplementation Improved Spatial Cognition via H₂S Signaling Pathway in Alzheimer’s Disease Model Rats
4. Alzheimer's Disease Clinical Scores Prediction based on the Label Distribution Learning using Brain Structural MRI
5. Alzheimer's Disease Detection via a Surrogate Brain Age Prediction Task using 3D Convolutional Neural Networks
6. Application of diffusion tensor imaging based on automatic fiber quantification in Alzheimer's disease.
7. Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
8. Deep Brain Stimulation for Alzheimer Disease: Physiological Considerations and Anesthetic Challenges
9. Deep learning and multimodal feature fusion for the aided diagnosis of Alzheimer's disease
10. Development and internal validation of a prognostic model for 15-year risk of Alzheimer dementia in primary care patients
11. Early-onset Alzheimer Disease Associated With Neuromyelitis Optica Spectrum Disorder
12. FDA to review another Alzheimer’s antibody
13. Faculty Opinions recommendation of Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease.
14. Insulin Resistance as a Risk Factor for Alzheimer's Disease
15. Mathematical model of Alzheimer’s disease with prion proteins interactions and treatment
16. Microtubule affinity regulating kinase (MARK/Par1) isoforms differentially regulate Alzheimer-like TAU missorting and Aβ-mediated synapse pathology
17. Neuropsychological Decline Stratifies Dementia Risk in Cognitively Unimpaired and Impaired Older Adults
18. Novel PSEN1 (P284S) Mutation Causes Alzheimer's Disease with Cerebellar Amyloid β-protein deposition
19. Pre-Training 3D Convolutional Neural Networks for Prodromal Alzheimer's Disease Classification
20. Prognosis of Alzheimer’s Disease Using Quantitative Mass Spectrometry of Human Blood Plasma Proteins and Machine Learning
21. Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum
22. SMIL-DeiT:Multiple Instance Learning and Self-supervised Vision Transformer network for Early Alzheimer's disease classification
23. Single-cell network biology characterizes cell type gene regulation for drug repurposing and phenotype prediction in Alzheimer’s disease
24. Sustained high body temperature exacerbates cognitive function and Alzheimer’s disease-related pathologies
25. The Alzheimer’s disease-associated gene TREML2 modulates inflammation by regulating microglia polarization and NLRP3 inflammasome activation
26. The Metabolic Syndrome Is Associated With Lower Cognitive Performance and Reduced White Matter Integrity in Midlife: The CARDIA Study
27. The TAS Test project: a prospective longitudinal validation of new online motor-cognitive tests to detect preclinical Alzheimer’s disease and estimate 5-year risks of cognitive decline and dementia
28. The effect of citalopram treatment on amyloid-β precursor protein processing and oxidative stress in human hNSC-derived neurons
29. The promise of music therapy for Alzheimer's disease: A review
30. Turning up the NAD⁺-mitophagy axis to treat Alzheimer’s disease
31. Ultrahigh Sensitive Detection of Tau Protein as Alzheimer's Biomarker via Microfluidics and Nanofunctionalized Optical Fiber Sensors

1. Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease
2. Decision letter for "Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta‐analysis"
3. Findings of ¹⁸ F‐PI ‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample
4. Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer’s Disease
5. NLRP1 Inflammasome Activation in the Hippocampal Formation in Alzheimer’s Disease: Correlation with Neuropathological Changes and Unbiasedly Estimated Neuronal Loss
6. [124I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease

1. A Method for Bridging Population-Specific Genotypes to Detect Gene Modules Associated with Alzheimer’s Disease
2. ComBat Harmonization: Empirical Bayes versus Fully Bayes Approaches
3. Dementia prevention: The potential long‐term cost‐effectiveness of the FINGER prevention program
4. Differences in the measurement of cognition for the assessment of dementia across geographic contexts: Recommendations for cross‐national research
5. Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI
6. The Effect of Lovastatin on the Electrophysiological Properties of CA1 Pyramidal Neurons in a Rat Model of Alzheimer Disease

1. A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer’s Disease
2. A review on comparative studies addressing exosome isolation methods from body fluids
3. Active Compounds and Targets of Yuanzhi Powder in Treating Alzheimer’s Disease and Its Relationship with Immune Infiltration Based on HPLC Fingerprint and Network Pharmacology
4. Alzheimer’s disease, cerebrovascular disease and dementia: lump, split or integrate?
5. An Overview on Dementia: A Major Symptom of Alzheimer's Disease
6. Author response for "Oral microbiome and serological analyses on association of Alzheimer's disease and periodontitis"
7. Characteristic of process analysis on instrumental activities of daily living according to the severity of cognitive impairment in community-dwelling older adults with Alzheimer’s disease
8. Cholinergic Neuron Targeting Nanosystem Delivering Hybrid Peptide for Combinatorial Mitochondrial Therapy in Alzheimer’s Disease
9. Cognitive performance protects against Alzheimer’s disease independently of educational attainment and intelligence
10. Correction: Hom et al. Cognitive Function during the Prodromal Stage of Alzheimer’s Disease in Down Syndrome: Comparing Models. Brain Sci. 2021, 11, 1220
11. Diagnosis of Alzheimer’s Disease using Multi-Layer Perceptron Network
12. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia
13. Elevated regional cerebral blood flow in adults with 22q11.2 deletion syndrome
14. Identification of circRNAs linked to Alzheimer’s disease and related dementias
15. Impactos na saúde e qualidade de vida de cuidadores e familiares de indivíduos com doença de Alzheimer: revisão integrativa
16. Interpretable Identification of Mild Cognitive Impairment Progression Using Stereotactic Surface Projections
17. Novel imaging markers for altered cerebrovascular morphology in aging, stroke, and Alzheimer's disease
18. P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
19. Prevalência de sarcopenia em pacientes com doença de Alzheimer
20. Preventive and therapeutic reduction of amyloid deposition and behavioral impairments in a model of Alzheimer’s disease by whole blood exchange
21. Review for "Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta‐analysis"
22. Review for "Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study"
23. Sexual Activity and Alzheimer’s disease: Neuroendocrine Rehabilitation Tools and Technologies
24. Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology
25. Trace Amine Associate Receptor 1 (TAAR1) as a New Target for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease
26. Type-I Interferons in Alzheimer's Disease and Other Tauopathies

1. Age-Related Eye Diseases in Individuals With Mild Cognitive Impairment and Alzheimer's Disease
2. Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages
3. Discovery of novel α‐carboline derivatives as glycogen synthase kinase‐3β inhibitors for the treatment of Alzheimer's disease
4. Dysfunctional gene splicing in glucose metabolism may contribute to alzheimer's disease
5. Etiología, factores de riesgo, tratamientos y situación actual de la enfermedad de Alzheimer en México
6. Free Radical Chain Reactions and Polyunsaturated Fatty Acids in Brain Lipids
7. Highly sensitive Curcumin-conjugated nanotheranostic platform for detecting amyloid-beta plaques by magnetic resonance imaging and reversing cognitive deficits of Alzheimer's disease via NLRP3-inhibition
8. Impaired astrocytic Ca2+ signaling in awake-behaving Alzheimer’s disease transgenic mice
9. Increased Risk of All-Cause, Alzheimer’s, and Vascular Dementia in Adults with Migraine in Korea: a population-based cohort study
10. Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment
11. MiR‐483‐3p improves learning and memory abilities via XPO1 in Alzheimer's disease
12. Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures
13. My First Patient With Alzheimer's
14. Systematic Review on Saliva Biomarkers in Patients Diagnosed with Morbus Alzheimer and Morbus Parkinson
15. Targeting the Post-Synaptic Proteome in Alzheimer Disease with Psychosis
16. The Potential Role of miRNA-Regulated Autophagy in Alzheimer’s Disease
17. Transcriptomically unique endolysosomal and homeostatic microglia populations in Alzheimer’s Disease and aged human brain
18. White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling
19. “Now at least we have something to call it”: Patient and care partner experiences receiving an amyloid PET scan

1. A neuroimagem no diagnóstico da doença de Alzheimer: uma revisão de literatura
2. An overview on microglial origin, distribution, and phenotype in Alzheimer's disease
3. Another monoclonal antibody for Alzheimer’s to get FDA review
4. Application of weighted co-expression network analysis and machine learning to identify the pathological mechanism of Alzheimer's disease
5. Differential Neuropathology, Genetics, and Transcriptomics in Two Kindred Cases with Alzheimer’s Disease and Lewy Body Dementia
6. Dysfunction of Mitochondria in Alzheimer’s Disease: ANT and VDAC Interact with Toxic Proteins and Aid to Determine the Fate of Brain Cells
7. ESTADO NUTRICIONAL DE INDIVÍDUOS COM A DOENÇA DE ALZHEIMER E A RELAÇÃO ENTRE A FISIOPATOLOGIA DA DOENÇA E A ALIMENTAÇÃO
8. Effects of α5 GABA _A receptor modulation on social interaction, memory, and neuroinflammation in a mouse model of Alzheimer's disease
9. Identification of potential anti‐Alzheimer agents from Pistacia atlantica Desf. galls using UPLC fingerprinting, chemometrics, and molecular docking analyses
10. Iron and Alzheimer’s Disease: From Pathology to Imaging
11. Mechanisms contributing to differential genetic risks for TREM2 R47H and R62H variants in Alzheimer’s Disease
12. Polygenic risk score analysis identifies deleterious protein-coding variants in novel immune pathway genes ATP8B4, FCGR1A, and LILRB1 that associate with Alzheimer’s disease
13. Polygenic score for Alzheimer’s disease identifies differential atrophy in hippocampal subfield volumes
14. The Impact of the COVID-19 Pandemic on Family-Focused Care of People With Alzheimer’s Disease and Related Dementias
15. The clinical and mechanistic roles of bile acids in depression, Alzheimer's disease, and stroke
16. The landscape of metabolic brain alterations in Alzheimer's disease
17. The perspectives of family caregivers of people with Alzheimer´s disease regarding advance care planning in China: a qualitative research

1. A Novel Based-Network Strategy to Identify Phytochemicals from Radix Salviae Miltiorrhizae (Danshen) for Treating Alzheimer’s Disease
2. A case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism
3. Alzheimer's disease
4. Alzheimer’s disease after mild traumatic brain injury
5. Atendimento odontológico em pacientes com Doença de Alzheimer: revisão de literatura / Dental care in patients with Alzheimer's disease: literature review
6. Bioinspired Self-assembly Nanochaperone Inhibits Tau-Derived PHF6 Peptide Aggregation in Alzheimer’s Disease
7. Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report
8. Classification of Alzheimer’s Disease Based on Deep Learning of Brain Structural and Metabolic Data
9. Communication Deficits due to Alzheimer’s Disease: A Multimodal Vision-and-Language Analysis (Preprint)
10. Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity
11. Decision letter for "Is Alzheimer's disease an infectious neurological disease? A review of the literature"
12. Differences in aphasia syndromes between progressive supranuclear palsy–Richardson’s syndrome, behavioral variant frontotemporal dementia and Alzheimer’s dementia
13. Incompleteness features in the descriptive discourse of Chinese elders with and without Alzheimer’s disease
14. MicroRNA-22-3p ameliorates Alzheimer’s disease by targeting SOX9 through the NF-κB signaling pathway in the hippocampus
15. Modulation of MAPK- and PI3/AKT-Dependent Autophagy Signaling by Stavudine (D4T) in PBMC of Alzheimer’s Disease Patients
16. Normative Data of Mini-Mental State Examination, Montreal Cognitive Assessment, and Alzheimer’s Disease Assessment Scale-Cognitive Subscale of Community-Dwelling Older Adults in Taiwan
17. Profile of TREM2-Derived circRNA and mRNA Variants in the Entorhinal Cortex of Alzheimer’s Disease Patients
18. Reduced HGF/MET Signaling May Contribute to the Synaptic Pathology in an Alzheimer's Disease Mouse Model
19. Role of Chemokines in the Development and Progression of Alzheimer’s Disease
20. Structural and Functional Brain Connectivity Uniquely Contribute to Episodic Memory Performance in Older Adults
21. Survey Results of Speech-Language Pathologists Working With Cognitive-Communication Disorders: Improving Practices for Mild Cognitive Impairment and Early-Stage Dementia From Alzheimer's Disease
22. The impacts of health insurance and resource on the burden of Alzheimer's disease and related dementias in the world population
23. The landscape of m6A regulators in multiple brain regions of Alzheimer's Disease
24. USO DA TECNOLOGIA NO CUIDADO À PESSOA IDOSA COM DOENÇA DE ALZHEIMER: REVISÃO INTEGRATIVA
25. Vitamin D supplementation worsens Alzheimer's progression: Animal model and human cohort studies

1. TREM2 ‐induced activation of microglia contributes to synaptic integrity in cognitively intact aged individuals with Alzheimer's neuropathology
2. A Bibliometric Review on Gut Microbiome and Alzheimer’s Disease Between 2012 and 2021
3. A Multi-scale Attention-based Convolutional Network for Identification of Alzheimer's Disease based on Hippocampal Subfields
4. A influência da Microbiota intestinal na patogênese da doença de Alzheimer: uma revisão integrativa / The influence of the intestinal Microbiota on the pathogenesis of Alzheimer's disease: an integrative review
5. A novel deep learning approach using AlexNet for the classification of electroencephalograms in Alzheimer's Disease and Mild Cognitive Impairment
6. Alzheimer's Disease Blood Biomarkers Associated With Neuroinflammation as Therapeutic Targets for Early Personalized Intervention
7. An Attention-Based CoT-ResNet With Channel Shuffle Mechanism for Classification of Alzheimer’s Disease Levels
8. An Automated Approach for the Detection of Alzheimer's Disease From Resting State Electroencephalography
9. An unsupervised region of interest extraction model for tau PET images and its application in the diagnosis of Alzheimer's disease
10. Aptamer-Functionalized Carbon Nanotube Field-Effect Transistor Biosensors for Alzheimer’s Disease Serum Biomarker Detection
11. Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease
12. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer’s disease
13. Automated speech based evaluation of mild cognitive impairment and Alzheimer’s disease detection using with deep belief network model
14. Bispectrum-based Cross-frequency Functional Connectivity: Classification of Alzheimer's disease
15. Brain Neural Underpinnings of Interoception and Decision-Making in Alzheimer's Disease: A Narrative Review
16. Characterizing TMS-EEG perturbation indexes using signal energy: initial study on Alzheimer's Disease classification
17. Cognitive Writing Process Characteristics in Alzheimer’s Disease
18. Cross-Modal Transfer Learning Methods for Alzheimer's Disease Diagnosis
19. Curriculum learning for early Alzheimer's Disease diagnosis
20. DNA Damage Response-Associated Cell Cycle Re-Entry and Neuronal Senescence in Brain Aging and Alzheimer’s Disease
21. Diagnosis of Alzheimer's disease and Mild Cognitive Impairment using EEG and Recurrent Neural Networks
22. Differential spatial distribution of white matter lesions in Parkinson’s and Alzheimer’s diseases and cognitive sequelae
23. Distinguishing Lewy Body Dementia from Alzheimer's Disease using Machine Learning on Heterogeneous Data: A Feasibility Study
24. Does Resting Motor Threshold correlate with severity of Alzheimer's disease?
25. Ebselen Interferes with Alzheimer’s Disease by Regulating Mitochondrial Function
26. Evaluating the neuropeptide–social cognition link in ageing: the mediating role of basic cognitive skills
27. Explainable AI Points to White Matter Hyperintensities for Alzheimer's Disease Identification: a Preliminary Study
28. Explore the Therapeutic Composition and Mechanism of Schisandra chinensis-Acorus tatarinowii Schott on Alzheimer’s Disease by Using an Integrated Approach on Chemical Profile, Network Pharmacology, and UPLC-QTOF/MS-Based Metabolomics Analysis
29. Exploring High Spectro-Temporal Resolution for Alzheimer’s Dementia Detection
30. Fair and Privacy-Preserving Alzheimer's Disease Diagnosis Based on Spontaneous Speech Analysis via Federated Learning
31. Fast detection of sulcal regions for classification of Alzheimer’s disease and Mild Cognitive Impairment
32. Golgi-Targeted Fluorescent Probe for Imaging NO in Alzheimer’s Disease
33. Identification and validation of Alzheimer’s disease-related metabolic brain pattern in biomarker confirmed Alzheimer’s dementia patients
34. In Vitro and in Silico Analysis of Phytochemicals From Fallopia dentatoalata as Dual Functional Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease
35. Modulation of Brain Activity and Functional Connectivity by Acupuncture Combined With Donepezil on Mild-to-Moderate Alzheimer's Disease: A Neuroimaging Pilot Study
36. Modulation of C5a–C5aR1 signaling alters the dynamics of AD progression
37. Multidomain trials to prevent dementia: addressing methodological challenges
38. Multiple Cost Optimisation for Alzheimer's Disease Diagnosis
39. MÔ TẢ ĐẶC ĐIỂM HÌNH ẢNH CỘNG HƯỞNG TỪ VÀ HÌNH ẢNH 18F-FDG PET/CT NÃO Ở CÁC BỆNH NHÂN MẮC BỆNH ALZHEIMER TẠI BỆNH VIỆN LÃO KHOA TRUNG ƯƠNG
40. New phosphinic and phosphonic acids: Synthesis, antidiabetic, anti-Alzheimer, antioxidant activity, DFT study and SARS-CoV-2 inhibition
41. Patterns of Healthcare Use and Mortality After Alzheimer’s Disease or Related Dementia Diagnosis Among Alaska Native Patients: Results of a Cluster Analysis in a Tribal Healthcare Setting
42. Pharmacotherapy for Alzheimer’s disease: what’s new on the horizon?
43. Phenazopyridine promotes RPS23RG1/Rps23rg1 transcription and ameliorates Alzheimer-associated phenotypes in mice
44. Preliminary study on the impact of EEG density on TMS-EEG classification in Alzheimer's disease
45. Robust Assessment of EEG Connectivity Patterns in Mild Cognitive Impairment and Alzheimer's Disease
46. S-EBM: Generalising event-based modelling of disease progression for simultaneous events
47. Sleep Quality and Aging: A Systematic Review on Healthy Older People, Mild Cognitive Impairment and Alzheimer’s Disease
48. Spatio-temporal Tensor Multi-Task Learning for Predicting Alzheimer's Disease in a Longitudinal study
49. Sympathoexcitatory Responses to Isometric Handgrip Exercise Are Associated With White Matter Hyperintensities in Middle-Aged and Older Adults
50. The Amyloid Cascade Hypothesis 2.0: On the Possibility of Once-in-a-Lifetime-Only Treatment for Prevention of Alzheimer’s Disease and for Its Potential Cure at Symptomatic Stages
51. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment
52. Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson’s Disease
53. Unstable Circadian Rhythm of Heart Rate of Alzheimer Dementia Based on Biological Data of Mattress Sensor
54. Upregulated Ca2+ Release from the Endoplasmic Reticulum Leads to Impaired Presynaptic Function in Familial Alzheimer’s Disease
55. ĐẶC ĐIỂM HÌNH ẢNH 18F-FDG PET/CT NÃO TRÊN 26 BỆNH NHÂN SA SÚT TRÍ TUỆ DO BỆNH ALZHEIMER TẠI BỆNH VIỆN LÃO KHOA TRUNG ƯƠNG
56. ĐẶC ĐIỂM HÌNH ẢNH 18F-FDG PET/CT NÃO Ở BỆNH NHÂN ALZHEIMER VÀ Ở NGƯỜI LÃO HÓA BÌNH THƯỜNG

1. EFFECTIVENESS OF THYMOKINO IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW IN RAT MODELS
2. The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians

1. A Review on Characteristics of Experimental Research on Acupuncture Treatment for Alzheimer’s Disease: Study Design
2. Decision letter for "Brain aging, Alzheimer's disease, and the role of stem cells in primate comparative studies"
3. Evolution of Human-Specific Alleles Protecting Cognitive Function of Grandmothers
4. Extracellular vesicles in Alzheimer’s disease: from pathology to therapeutic approaches
5. Inter- and intra-chromosomal modulators of the APOE ɛ2 and ɛ4 effects on the Alzheimer’s disease risk
6. Lamotrigine protects against cognitive deficits, synapse and nerve cell damage, and hallmark neuropathologies in a mouse model of Alzheimer’s disease
7. Myelin lipid deficiency: a new key driver of Alzheimer’s disease
8. Review for "Brain aging, Alzheimer's disease, and the role of stem cells in primate comparative studies"
9. The neuroprotective effects of oxygen therapy in Alzheimer’s disease: a narrative review

1. Adjustment for biased sampling using NHANES derived propensity weights
2. Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer’s Disease Therapy
3. Alzheimer : combattre la somnolence
4. Alzheimer’s disease: Ablating single master site abolishes tau hyperphosphorylation
5. Differentially Aquaporin 5 Expression in Submandibular Glands and Cerebral Cortex in Alzheimer’s Disease
6. Editorial: Progress of Translational Medicine in Alzheimer's Disease
7. Effects of antidiabetic agents on Alzheimer’s disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin
8. Functionalized Allopurinols Targeting Amyloid-Binding Alcohol Dehydrogenase Rescue Aβ-Induced Mitochondrial Dysfunction
9. Icariin: A Potential Neuroprotective Agent in Alzheimer’s Disease and Parkinson’s Disease
10. Molecular and electrophysiological features of GABAergic neurons in the dentate gyrus reveal limited homology with cortical interneurons
11. Nanomedicines in the Management of Alzheimer’s Disease: Current View and Future Prospects
12. Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions
13. The Longitudinal Association of Lifestyle with Cognitive Health and Dementia Risk: Findings from the HELIAD Study
14. Trend Analysis on Alzheimer's Disease Based on Topic Mode

1. A multi-pronged human microglia response to Alzheimer’s disease Aβ pathology
2. Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer’s Disease Patients
3. Automated detection of mild cognitive impairment and dementia from voice recordings: A natural language processing approach
4. Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention
5. Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer’s Disease Pathology, and Cognitive Decline
6. Decreased Frontal Gamma Activity in Alzheimer Disease Patients
7. Design, Synthesis, and Pharmacological Evaluation of N-Propargylated Diphenylpyrimidines as Multitarget Directed Ligands for the Treatment of Alzheimer’s Disease
8. Engineered Carbon Nanostructures for Preventing Alzheimer’s Disease
9. Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer’s disease
10. Genetic Association Between Epigenetic Aging-Acceleration and the Progression of Mild Cognitive Impairment to Alzheimer’s Disease
11. Hub Genes, Diagnostic Model, and Predicted Drugs Related to Iron Metabolism in Alzheimer's Disease
12. Impact of the COVID-19 Pandemic and Lockdown on Anxiety, Depression and Nursing Burden of Caregivers in Alzheimer's Disease, Dementia With Lewy Bodies and Mild Cognitive Impairment in China: A 1-Year Follow-Up Study
13. Impaired hippocampal neurogenesis in vitro is modulated by dietary-related endogenous factors and associated with depression in a longitudinal ageing cohort study
14. Novel Neuroprotective Potential of Bunchosia armeniaca (Cav.) DC against Lipopolysaccharide Induced Alzheimer’s Disease in Mice
15. O USO DO GINKGO BILOBA NO TRATAMENTO DO ALZHEIMER
16. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
17. REVISÃO BIBLIOGRÁFICA SOBRE A DOENÇA DO ALZHEIMER: HIPERFOSFORILAÇÃO DA PROTEÍNA TAU E DEPOSIÇÃO DO PEPTÍDEO β-AMILOSE.
18. Reproducibility of neuroimaging studies of brain disorders with hundreds -not thousands- of participants
19. Scalar on time-by-distribution regression and its application for modelling associations between daily-living physical activity and cognitive functions in Alzheimer’s Disease
20. Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of diabetic patients based on their cognitive status
21. Structural analysis on mutations related to Alzheimer’s disease
22. The Knowledge and Attitudes of Primary Care and the Barriers to Early Detection and Diagnosis of Alzheimer’s Disease
23. The effect of framing on attitudes towards Alzheimer’s disease. A comparative study between younger and older adults
24. “Living Well” Trajectories Among Family Caregivers of People With Mild-to-Moderate Dementia in the IDEAL Cohort

1. 732 BGRS/SB-2022 Effects of two types of the central (intracerebroventricular vs. intrahippocampal) administration of Aβ25-35 on the induction of Alzheimer’s disease-like pathology in mice
2. 744 BGRS/SB-2022 Oral trehalose intake as an experimental therapy for Alzheimer’s disease in a mouse model induced by the central administration of amyloid-β
3. A self-administered home-based approach for treating anomia in Alzheimer’s disease
4. AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation
5. All-D-enantiomeric peptide designed for Alzheimer´s disease treatment dynamically interacts with amyloidogenic region of membrane-bound amyloid-β peptide precursor
6. Alteration of hippocampal glial support during early postnatal development as a possible premise of Alzheimer’s disease
7. Alterations of glutamatergic/GABAergic systems during healthy aging and Alzheimer’s disease-like pathology in rats
8. Alternative processing of human HTT mRNA with implications for Huntington’s disease therapeutics
9. Analysis of changes in microglia and cerebral endothelium in hippocampus of OXYS rats during progression of Alzheimer's disease-like pathology
10. Analysis of mitochondrial supply of neuronal processes during the postnatal brain maturation in OXYS rats – a model of sporadic Alzheimer’s disease
11. Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia
12. Aβ/Amyloid Precursor Protein-Induced Hyperexcitability and Dysregulation of Homeostatic Synaptic Plasticity in Neuron Models of Alzheimer’s Disease
13. BGRS/SB-2022 731 Combined treatment with autophagy inducers rapamycin and trehalose as an experimental therapy for Alzheimer’s disease-like pathology in mice
14. Bipolar Disorder and Manic-like Symptoms in Alzheimer’s, Vascular and Frontotemporal Dementia: A Systematic Review
15. Dysregulation of Sphingosine-1-Phosphate (S1P) and S1P Receptor 1 Signaling in the 5xFAD Mouse Model of Alzheimer’s Disease
16. Effects of amisulpride on the Tau-protein hyperphosphorilation in OXYS rats – a model of sporadic Alzheimer’s disease
17. Fibrinogen in Alzheimer’s Disease, Parkinson’s Disease and Lewy Body Dementia: A Mendelian Randomization Study
18. Fighting Alzheimer's disease: is there a chance to conquer?
19. How a Medicare payment model is affecting care for older adults with Alzheimer's disease and related dementias
20. Immune Response at the Crossroads of Atherosclerosis and Alzheimer's Disease
21. Longitudinal Intraindividual Cognitive Variability Is Associated With Reduction in Regional Cerebral Blood Flow Among Alzheimer’s Disease Biomarker-Positive Older Adults
22. Longitudinal changes in brain oxygen extraction fraction (OEF) in older adults: Relationship to markers of vascular and Alzheimer's pathology
23. Mitophagy: An Emergence of New Player in Alzheimer’s Disease
24. Neuron‐specific translational control shift ensures proteostatic resilience during ER stress
25. New 1,2,3-Triazole-genipin Analogues and Their Anti-Alzheimer’s Activity
26. Perceptions of Research Burden and Retention Among Participants in ADRC Cohorts
27. Periarteriolar spaces modulate cerebrospinal fluid transport into brain and demonstrate altered morphology in aging and Alzheimer’s disease
28. Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons
29. Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
30. The rat brain transcriptome: from infancy to aging and sporadic Alzheimer’s disease-like pathology
31. Toward rational use of cognitive training in those with mild cognitive impairment
32. Use of α1‐adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease
33. “She starts to be her old self again”: familial reflections on pre- and post-onset identity in people with Alzheimer’s and behavioural-variant frontotemporal dementia

1. A Proposal of Cognitive Intervention in Patients with Alzheimer’s Disease through an Assembling Game: A Pilot Study
2. A locus at 19q13.31 significantly reduces the ApoE ε4 risk for Alzheimer’s Disease in African Ancestry
3. A systematic review and meta-analysis of cerebrospinal fluid amyloid and tau levels in patients progressing from Mild Cognitive Impairment to Alzheimer’s Disease
4. Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease
5. Advancing Research on Alzheimer's Disease and AD‐Related Dementias (NIA/NINDS)
6. Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer’s disease in TgF344-AD rats
7. Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt–Jakob disease and autoimmune encephalitis
8. Analysis of a stochastic reaction–diffusion Alzheimer’s disease system driven by space–time white noise
9. Charting the meningeal lymphatic network
10. Clinical Trial Design in Alzheimer's Disease
11. Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis
12. Computational insight into the binding of bryostatin 1 with ferritin: implication of natural compounds in Alzheimer’s disease therapeutics
13. Early reduction of cerebral lactate in Alzheimer’s disease mouse model: The relationship with Aβ production
14. Excessive/Aberrant and Maladaptive Synaptic Plasticity: A Hypothesis for the Pathogenesis of Alzheimer’s Disease
15. Neuroprotection by resveratrol: A review on brain delivery strategies for Alzheimer’s and Parkinson’s disease
16. Screening of Human Circular RNAs as Biomarkers for Early Onset Detection of Alzheimer’s Disease
17. Sex-Related Microglial Perturbation Is Related to Mitochondrial Changes in a Model of Alzheimer’s Disease
18. Targeting Neuroplasticity for the Management of Pain and Agitation in Alzheimer’s Disease via Bergamot Nanotherapy
19. The Alzheimer risk factor CD2AP causes dysfunction of the brain vascular network
20. WNT/β-catenin Pathway: a Possible Link Between Hypertension and Alzheimer’s Disease

1. A Novel Multifunctional 5,6-Dimethoxy-Indanone-Chalcone-Carbamate Hybrids Alleviates Cognitive Decline in Alzheimer’s Disease by Dual Inhibition of Acetylcholinesterase and Inflammation
2. Altered mitochondrial microenvironment at the spotlight of musculoskeletal aging and Alzheimer’s disease
3. Altered visual entrainment in patients with Alzheimer’s disease: magnetoencephalography evidence
4. CSF biomarkers in patients with epilepsy in Alzheimer’s disease: a nation-wide study
5. Causal links among amyloid, tau, and neurodegeneration
6. Cysteine string protein alpha accumulates with early pre-synaptic dysfunction in Alzheimer’s disease
7. Development of prognostic models for survival and care status in sporadic Creutzfeldt-Jakob disease
8. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years
9. Evaluating the Impact of Community Gardening on Sense of Purpose for Persons Living with Dementia: A Cluster-Randomized Pilot Study
10. Identification of Alzheimer’s Disease Progression Stages Using Topological Measures of Resting-State Functional Connectivity Networks: A Comparative Study
11. Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis
12. Insights Into the Role of Mortalin in Alzheimer’s Disease, Parkinson’s Disease, and HIV-1-Associated Neurocognitive Disorders
13. Khaya grandifoliola active fraction as a source of therapeutic compounds for Alzheimer’s disease treatment: In silico validation of identified compounds
14. Repopulated microglia induce expression of Cxcl13 with differential changes in Tau phosphorylation but do not impact amyloid pathology
15. Salidroside attenuates neuronal ferroptosis by activating the Nrf2/HO1 signaling pathway in Aβ1-42-induced Alzheimer’s disease mice and glutamate-injured HT22 cells
16. Synthesis and QSAR of Novel Ketoprofen–Chalcone-Amide Hybrides as Acetylcholinesterase (AChE) Inhibitors for Possible Treatment of Alzheimer Disease
17. Transcranial magnetic stimulation treatment in Alzheimer’s disease: a meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization

1. Alzheimer’s disease: a scoping review of biomarker research and development for effective disease diagnosis
2. Dignity for Deeply Forgetful People: How Caregivers Can Meet the Challenges of Alzheimer’s Disease
3. Early Electrophysiological Aberrations in the Hippocampus of the TgF344-AD Rat Model as a Potential Biomarker for Alzheimer’s Disease Prognosis
4. Effect of nutritional supports on malnutrition, cognition, function and biomarkers of Alzheimer’s disease: a systematic review
5. FMRI complexity correlates with tau-PET in Late-Onset and Autosomal Dominant Alzheimer’s Disease
6. High Frequency Oscillations (250-500Hz) in Animal Models of Alzheimer’s Disease and Two Animal Models of Epilepsy
7. Loss of LAMP5 interneurons drives neuronal network dysfunction in Alzheimer’s disease
8. Revealing Individual Neuroanatomical Heterogeneity in Alzheimer’s Disease

1. A eficácia da musicoterapia nas práticas de enfermagem em pacientes com Alzheimer uma revisão narrativa
2. Blood extracellular vesicles carrying synaptic function‐ and brain‐related proteins as potential biomarkers for Alzheimer's disease
3. Decision letter for "White matter integrity and key structures affected in Alzheimer’s disease characterized by diffusion tensor imaging"
4. Elevated blood pressure is associated with advanced brain aging in mid‐life: A 30‐year follow‐up of The CARDIA Study
5. Modelling the contributions to hyperexcitability in a mouse model of Alzheimer’s disease
6. Review for "Brain aging, Alzheimer's disease, and the role of stem cells in primate comparative studies"
7. Silencing of ApoE with Divalent siRNAs Drives Activation of Immune Clearance Pathways and Improves Amyloid Pathology in Mouse Models of Alzheimer’s Disease
8. Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer’s disease mouse model
9. Text mining and portal development for gene-specific publications on Alzheimer’s disease and other neurodegenerative diseases

1. A Review of the Brain-Gut-Microbiome Axis and the Potential Role of Microbiota in Alzheimer’s Disease
2. Alzheimer’s Disease: Treatment of Multi-Factorial Disorders with Multi-Target Approach
3. An Investigation into the Effects of Outer Membrane Vesicles and Lipopolysaccharide of Porphyromonas gingivalis on Blood-Brain Barrier Integrity, Permeability, and Disruption of Scaffolding Proteins in a Human in vitro Model
4. Analysis of the Effects of Curculin on Neuronal Cells, Glutamate Transporter Solute Carrier Family 1, Learning and Memory in Alzheimer’s Disease Rats
5. Apolipoprotein E ε4 Mediates Myelin Breakdown by Targeting Oligodendrocytes in Sporadic Alzheimer Disease
6. Association between Alzheimer’s Disease and Oral and Gut Microbiota: Are Pore Forming Proteins the Missing Link?
7. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease
8. Associations between proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening cohort
9. Author response for "Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta‐analysis"
10. Bacterial Amyloid Curli Associated Gut Epithelial Neuroendocrine Activation Predominantly Observed in Alzheimer’s Disease Mice with Central Amyloid-β Pathology
11. Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer’s Disease
12. Bioactive Food Abates Metabolic and Synaptic Alterations by Modulation of Gut Microbiota in a Mouse Model of Alzheimer’s Disease
13. Can Better Management of Periodontal Disease Delay the Onset and Progression of Alzheimer’s Disease?
14. Circulating Cell-Free Mitochondrial DNA in Pregnancy
15. Clinical Manifestations of Early-Onset Dementia With Lewy Bodies Compared With Late-Onset Dementia With Lewy Bodies and Early-Onset Alzheimer Disease
16. Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System
17. Clinical and Bacterial Markers of Periodontitis and Their Association with Incident All-Cause and Alzheimer’s Disease Dementia in a Large National Survey
18. Derin Öğrenme ile Alzheimer Hastalığı Teşhisi İçin Model Önerisi
19. Diet Patterns, the Gut Microbiome, and Alzheimer’s Disease
20. Disclosing Alzheimer Disease Biomarker Results to Research Participants
21. Discovery of Gut Bacteria Specific to Alzheimer’s Associated Diseases Is a Clue to Understanding Disease Etiology: Meta-Analysis of Population-Based Data on Human Gut Metagenomics and Metabolomics
22. Do Periodontal Pathogens or Associated Virulence Factors Have a Deleterious Effect on the Blood-Brain Barrier, Contributing to Alzheimer’s Disease?
23. Drosophila as a Model for Microbiota Studies of Neurodegeneration
24. Effects of Probiotic Supplementation on Short Chain Fatty Acids in the AppNL–G–F Mouse Model of Alzheimer’s Disease
25. Escalation of Tau Accumulation after a Traumatic Brain Injury: Findings from Positron Emission Tomography
26. Geographical Distribution and Diversity of Gut Microbial NADH: Ubiquinone Oxidoreductase Sequence Associated with Alzheimer’s Disease
27. Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer’s Disease or Mild Cognitive Impairment
28. Gut Microbiota Alteration and Its Time Course in a Tauopathy Mouse Model
29. Gut Microbiota Alterations and Cognitive Impairment Are Sexually Dissociated in a Transgenic Mice Model of Alzheimer’s Disease
30. Gut Microbiota and Alzheimer’s Disease: Pathophysiology and Therapeutic Perspectives
31. Gut Microbiota as a Hidden Player in the Pathogenesis of Alzheimer’s Disease
32. Handbook of Microbiome and Gut-Brain-Axis in Alzheimer’s Disease
33. High Salt Elicits Brain Inflammation and Cognitive Dysfunction, Accompanied by Alternations in the Gut Microbiota and Decreased SCFA Production
34. How does Apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model
35. Human Gut Microbiota in Health and Alzheimer’s Disease
36. Hyperparameter Tuning with High Performance Computing Machine Learning for Imbalanced Alzheimer’s Disease Data
37. Influence of the Microbiota-Gut-Brain Axis on Cognition in Alzheimer’s Disease
38. Interaction Between Diet and Microbiota in the Pathophysiology of Alzheimer’s Disease: Focus on Polyphenols and Dietary Fibers
39. Interdependent Attribute Interference Fuzzy Neural Network-Based Alzheimer Disease Evaluation
40. Investigating Casual Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study
41. Investigation of Cyclo-Z Therapeutic Effect on Insulin Pathway in Alzheimer's Rat Model: Biochemical and Electrophysiological Parameters
42. Investigation of Potential Brain Microbiome in Alzheimer’s Disease: Implications of Study Bias
43. La enfermedad periodontal es un factor de riesgo para la enfermedad de Alzheimer
44. Molecular pathology and biomarker of progression in Alzheimer’s disease
45. Neuroprotective Effects of Hesperidin and Naringin in SK-N-AS Cell as an In Vitro Model for Alzheimer’s Disease
46. New Approaches to Profile the Microbiome for Treatment of Neurodegenerative Disease
47. Oral Infections and Cytokine Levels in Patients with Alzheimer’s Disease and Mild Cognitive Impairment Compared with Controls
48. Oral Inflammation, Tooth Loss, Risk Factors, and Association with Progression of Alzheimer’s Disease
49. PHOSPHODIESTERASE (PDE) INHIBITORS IN ALZHEIMER’S DISEASE: ROLE AND CURRENT STATUS
50. Paternal Occupation and Delirium Risk in Older Adults: A Potential Marker of Early-Life Exposures
51. Patient-Derived Fibroblasts With Presenilin-1 Mutations, That Model Aspects of Alzheimer’s Disease Pathology, Constitute a Potential Object for Early Diagnosis
52. Patients With Severe Alcohol-Related Cognitive Impairment Improve in Flexibility When Abstinence Is Maintained: A Comparative Study With Alzheimer’s Disease
53. Periodontal Inflammation in Relation to Cognitive Function in an Older Adult Danish Population
54. Periodontitis Deteriorates Cognitive Function and Impairs Neurons and Glia in a Mouse Model of Alzheimer’s Disease
55. Preprint Highlight: Transcriptomic changes highly similar to Alzheimer's disease are observed in a subpopulation of individuals during normal brain aging
56. Psychometric Evaluation of Self-assessment Persian Version of the Alzheimer Questionnaire (AQ)
57. Rare APOE Missense Variants—Can We Overcome APOE ε4 and Alzheimer Disease Risk?
58. Relationship Between Plasma Lipopolysaccharides, Gut Microbiota, and Dementia: A Cross-Sectional Study
59. Relationship Between Plasma Neurofilament Light Chain, Gut Microbiota, and Dementia: A Cross-Sectional Study
60. Relationship Between the Gut Microbiota and Alzheimer’s Disease: A Systematic Review
61. Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer’s Disease
62. Teaching Protein–Ligand Interactions Using a Case Study on Tau in Alzheimer’s Disease
63. The Association Between Cancer and Alzheimer's-Type Neuropathology: A Community-Based Cohort Study
64. The Association of Post-Stroke Cognitive Impairment and Gut Microbiota and its Corresponding Metabolites
65. The Gut Microbiota and Alzheimer’s Disease
66. The Role of the Gut Microbiota in the Metabolism of Polyphenols as Characterized by Gnotobiotic Mice
67. Vascular Cognitive Impairment and the Gut Microbiota
68. “Muscle-Gut-Brain Axis”: Can Physical Activity Help Patients with Alzheimer’s Disease Due to Microbiome Modulation?

1. 29  Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: An individual patient data network meta-analysis
2. A ketogenic intervention improves dorsal attention network functional and structural connectivity in mild cognitive impairment
3. A monomeric polysaccharide from Polygonatum sibiricum improves cognitive functions in a model of Alzheimer's disease by reshaping the gut microbiota
4. A novel Alzheimer’s disease detection approach using GAN-based brain slice image enhancement
5. A novel multi-target strategy for Alzheimer's disease treatment via sublingual route: Donepezil/memantine/curcumin-loaded nanofibers
6. A single-molecule with multiple investigations: Synthesis, characterization, computational methods, inhibitory activity against Alzheimer's disease, toxicity, and ADME studies
7. A systematic review of music interventions for the cognitive and behavioural symptoms of mild cognitive impairment (non-dementia)
8. A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?
9. ACADEMIA-INDUSTRY COOPERATION FOR THE THERAPY OF ALZHEIMER AND MILD DEMENTIA: A SHARED TRAINING AND RESEARCH PROJECT
10. AD-CovNet: An exploratory analysis using a hybrid deep learning model to handle data imbalance, predict fatality, and risk factors in Alzheimer's patients with COVID-19
11. ADHD drugs may help Alzheimer's
12. Access to Disease-Modifying Alzheimer’s Therapies: Addressing Possible Challenges Using Innovative Payment Models
13. Activating transcription factor 6 regulates cystathionine to increase autophagy and restore memory in Alzheimer’ s disease model mice
14. Altered protein expression of membrane transporters in isolated cerebral microvessels and brain cortex of a rat Alzheimer's disease model
15. Alzheimer's disease and increasing the uptake of influenza vaccination
16. Alzheimer’s disease is a result of loss of full brain buoyancy
17. Alzheimer’s neuroinflammation: A crosstalk between immune checkpoint PD1-PDL1 and ApoE-Heparin interactions?
18. Amyloid-β oligomers interact with NMDA receptors containing GluN2B subunits and metabotropic glutamate receptor 1 in primary cortical neurons: Relevance to the synapse pathology of Alzheimer’s disease
19. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
20. An Overview of Tetramethylpyrazine (Ligustrazine) and its Derivatives as Potent Anti-Alzheimer’s Disease Agents
21. Anti-Alzheimer's and Antioxidant Activity of Ethanolic Seed Extract of Sapindus emarginatus Vahl on Scopolamine-Induced Cognitive Impairment in Mice
22. Antibody binding modulates the dynamics of the membrane-bound prion protein
23. ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
24. Articulating target-mining techniques to disinter Alzheimer's specific targets for drug repurposing
25. Association of cognitive reserve with stroke outcome: a protocol for a systematic review
26. Association of periodontitis and oral microbiomes with Alzheimer’s disease: A narrative systematic review
27. Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome
28. Bimodal regulation of axonal transport by the GDNF-RET signalling axis in healthy and diseased motor neurons
29. Bioinformatics-Based Approach for Exploring the Immune Cell Infiltration Patterns in Alzheimer’s Disease and Determining the Intervention Mechanism of Liuwei Dihuang Pill
30. Blutbasierte Biomarker zur Optimierung der Früh- und Differentialdiagnostik der Alzheimer-Demenz
31. CO147 Driving Outcomes in Mild Cognitive Impairment/Alzheimer's Disease - a Review of Association between Driving Simulator Measures and Clinical Outcomes Assessments
32. Central Executive Network and Executive Function in Patients With Alzheimer’s Disease and Healthy Individuals: Meta-Analysis of Structural and Functional MRI
33. Changes in Measures of Vestibular and Balance Function and Hippocampus Volume in Alzheimer’s Disease and Mild Cognitive Impairment
34. Characterizing the propagation pathway of neuropathological events of Alzheimer's disease using harmonic wavelet analysis
35. Cholesterol and obesity: A marker for Alzheimer’s disease
36. Chronic exposure to traffic-related air pollution reduces lipid mediators of linoleic acid and soluble epoxide hydrolase in serum of female rats
37. Classifying the lifestyle status for Alzheimer’s disease from clinical notes using deep learning with weak supervision
38. Clusterin in Alzheimer's disease: An amyloidogenic inhibitor of amyloid formation?
39. Comment on “Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism” Clinical Nutrition 2022
40. Comorbidities confound Alzheimer’s blood tests
41. Computational investigation of the dynamic control of cAMP signaling by PDE4 isoform types
42. Construction of a confounder-free clinical MRI dataset in the Mass General Brigham system for classification of Alzheimer's disease
43. Corrigendum to Impact of plate shape on the conservation of food praxis in institutionalised elderly adults with severe Alzheimer's disease or mixed dementia: Praxalim an observational before-after non-randomized study
44. Cross-seeding of WT amyloid-β with Arctic but not Italian familial mutants accelerates fibril formation in Alzheimer's disease
45. Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease
46. CurvMRI: A Curvelet Transform-Based MRI Approach for Alzheimer's Disease Detection
47. Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline
48. Development of a three tiered cognitive hybrid machine learning algorithm for effective diagnosis of Alzheimer’s disease
49. Diagnostic accuracy study of automated stratification of Alzheimer’s disease and mild cognitive impairment via deep learning based on MRI
50. Differential gene expression by RNA-seq during Alzheimer’s disease-like progression in the Drosophila melanogaster model
51. Drug delivery of memantine with carbon dots for Alzheimer’s disease: blood–brain barrier penetration and inhibition of tau aggregation
52. EE200 Economic Evaluation of an Opportunistic Screening Program for Alzheimer's Disease in Luohu, China
53. EE263 Impact of Treatment Duration on the Potential Cost-Effectiveness of Disease-Modifying Therapies for the Treatment of Early Symptomatic Alzheimer's Disease
54. EE354 Heterogeneity in the Economic Value of Early Alzheimer's Disease-Modifying Therapies: An Analysis of Patient Subgroups
55. EE380 Economic Burden of Alzheimer's Disease and Mild Cognitive Decline in Colombia
56. EE399 AD Valorem: Alzheimer’s Disease, Atopic Dermatitis, and Challenges for Value Assessment in Chronic Conditions
57. EPH144 Hormone Therapy and Risk of Alzheimer's Disease in Women: A Systematic Review and Meta-Analysis
58. EPH145 Assessing the Relationship between Heart Disease and Related Comorbidities with Dementia and Alzheimer's Disease
59. EPH163 Risk of Memantine Initiation with Use of Antimuscarinics and/or Cholinesterase Inhibitors in Older Adults with Alzheimer's Disease
60. EPH99 Antipsychotic Initiation Among Older Alzheimer's Disease Patients Using Cholinesterase Inhibitors and/or Antimuscarinics
61. Early detection of Alzheimer's disease using single nucleotide polymorphisms analysis based on gradient boosting tree
62. Early diagnosis of Alzheimer's disease based on deep learning: A systematic review
63. Effect of cerebellum stimulation on cognitive recovery in patients with Alzheimer disease: A randomized clinical trial
64. Effects of the combination of high-intensity interval training and Ecdysterone on learning and memory abilities, antioxidant enzyme activities, and neuronal population in an Amyloid-beta-induced rat model of Alzheimer's disease
65. Emerging Neuropsychiatric Symptoms May Represent an Early Manifestation of Preclinical Alzheimer’s Disease
66. Establishment of KEIOi005-A iPSC line from urine-derived cells (UDCs) of a mild Alzheimer’s disease (AD) donor with multiple risk SNPs for sporadic Alzheimer’s disease (sAD)
67. Exosomal MicroRNA-Based Predictive Model for Preclinical Alzheimer’s Disease: A Multicenter Study
68. Experimental and computational modeling of the biological activity of benzaldehyde sulphur trioxide as a potential drug for the treatment of Alzheimer disease
69. Extracellular matrix metalloproteinase-9 (MMP-9) is required in female mice for 17β-estradiol enhancement of hippocampal memory consolidation
70. Fitness training programs for Alzheimer's disease patients during the COVID-19 pandemic
71. Generation of two iPSC lines (UMi038-A & UMi039-A) from siblings bearing an Alzheimer’s disease-associated variant in SORL1
72. Genetic Evidence Supporting a Causal Role of Depression in Alzheimer’s Disease
73. Graph convolutional network with sample and feature weights for Alzheimer’s disease diagnosis
74. Green tea, epigallocatechin gallate and the prevention of Alzheimer’s disease: Clinical evidence
75. HEBP1 - An early trigger for neuronal cell death and circuit dysfunction in Alzheimer’s disease
76. Human Genetics Clarifies the Relationship Between Depression and Alzheimer’s Disease
77. Hyperinsulinemia alters insulin receptor presentation and internalization in brain microvascular endothelial cells
78. Impaired time-distance reconfiguration patterns in Alzheimer's disease: a dynamic functional connectivity study with 809 individuals from 7 sites
79. In silico identification of putative acetylcholinesterase inhibitor in the context of Alzheimer’s disease
80. Infection and inflammation: New perspectives on Alzheimer's disease
81. Infliximab and/or MESNA alleviate doxorubicin-induced Alzheimer's disease-like pathology in rats: A new insight into TNF-α/Wnt/β-catenin signaling pathway
82. Integrated approach on UPLC-QTOF/MS based active plasma component and metabolomics analysis of Gan Mai Da Zao decoction on the treatment of Alzheimer's disease in rats plasma and urine
83. Iranian thyme honey plays behavioral, cellular and molecular important roles as an amazing preventive and therapeutic agent in the brain of Alzheimer's rat model
84. Issue Information
85. Join your colleagues at AAIC ^® 2022
86. Kognitive Interventionen bei der Alzheimer-Krankheit
87. Latest progress in the development of multitarget ligands for Alzheimer's disease based on the Hantzsch reaction
88. Levetiracetam in Alzheimer’s Disease: Do Epileptologists Already Have the Cure?
89. Longitudinal Analysis of the Retina and Choroid in Cognitively Normal Individuals at Higher Genetic Risk of Alzheimer Disease
90. Longitudinal retinal imaging study of newly diagnosed relapsing-remitting multiple sclerosis in Scottish population: baseline and 12 months follow-up profile of FutureMS retinal imaging cohort
91. MSR33 Physicians' Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer's Disease (AD)
92. MST1 mediates neuronal loss and cognitive deficits: A novel therapeutic target for Alzheimer’s disease
93. Medha Plus – A novel polyherbal formulation ameliorates cognitive behaviors and disease pathology in models of Alzheimer’s disease
94. MicroRNA modulation is a potential molecular mechanism for neuroprotective effects of intranasal insulin administration in amyloid βeta oligomer induced Alzheimer's like rat model
95. Model scenarios for cell cycle re-entry in Alzheimer's disease
96. Molecular interaction of stress granules with Tau and autophagy in Alzheimer's disease
97. Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease
98. Multigroup recognition of dementia patients with dynamic brain connectivity under multimodal cortex parcellation
99. Multimodality Alzheimer's Disease Analysis in Deep Riemannian Manifold
100. NO TITLE
101. P18 Rural–Urban Differences in Provider Types Diagnosing and Prescribing for Patients with Alzheimer's Disease
102. P20 Risk of Antimuscarinic Initiation with Cholinesterase Inhibitor Use in Patients with Alzheimer's Disease
103. PCR24 The Impact of Informal Caregiving in Alzheimer’s Disease Dementia: A Health Utility Study in the UK
104. PCR59 Assessing the Utility Associated with Caregiving in Alzheimer's Disease (AD) with Mild Cognitive Impairment (MCI) and AD Dementia in Japan
105. Pharmacological Exploration of Triazole-based Therapeutics for Alzheimer’s Disease: An Overview
106. Postsecondary Education and Late-life Cognitive Outcomes Among Black and White Participants in the Project Talent Aging Study
107. Potential role of IP3/Ca2+ signaling and phosphodiesterases: Relevance to neurodegeneration in Alzheimer’s disease and possible therapeutic strategies
108. Predicting brain structural network using functional connectivity
109. Processo de nutrição para prevenção e acompanhamento de doentes em alzheimer
110. Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases
111. Retraction Notice to: circTulp4 functions in Alzheimer’s disease pathogenesis by regulating its parental gene, Tulp4
112. Retraction notice to “MicroRNA-125b promotes neurons cell apoptosis and tau phosphorylation in Alzheimer’s disease” [Neurosci. Lett. 661 (2017) 57–62]
113. Right Temporal Lobe Variant of Frontotemporal Dementia
114. Role of Long Non-coding RNAs in the Pathogenesis of Alzheimer’s and Parkinson’s Diseases
115. Saffron reduces some inflammation and oxidative stress markers in donepezil-treated mild-to-moderate Alzheimer's Disease patients: A randomized double-blind placebo-control trial
116. Saikogenin F From Bupleurum smithii Ameliorates Learning and Memory Impairment via Antiinflammation Effect in an Alzheimer’s Disease Mouse Model
117. Salivary cortisol in longitudinal associations between affective symptoms and midlife cognitive function: A British birth cohort study
118. Shared pathophysiology: Understanding stroke and Alzheimer’s disease
119. Should Alexa diagnose Alzheimer’s?: Legal and ethical issues with at-home consumer devices
120. Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease
121. Study of Alzheimer's disease- and frontotemporal dementia-associated genes in the Cretan Aging Cohort
122. Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down's syndrome
123. The Locus Coeruleus – Noradrenaline system: Looking into Alzheimer’s therapeutics with rose coloured glasses
124. The Perspective of Exosomal MicroRNAs as Biomarkers for Preclinical Alzheimer’s Disease
125. The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer’s disease
126. The genetic architecture of Alzheimer disease risk in the Ohio and Indiana Amish
127. The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer’s disease
128. The role of genetic risk factors of Alzheimer's disease in synaptic dysfunction
129. The role of mitochondrial dysfunction in Alzheimer's disease: A potential pathway to treatment
130. Treadmill exercise improve recognition memory by TREM2 pathway to inhibit hippocampal microglial activation and neuroinflammation in Alzheimer's disease model
131. Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease
132. Type-I-interferon signaling drives microglial dysfunction and senescence in human iPSC models of Down syndrome and Alzheimer’s disease
133. Updates in the Management of Mild Cognitive Impairment and Alzheimer Disease
134. Vitamin B12 as a cholinergic system modulator and blood brain barrier integrity restorer in Alzheimer's disease
135. p-Coumaric acid mitigates passive avoidance memory and hippocampal synaptic plasticity impairments in aluminum chloride-induced Alzheimer's disease rat model
136. ¿Se Podrá Recomendar el Tratamiento con Litio Para el Deterioro Cognitivo Leve y la Demencia por Enfermedad de Alzheimer? Falta Evidencia Sobre su Eficacia y su Seguridad: Revisión Sistemática y Metanálisis
137. “Who will I be?”: The future of the self as described by Alzheimer's disease (AD) patients

1. ANA Investigates: The Future of Biomarkers in Alzheimer Disease
2. A Dichotomous Role for FABP7 in Sleep and Alzheimer’s Disease Pathogenesis: A Hypothesis
3. A Review of NeuroAiDTM II (MLC901) Development in Alzheimer’s Disease Treatment: Promises of A Multimodal Pathway
4. A Study on the Correlation Between Age-Related Macular Degeneration and Alzheimer's Disease Based on the Application of Artificial Neural Network
5. A relação existente entre o diabetes mellitus e o Alzheimer
6. Alzheimer's disease
7. An Approach to Fight Alzheimer's by Finding Its Causes and Risk Factors
8. Brain MR Images Classification for Alzheimer’s Disease
9. CONCEPTUAL DESCRIPTION AND PHILOSOPHICAL UNDERPINNING OF THE SOCIAL INTERVENTION ‘ALZHEIMER WHISPERING’
10. Comprehensive analysis of lncRNA‑miRNA‑mRNA regulatory networks for Alzheimer’s disease
11. Demans ve Alzheimer Hastaları için Dijital Öneriler: REMEM Örneği
12. Early Detection of Stages of Alzheimer\\'s Disease from MRI Scans using Analysis of Hippocampus Region
13. Effects of Catalpol on Alzheimer’s Disease and Its Mechanisms
14. Emotional socialization and agency: Representations of coping with old age dementia and Alzheimer’s in graphic novels
15. Establishment and Analysis of a Combined Diagnostic Model of Alzheimer's Disease With Random Forest and Artificial Neural Network
16. Genome Sequencing Variations in the Octodon degus, an Unconventional Natural Model of Aging and Alzheimer's Disease
17. Genome‐wide association and multi‐omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women
18. Hippocampal grading provides higher Alzheimer’s Disease prediction accuracy than hippocampal volume
19. Identification of bioactive peptides from a Brazilian kefir sample, and their anti-Alzheimer potential in Drosophila melanogaster
20. Identifying the Relationship between Leisure Walking and Prevalence of Alzheimer’s Disease and Other Dementias
21. Image Processing for Alzheimer\'s disease Detection
22. Impaired neuromodulator crosstalk delays vigilance-dependent astroglia Ca²⁺ activation in mouse models of Alzheimer’s disease
23. Interaction Between anti-Alzheimer’s Disease Drugs and Antipsychotic Agents in the Treatment of Behavioral and Psychological Symptoms: Extrapyramidal Side Effects
24. Intranasal Delivery of BACE1 siRNA and Rapamycin by Dual Targets Modified Nanoparticles for Alzheimer's Disease Therapy
25. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum
26. Modulation of Memory and Neurochemical Changes by Resveratrol and Environmental Enrichment in Rodent Model of Alzheimer’s Disease
27. Novel Coumarin–Pyridine Hybrids as Potent Multi-Target Directed Ligands Aiming at Symptoms of Alzheimer’s Disease
28. POTENSI TERAPI PROBIOTIK SEBAGAI TERAPI ALZHEIMER MELALUI GUT-BRAIN AXIS
29. Partial Endothelial Nitric Oxide Synthase Deficiency Exacerbates Cognitive Deficit and Amyloid Pathology in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease
30. Prominent Effects of Berbamine Hydrochloride on Alzheimer’s Disease Model Mice
31. Study protocol for the Alzheimer and music therapy study: An RCT to compare the efficacy of music therapy and physical activity on brain plasticity, depressive symptoms, and cognitive decline, in a population with and at risk for Alzheimer’s disease
32. The Role of Microglia in Alzheimer’s Disease From the Perspective of Immune Inflammation and Iron Metabolism
33. The nervous system during COVID ‐19: Caught in the crossfire
34. Tracing the Location of Alzheimer\'s Patient Using Location Fingerprinting
35. Treatment Efficacy of Working Memory Plus Melodic Intonation Therapy for People with Dementia of Alzheimer’s Type
36. White matter pathology in alzheimer’s transgenic mice with chronic exposure to low-level ambient fine particulate matter

1. A Histochemical Analysis of Neurofibrillary Tangles in Olfactory Epithelium, a Study Based on an Autopsy Case of Juvenile Alzheimer’s Disease
2. A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer’s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration
3. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease
4. ASSOCIAÇÃO ENTRE HIPOGLICEMIA, DÉFICIT COGNITIVO, DEMÊNCIA VASCULAR E DEMÊNCIA DE ALZHEIMER EM IDOSOS COM DIABETES MELLITUS TIPO 2: UMA REVISÃO DA LITERATURA
5. Alzheimer's Disease: Considerations in the Light of Transactional Analysis
6. Analysis of Alzheimer’s disease Polygenic Risk Scores using RNA-sequencing provides further novel biological pathways
7. Automated Segmentation of Lateral Ventricles in Alzheimer’s Conditions Using UNET++ Model
8. Azo-Stilbene and Pyridine–Amine Hybrid Multifunctional Molecules to Target Metal-Mediated Neurotoxicity and Amyloid-β Aggregation in Alzheimer’s Disease
9. Classification of Alzheimer's Disease via Vision Transformer
10. Clinical Observation of Computer Vision Technology Combined with Music Therapy in the Treatment of Alzheimer’s Disease
11. DOENÇAS NEURODEGENERATIVAS: ALTERNATIVAS TERAPÊUTICAS PARA A DOENÇA DE ALZHEIMER
12. Erratum for: TRPML1 Participates in the Progression of Alzheimer's Disease by Regulating the PPARγ/AMPK/Mtor Signalling Pathway
13. Genetic prion diseases presenting as frontotemporal dementia: clinical features and diagnostic challenge
14. Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition
15. Mechanistic and Etiological Similarities in Diabetes Mellitus and Alzheimer’s Disease: Antidiabetic Drugs as Optimistic Therapeutics in Alzheimer’s Disease.
16. Multivariate morphometry statistics reveal the morphological change pattern of hippocampus during normal aging
17. NEU1—A Unique Therapeutic Target for Alzheimer’s Disease
18. Neurovascular Dysfunction in Diverse Communities With Health Disparities—Contributions to Dementia and Alzheimer’s Disease
19. Orthopedic Surgery Causes Gut Microbiome Dysbiosis and Intestinal Barrier Dysfunction in Prodromal Alzheimer Disease Patients
20. PROCare4Life: An integrated care platform to improve the quality of life of Parkinson’s and Alzheimer’s patients
21. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
22. Positive experiences in dementia care-giving: findings from the IDEAL programme
23. Preclinical efficacy of bacosides-lauric acid nano-herbal formulation in comparison to rivastigmine for treatment of Alzheimer’s disease
24. Reflections on Mentorship From Scientists and Mentors in an Alzheimer’s Disease Focused Research Training Program
25. Retraction of: Protective Effects of Colivelin Against Alzheimer's Disease in a PDAPP Mouse Model
26. Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer’s Disease
27. Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression
28. Six genetically linked mutations in the CD36 gene significantly delay the onset of Alzheimer's disease
29. Statistical power of transcriptome‐wide association studies
30. The Spanish‐English bilingual experience and cognitive change in Hispanics/Latinos from the Hispanic Community Health Study/Study of Latinos‐Investigation of Neurocognitive Aging
31. Traumatic brain injury and post‐traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers
32. Um Modelo para Acompanhamento de Pessoas com Doença de Alzheimer utilizando Análise de Históricos de Contextos
33. Upregulation of ribosome complexes at the blood-brain barrier in Alzheimer's disease patients
34. Validation of a Multivariate Prediction Model of the Clinical Progression of Alzheimer’s Disease in a Community-Dwelling Multiethnic Cohort
35. White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer’s disease that emerge prior to dementia

1. A Signal Detection Analysis of Olfactory Learning in 12-Month-Old 5xFAD Mice
2. A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer’s disease
3. A novel explainable neural network for Alzheimer’s disease diagnosis
4. Aberrant Cross-Tissue Functional Connectivity in Alzheimer’s Disease: Static, Dynamic, and Directional Properties
5. Alzheimer's Disease and the Possible Role of Vitamin D
6. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease
7. An Optimized Hyperparameter of Convolutional Neural Network Algorithm for Bug Severity Prediction in Alzheimer’s-Based IoT System
8. Analyzing of Alzheimer’s Disease Based on Biomedical and Socio-Economic Approach Using Molecular Communication, Artificial Neural Network, and Random Forest Models
9. Association of Peripheral Lymphocyte Subsets with Cognitive Decline and Dementia: The Cardiovascular Health Study
10. Astragalus mongholicus Bunge (Fabaceae): Bioactive Compounds and Potential Therapeutic Mechanisms Against Alzheimer’s Disease
11. Ações educativas do enfermeiro para a qualidade de vida de pessoas idosas com Alzheimer
12. BDNF and KIBRA Polymorphisms Are Related to Altered Resting State Network Connectivity in Middle Age
13. Bacterial Amyloid Curli Associated Gut Epithelial Neuroendocrine Activation Predominantly Observed in Alzheimer’s Disease Mice with Central Amyloid-β Pathology
14. Beneficial Effects of Snail Helix aspersa Extract in an Experimental Model of Alzheimer’s Type Dementia
15. Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer’s Disease and Neurodegeneration stratified by sex
16. CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease
17. Carotid Intima-Media Thickness and Amyloid-β Deposition: The ARIC-PET Study
18. Cattle Encephalon Glycoside and Ignotin Ameliorate Palmitoylation of PSD-95 and Enhance Expression of Synaptic Proteins in the Frontal Cortex of a APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease
19. Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer’s Disease
20. Concordance Between Self-Reported Medical Diagnosis of Mild Cognitive Impairment/Dementia and Neurocognitive Function Among Middle-Aged and Older Hispanic/Latino Adults: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA)
21. Crosstalk Between Gut Microflora and Vitamin D Receptor SNPs Are Associated with the Risk of Amnestic Mild Cognitive Impairment in a Chinese Elderly Population
22. DNA Damage Increases Secreted Aβ40 and Aβ42 in Neuronal Progenitor Cells: Relevance to Alzheimer’s Disease
23. Data-Driven Analyses of Longitudinal Hippocampal Imaging Trajectories: Discrimination and Biomarker Prediction of Change Classes
24. Deep Neural Network Model for Automated Detection of Alzheimer’s Disease using EEG Signals
25. Education and Literacy as Risk Factors of Dementia after Stroke and Transient Ischemic Attack: NEDICES Study
26. Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
27. Erratum to: JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model
28. Ethnic-Specific Type 2 Diabetes Risk Factor PAX4 R192H Is Associated with Attention-Specific Cognitive Impairment in Chinese with Type 2 Diabetes
29. Experimental Periodontitis Deteriorates Cognitive Function and Impairs Insulin Signaling in a Streptozotocin-Induced Alzheimer’s Disease Rat Model
30. Expression of Olfactory-Related Genes in the Olfactory Epithelium of an Alzheimer’s Disease Mouse Model
31. Faculty Opinions recommendation of A Real-Time Sensing System for Monitoring Neural Network Degeneration in an Alzheimer's Disease-on-a-Chip Model.
32. Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging
33. Gut Microbiota and Subjective Memory Complaints in Older Women
34. Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer’s Disease and Primary Tauopathy Postmortem Brains
35. Impact of Sarcopenia on Decline in Quality of Life in Older People with Mild Cognitive Impairment
36. Insulin-Like Growth Factor, Inflammation, and MRI Markers of Alzheimer’s Disease in Predominantly Middle-Aged Adults
37. Interplay Between Hippocampal Glutathione Depletion and pH Increment in Alzheimer’s Disease
38. Migraine, Cognitive Decline, and Dementia in Older Adults: A Population-Based Study
39. NF-kB (p50/p65)-Mediated Pro-Inflammatory microRNA (miRNA) Signaling in Alzheimer's Disease (AD)
40. Nocturnal Hypoxia and Sleep Fragmentation May Drive Neurodegenerative Processes: The Compared Effects of Obstructive Sleep Apnea Syndrome and Periodic Limb Movement Disorder on Alzheimer’s Disease Biomarkers
41. Novel Invisible Spectral Flicker Induces 40 Hz Neural Entrainment with Similar Spatial Distribution as 40 Hz Stroboscopic Light
42. Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes
43. Phase 3 data show brexpiprazole reduces agitation in Alzheimer’s dementia
44. Post-Translationally Regulated Protein Arginine-to-Proline Conversion in Alzheimer’s Brains
45. Postoperative Cognitive Dysfunction and Alzheimer’s Disease: A Transcriptome-Based Comparison of Animal Models
46. Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis
47. Prefrontal Activation During Effortful Processing Differentiates Memory Abilities in Adults with Memory Complaints
48. Release of Endogenous Brain-derived Neurotrophic Factor into the Lateral Entorhinal Cortex from the Paraventricular Thalamus Ameliorates Social Memory Deficits in a Mouse Model of Alzheimer’s Disease
49. The Correlations of Plasma Liver-Type Fatty Acid-Binding Protein with Amyloid-β and Tau Levels in Patients with Alzheimer’s Disease
50. The Role of Exosomes as Mediators of Neuroinflammation in the Pathogenesis and Treatment of Alzheimer’s Disease
51. The association of depression and apathy with Alzheimer’s disease biomarkers in a cross-cultural sample
52. The role of the immune system in early Lewy Body and Alzheimer’s disease
53. Verbal Encoding Deficits Impact Recognition Memory in Atypical “Non-Amnestic” Alzheimer’s Disease

1. A Practical Multiclass Classification Network for the Diagnosis of Alzheimer’s Disease
2. A ingestão de cafeína como fator protetor no desenvolvimento e na progressão da Doença de Parkinson e na Doença de Alzheimer: uma revisão integrativa
3. Bacillus Calmette–Guérin in Immuno-Regulation of Alzheimer’s Disease
4. Brain functional topology differs by sex in cognitively normal older adults
5. Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline
6. Comprehensive Characterization of CK1δ-Mediated Tau Phosphorylation in Alzheimer’s Disease
7. Correlative Chemical Imaging and Spatial Chemometrics Delineate Alzheimer Plaque Heterogeneity at High Resolution
8. Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer’s Disease Brain
9. Effect of simultaneous dual-task training on regional cerebral blood flow in older adults with amnestic mild cognitive impairment
10. Formal caregivers' competence of Alzheimer patients in long-term care institutions
11. Genetic prediction of impulse control disorders in Parkinson's disease
12. Genotypic effects of APOE-ε4 on resting-state connectivity in cognitively intact individuals support functional brain compensation
13. Hypertension and Alzheimer's disease pathology at autopsy: A systematic review
14. Item-Level Story Recall Predictors of Amyloid-Beta in Late Middle-Aged Adults at Increased Risk for Alzheimer’s Disease
15. Lipid-based nanocarriers via nose-to-brain pathway for Alzheimer's and Parkinson's disease.
16. Molecular Dynamics Simulations of the Tau Amyloid Fibril Core Dimer at the Surface of a Lipid Bilayer Model: I. In Alzheimer’s Disease
17. Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer’s Disease
18. Neurofilament light-associated connectivity in young-adult Huntington’s disease is related to neuronal genes
19. Neuroprotection of Multitargeted Phytochemicals against Alzheimer: A Desperate Need from Nature
20. Primary Sjögren’s syndrome presenting with rapidly progressive dementia: a case report.
21. Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimer’s Disease Model Mice
22. Sparse Function Learning for Alzheimer’s Disease Detection Dependent on Magnetic Characteristics Imaging with Mark Information
23. Structure–Activity Relationship Analysis of Flavonoids and Its Inhibitory Activity Against BACE1 Enzyme Toward a Better Therapy for Alzheimer’s Disease
24. Targeting Microglia in Alzheimer’s Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules
25. The Alzheimer’s disease GWAS risk alleles in the ABCA7 promoter and 5’ region reduce ABCA7 expression
26. The Risk of Developing Alzheimer’s Disease and Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis
27. The extracellular matrix and perineuronal nets in memory
28. Toward harmonization of strategies for investigating lucidity in AD/ADRD: A preliminary research framework

1. Faculty Opinions recommendation of Alzheimer-like tau accumulation in dentate gyrus mossy cells induces spatial cognitive deficits by disrupting multiple memory-related signaling and inhibiting local neural circuit.
2. Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer’s Disease
3. Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease
4. Vascular Dysfunction Is Central to Alzheimer’s Disease Pathogenesis in APOE e4 Carriers

1. Spatial–temporal graph convolutional network for Alzheimer classification based on brain functional connectivity imaging of electroencephalogram
2. A New Bistable Switch Model of Alzheimer’s Disease Pathogenesis
3. Conhecimento da equipe de enfermagem de uma instituição de longa permanência quanto aos cuidados com o idoso portador de Alzheimer no município de Vitória da Conquista - Bahia
4. Engagement of people with lived experience of dementia advisory group and cross-cutting program: reflections on the first year
5. Olfactory Bulb Amyloid-β Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment
6. Prescribing Alzheimer’s Disease treatments by provider type and geographic region: a comparison among physicians, nurse practitioners, and physician assistants
7. The “Cerebrospinal Fluid Sink Therapeutic Strategy” in Alzheimer’s Disease—From Theory to Design of Applied Systems

1. A Metallomic Approach to Assess Associations of Plasma Metal Levels with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: An Exploratory Study
2. Associations between Homelessness and Alzheimer’s Disease and Related Dementia: A Systematic Review
3. CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer’s disease
4. Computational Analysis of Pathogenetic Pathways in Alzheimer’s Disease and Prediction of Potential Therapeutic Drugs
5. Current peptide vaccine and immunotherapy approaches against Alzheimer's disease
6. Decision letter for "Calcium Inhibits Penetration of Alzheimer's Aβ _1‐42 Monomers into the Membrane"
7. Design, synthesis, and biological evaluation of thienopyrimidine and thienotriazine derivatives as multitarget anti‐Alzheimer agents
8. Detection and Classification of Alzheimer’s disease Stages using Deep Learning Approach
9. Differential perivascular microglial activation in the deep white matter in vascular dementia developed post‐stroke
10. Discriminant Subspace Low-Rank Representation Algorithm for Electroencephalography-Based Alzheimer’s Disease Recognition
11. Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys
12. Estimating the longitudinal trajectory of cognitive function measurement using short‐term data with different disease stages: Application in Alzheimer's disease
13. Evaluation of Feature Selection for Alzheimer’s Disease Diagnosis
14. Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity
15. High-Density Lipoprotein Changes in Alzheimer’s Disease Are APOE Genotype-Specific
16. High-intensity interval training ameliorate diabetes-induced disturbances in Alzheimer's-related factors in the hippocampus through adiponectin signaling
17. Impact of fish consumption on all-cause mortality in older people with and without dementia: a community-based cohort study
18. Modeling the Competition between Misfolded Aβ Conformers That Produce Distinct Types of Amyloid Pathology in Alzheimer’s Disease
19. Most Pathways Can Be Related to the Pathogenesis of Alzheimer’s Disease
20. Neuropsychiatric or Behavioral and Psychological Symptoms of Dementia (BPSD): Focus on Prevalence and Natural History in Alzheimer's Disease and Frontotemporal Dementia
21. Optimal Evaluation and Detection of Alzheimer's
22. PITRM1 interaction studies with amyloidogenic nonapeptide mutants of familial Alzheimer’s disease
23. Plcg2M28L Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice
24. Procedural learning, declarative learning, and working memory as predictors of learning the use of a memory compensation tool in persons with amnestic mild cognitive impairment
25. Review for "A review of stem cell therapy: An emerging treatment for dementia in Alzheimer's and Parkinson's disease"
26. STUDI PENAMBATAN MOLEKUL DAN PREDIKSI ADMET SENYAWA METABOLIT SEKUNDER TANAMAN KELOR (Moringa oleifera L.) SEBAGAI INHIBITOR BACE1 PADA PENYAKIT ALZHEIMER
27. Tau-aggregation inhibition: promising role of nanoencapsulated dietary molecules in the management of Alzheimer’s disease
28. The Interplay between cGMP and Calcium Signaling in Alzheimer’s Disease
29. Tracking the binding of multi‐functional fluorescent tags for Alzheimer's disease using quantitative multiphoton microscopy

1. Abdominal fullness and discomfort induced by an extract of the Japanese herbal medicine Tsumura Ninjin'yoeito: The cases of two patients with Alzheimer's disease and anorexia
2. Alzheimer’s Disease and the Invisible Person: The Missing Patient Voice
3. Alzheimer’s disease pattern derived from relative cerebral flow as an alternative for the metabolic pattern using SSM/PCA
4. An MRI Scans-Based Alzheimer’s Disease Detection via Convolutional Neural Network and Transfer Learning
5. Anticholinesterase Inhibition, Drug-Likeness Assessment, and Molecular Docking Evaluation of Milk Protein-Derived Opioid Peptides for the Control of Alzheimer’s Disease
6. Brain aerobic glycolysis and resilience in Alzheimer disease
7. Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)
8. Cuidados paliativos em idosos com Doenças Neurodegenerativas: ênfase na doença de Alzheimer / palliative care in the elderly with Neurodegenerative Diseases: emphasis on Alzheimer's disease
9. EVALUATION OF WEARABLE HEALTH TECHNOLOGIES IN ALZHEIMER’S PATIENTS:A SYSTEMATIC REVIEW
10. Epigenetics in Alzheimer’s Disease
11. Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
12. P. edulis Extract Protects Against Amyloid-β Toxicity in Alzheimer’s Disease Models Through Maintenance of Mitochondrial Homeostasis via the FOXO3/DAF-16 Pathway
13. Pathological and neurophysiological outcomes of seeding human-derived tau pathology in the APP-KI NL-G-F and NL-NL mouse models of Alzheimer’s Disease
14. Review for "Calcium Inhibits Penetration of Alzheimer's Aβ _1‐42 Monomers into the Membrane"
15. Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimer’s Disease
16. Signatures of somatosensory cortical dysfunction in Alzheimer’s disease and HIV-associated neurocognitive disorder
17. Small Molecule Drugs for Treatment of Alzheimer’s Diseases Developed on the Basis of Mechanistic Understanding of the Serotonin Receptors 4 and 6
18. The Periodontal Pathogen Fusobacterium nucleatum Exacerbates Alzheimer’s Pathogenesis via Specific Pathways
19. The unfolded protein response transcription factor XBP1s ameliorates Alzheimer’s disease by improving synaptic function and proteostasis
20. Vascular narrowing linked to Alzheimer’s disease
21. Verbal fluency discrepancies as a marker of the prehippocampal stages of Alzheimer’s disease.

1. Abnormal whisker movements in the 3xTg‐AD mouse model of Alzheimer's disease
2. Andrographolide attenuates short-term spatial and recognition memory impairment and neuroinflammation induced by a streptozotocin rat model of Alzheimer’s disease
3. Anticipated reactions to learning Alzheimer’s disease biomarker results
4. Brain Imaging Can Help Patients With Alzheimer’s Disease
5. CEND1 deficiency induces mitochondrial dysfunction and cognitive impairment in Alzheimer’s disease
6. Cognitive Correlates of Impaired Testamentary Capacity in Alzheimer’s Dementia
7. Edible Folic and Folinic acid supplementation promotes myocardial cell survival and anti-apoptotic effects in Aging triple-transgenic Alzheimer's mice heart
8. Emerging Pathophysiological Mechanisms Linking Diabetes Mellitus and Alzheimer’s Disease: An Old Wine in a New Bottle
9. Exosomal circRNA-miRNA Expression profile from plasma in Alzheimer’s Disease Patients by Bioinformatics and Integrative Analysis
10. Exploring the impact of community-based choral participation on cognitive function and well-being for persons with dementia: evidence from the Voices in Motion project
11. Foresee novel targets for Alzheimer’s disease by investigating repurposed drugs
12. Increased Levels of Plasma Alzheimer’s Disease Biomarkers and Their Associations with Brain Structural Changes and Carotid Intima-Media Thickness in Cognitively Normal Obstructive Sleep Apnea Patients
13. Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders
14. Laser tweezers Raman spectroscopy combined with machine learning for diagnosis of Alzheimer’s disease
15. Logogenic Primary Progressive Aphasia or Alzheimer Disease: Contribution of Acoustic Markers in Early Differential Diagnosis
16. Loss of glucocorticoid receptor phosphorylation contributes to cognitive and neurocentric damages of the amyloid-β pathway
17. Mechanism of Neural Regeneration Induced by Natural Product LY01 in the 5×FAD Mouse Model of Alzheimer’s Disease
18. Multi-Platform Proteomic Analysis of Alzheimer’s Disease Cerebrospinal Fluid and Plasma Reveals Network Biomarkers Associated with Proteostasis and the Matrisome
19. Neural Mechanisms of Motor Dysfunction in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review
20. Neuronal hyperexcitability in Alzheimer’s disease: what are the drivers behind this aberrant phenotype?
21. Personal Memories and Bodily-Cues Influence Our Sense of Self
22. Pinpointing novel risk loci for Lewy body dementia and the shared genetic etiology with Alzheimer’s disease and Parkinson’s disease: a large-scale multi-trait association analysis
23. Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts
24. REPS1 as a Potential Biomarker in Alzheimer’s Disease and Vascular Dementia
25. Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer’s Disease
26. Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia
27. Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
28. Structural Analysis and Development of Notum Fragment Screening Hits
29. The Influence of 24-h Ambulatory Blood Pressure on Cognitive Function and Neuropathological Biomarker in Patients With Alzheimer's Disease
30. The dense-core plaques of Alzheimer’s disease are granulomas
31. Therapeutic Potential of Allicin and Aged Garlic Extract in Alzheimer’s Disease
32. Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics
33. [18F]ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer’s disease pathology in APP/PS1 mice
34. mGluR1α expression in the hippocampus, subiculum, entorhinal cortex and superior temporal gyrus in Alzheimer’s disease

1. A mechanistic model explains oscillatory slowing and neuronal hyperactivity in Alzheimer’s disease
2. Alzheimer's disease genetic burden is associated with mid‐life depression among persons with normal cognition
3. Assessment of breast lesions by the Kaiser score for differential diagnosis on MRI: the added value of ADC and machine learning modeling
4. Biophysical Kv3 channel alterations dampen excitability of cortical PV interneurons and contribute to network hyperexcitability in early Alzheimer’s
5. Brain Structural and Functional Changes in Cognitive Impairment Due to Alzheimer’s Disease
6. Can we improve prediction of Alzheimer's disease and Mild Cognitive Impairment by combining MMSE score and MRI-based imaging data?
7. Classification of early-MCI patients from healthy controls using evolutionary optimization of graph measures of resting-state fMRI, for the Alzheimer’s disease neuroimaging initiative
8. Denoising Approach Affects Diagnostic Differences in Brain Connectivity across the Alzheimer’s Disease Continuum
9. Epidemiological Characteristics and Factors Associated Alzheimer's Disease and Mild Cognitive Impairment among the Elderly in Urban and Rural Areas of Hubei Province
10. Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort
11. Evaluating the Causal Effects of Gestational Diabetes Mellitus, Heart Disease, and High Body Mass Index on Maternal Alzheimer’s Disease and Dementia: Multivariable Mendelian Randomization
12. Evolution of Alzheimer's disease research from a health-tech perspective: Insights from text mining
13. Formulation and Development of a Curcumin-Piperine Loaded Nanoemulsion for the Treatment of Alzheimer’s Disease
14. Functionally linked potassium channel activity in cerebral endothelial and smooth muscle cells is compromised in Alzheimer’s disease
15. Identification of plasma metabolites associated with modifiable risk factors and biomarkers reflecting Alzheimer’s disease pathology
16. Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites
17. Machine Learning for Alzheimer’s Disease Detection Based on Neuroimaging techniques: A Review
18. Microglia-Mediated Aβ Propagation in Alzheimer’s Disease
19. Mouse Models of Alzheimer’s Disease
20. Network Pharmacology-Based Strategy to Investigate the Pharmacologic Mechanisms of Coptidis Rhizoma for the Treatment of Alzheimer's Disease
21. New Test to Help Diagnose Alzheimer Disease
22. Nicotinamide riboside and caffeine partially restore diminished NAD availability but not altered energy metabolism in Alzheimer's disease
23. O impacto da prática de exercícios físicos em indivíduos com doença de Alzheimer em estágio inicial / The impact of physical exercise in individuals with mild stage of Alzheimer's disease
24. Posterior cingulate cortex reveals an expression profile of resilience in cognitively intact elders
25. Review for "White matter integrity and key structures affected in Alzheimer’s disease characterized by diffusion tensor imaging"
26. The Role of Mesenchymal Stem Cells in Regulating Astrocytes-Related Synapse Dysfunction in Early Alzheimer’s Disease
27. The neural signatures of psychoses in Alzheimer’s disease: a neuroimaging genetics approach
28. Ultrastructural characterization of dark microglia during aging in a mouse model of Alzheimer’s disease pathology and in human post-mortem brain samples

1. 4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer’s Disease
2. A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease
3. Adapting the Namaste Care Program for Use with Caregivers of Community-Dwelling Older Adults with Moderate to Advanced Dementia: A Qualitative Descriptive Study
4. Analysis of mutations in APP1 protein associated with development and protection against Alzheimer's disease - an In silico approach / Análise de mutações na proteína APP1 associadas ao desenvolvimento e proteção contra a doença de Alzheimer - uma abordagem In silico
5. Author Correction: A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease
6. Combined therapy for Alzheimer's disease
7. DYRK1A inhibitors and perspectives for the treatment of Alzheimer's disease
8. Depressive Symptoms Have Distinct Relationships With Neuroimaging Biomarkers Across the Alzheimer’s Clinical Continuum
9. Enhanced Anxiety and Olfactory Microglial Activation in Early-Stage Familial Alzheimer’s Disease Mouse Model
10. Functional Redundancy of the Posterior Hippocampi, but not Anterior Hippocampi or Left Frontal Cortex, is Disrupted in Pathological Brain Aging
11. Incremental diagnostic value of 18F-Fluetemetamol PET in differential diagnoses of Alzheimer’s Disease-related neurodegenerative diseases from an unselected memory clinic cohort
12. Investigating binding mechanism of thymoquinone to human transferrin, targeting Alzheimer's disease therapy
13. Microtube Array Membrane Encapsulated Cell Therapy: A Novel Platform Technology Solution for Treatment of Alzheimer’s Disease
14. Multimodal deep learning for Alzheimer’s disease dementia assessment
15. Neuropsychiatric disorders correction in Alzheimer's disease
16. PET-Based Model Could Aid in Staging of Alzheimer's Patients
17. Role of Ginkgo Biloba in Alzheimer Disease
18. Spray Dried Mucoadhesive Microparticles of Donepezil with Chitosan and Carbopol in Alzheimer’s Disease
19. Supplemental Material for Verbal Fluency Discrepancies as a Marker of the Prehippocampal Stages of Alzheimer’s Disease
20. The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
21. Using genetically engineered calcium indicator to identify the role of astrocytes in the development of Alzheimer's disease
22. Vascular lesions and brain atrophy in Alzheimer’s, vascular and mixed dementia: an optimized 3T MRI protocol reveals distinctive radiological profiles

1. Adipose tissue‐derived stem cells as a potential candidate in treatment of Alzheimer's disease: A systematic review on preclinical studies
2. Elucidating the Molecular Targets and Mechanisms of Chlorogenic Acid against Alzheimer’s Disease via Network Pharmacology and Molecular Docking
3. Probiotic Bifidobacterium breve MCC1274 Mitigates Alzheimer’s Disease-Related Pathologies in Wild-Type Mice
4. The Prophylactic and Multimodal Activity of Two Isatin Thiosemicarbazones against Alzheimer’s Disease In Vitro

1. 1,8-Cineole Ameliorates Advanced Glycation End Products-Induced Alzheimer’s Disease-like Pathology In Vitro and In Vivo
2. Cognitive functioning, cerebrospinal fluid Alzheimer's disease biomarkers and cerebral glucose metabolism in late‐onset epilepsy of unknown aetiology: A prospective study
3. Dysregulated Ca2+ Homeostasis as a Central Theme in Neurodegeneration: Lessons from Alzheimer’s Disease and Wolfram Syndrome
4. Early detection of Alzheimer's diseases through IoT
5. Early-Stage Alzheimer’s Disease Categorization Using PET Neuroimaging Modality and Convolutional Neural Networks in the 2D and 3D Domains
6. Hope or hype? Aducanumab as a magic bullet for Alzheimer’s disease
7. Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease
8. Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease

1. A Potential Notion on Alzheimer’s Disease: Nanotechnology as an Alternative Solution
2. A multi-omics approach identifies a blood-based miRNA signature of cognitive decline in two large observational trials
3. Abnormal Functional Hierarchies of EEG Networks in Familial and Sporadic Prodromal Alzheimer's Disease During Visual Short-Term Memory Binding
4. Absolute Winding Number Differentiates Mouse Spatial Navigation Strategies With Genetic Risk for Alzheimer’s Disease
5. Alterations in protein kinase networks in astrocytes and neurons derived from patients with familial Alzheimer’s Disease
6. Alzheimer’s Amyloid-β Accelerates Human Neuronal Cell Senescence Which Could Be Rescued by Sirtuin-1 and Aspirin
7. Application of automated fiber-tract quantification technology in the early stage of Alzheimer's disease
8. Autologous skin-derived neural precursor cell therapy reverses canine Alzheimer dementia-like syndrome in a proof of concept veterinary trial
9. Curcumin Scaffold as a Multifunctional Tool for Alzheimer’s Disease Research
10. Day service use and improved Serial 7 and Verbal fluency scores in patients with Alzheimer's disease
11. Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study
12. Early and lifelong effects of APOE4 on neuronal gene expression networks relevant to Alzheimer’s disease
13. Effect of Curcumin on Clzheimer's disease: a systematic review / Efeito da Curcumina na doença de Alzheimer: revisão sistemática
14. Global incidence of young‐onset dementia: A systematic review and meta‐analysis
15. Integrated Proteomics Identifies Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer’s Disease
16. Inter- and intra-chromosomal modulators of the APOE ε2 and ε4 effects on the Alzheimer’s disease risk
17. Neuroprotective Effects of Oligosaccharides in Rehmanniae Radix on Transgenic Caenorhabditis elegans Models for Alzheimer’s Disease
18. Neuroprotective effects of Ficusdalhousie and Melissa parviflora benth against aluminium chloride induced Alzheimer's disease in rat model
19. Perceptions of and Knowledge Acquisition about Brain Health and Aging among Latin American Immigrants:A QualitativePaper
20. Promising application of polyoxometalates in the treatment of cancer, infectious diseases and Alzheimer’s disease
21. Pure word deafness: a case report of an atypical manifestation of Alzheimer’s disease
22. Restoring synapse integrity and memory in Alzheimer’s disease by downregulation of the Wnt antagonist Dickkopf-3
23. SARS-CoV-2 Neuroinvasion, Inflammatory Neurodegeneration and Alzheimer's Disease
24. Trajectories of cognitive decline and dementia development: A 12‐year longitudinal study
25. Transcriptomic profiling of Early-onset sporadic Alzheimer’s disease patients
26. Venular amyloid accumulation subsequent to cerebral amyloid angiopathy in transgenic Fischer 344 Alzheimer’s disease rats
27. Vulnerable Brain Networks Associated with Risk for Alzheimer’s Disease
28. Why Women Are Predisposed to Alzheimer’s Disease

1. A novelty detection approach to effectively predict conversion from mild cognitive impairment to Alzheimer’s disease
2. A single-cell atlas of the human brain in Alzheimer’s disease and its implications for personalized drug repositioning
3. Amyloid Beta Peptide-Mediated Alterations in Mitochondrial Dynamics and its Implications for Alzheimer’s Disease
4. Amyloid-β impairs mitochondrial dynamics and autophagy in Alzheimer’s disease experimental models
5. Assessment of Instrumental Activities of Daily Living in Preclinical Alzheimer Disease
6. Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials
7. Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression
8. Case Report: Alzheimer's Dementia Associated With Cerebrospinal Fluid Neurochondrin Autoantibodies
9. Clinical Features and Potential Mechanisms Relating Neuropathological Biomarkers and Blood-Brain Barrier in Patients With Alzheimer’s Disease and Hearing Loss
10. Constructing Domain Ontology for Alzheimer Disease Using Deep Learning Based Approach
11. Cost-effectiveness of Alzheimer’s disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
12. Differential Patterns of Domain-Specific Cognitive Complaints and Awareness Across the Alzheimer’s Disease Spectrum
13. EEG-based Graph Neural Network Classification of Alzheimer’s Disease: An Empirical Evaluation of Functional Connectivity Methods
14. Effect of Physical Exercise on Cognitive Function of Alzheimer's Disease Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
15. Establishment of combined diagnostic models of Alzheimer’s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS)
16. Factors influencing resilience to postoperative delirium in adults undergoing elective orthopaedic surgery
17. Friend or Foe? Defining the Role of Glutamate in Aging and Alzheimer’s Disease
18. Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s Disease
19. Hormone therapy and the decreased risk of dementia in women with depression: a population-based cohort study
20. Insulin and insulin-like growth factor-I receptors in astrocytes exert different effects on behavior and Alzheimer´s-like pathology
21. Join the Longest Day Event June 21 to Raise Alzheimer’s Awareness
22. Madhuca longifolia – bark and leaves: An outlook for natural therapeutic approach for Alzheimer’s disease
23. Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches
24. Muscle Strength Seems to be Related to The Functional Status and Severity of Dementia in Older Adults with Alzheimer’s Disease
25. Object-based practice effects recover the graphic object concept in Alzheimer’s dementia.
26. Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer’s Disease
27. Primary progressive aphasia: ReADing the clinical GRANularity
28. Protective effect of pterostilbene in a streptozotocin‐induced mouse model of Alzheimer's disease by targeting monoamine oxidase B
29. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia
30. Research Progress of Pyroptosis in Alzheimer’s Disease
31. Retinal Aging in 3× Tg-AD Mice Model of Alzheimer's Disease
32. Sensory experience selectively reorganizes the late component of evoked responses
33. Sex Differences in Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer’s Disease Patients
34. Study of nonlinear optical responses of phytochemicals of Clitoria ternatea by quantum mechanical approach and investigation of their anti-Alzheimer activity with in silico approach
35. The Latin American Brain Health Institute, a regional initiative to reduce the scale and impact of dementia
36. The Role of Astrocytes in Synapse Loss in Alzheimer's Disease: A Systematic Review
37.  Sex, menopause, and Alzheimer’s risk: a 31P-MR spectroscopy study of brain mitochondrial function in association with 11C-PiB PET amyloid-beta load

1. Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest Old
2. Autophagic plasmid expressing SIRT3 and SIRT4 to improve Alzheimer’s disease
3. Cerebrospinal Fluid Biomarkers for Early and Differential Diagnosis of Alzheimer's Disease
4. DHA Ameliorates Cognitive Ability, Reduces Amyloid Deposition, and Nerve Fiber Production in Alzheimer’s Disease
5. Declínio cognitivo e Demência de Alzheimer: existe relação com o desempenho funcional?
6. Dietary Glycemic Load and Plasma Amyloid-β Biomarkers of Alzheimer’s Disease
7. Early-life stress elicits peripheral and brain immune activation differently in wild type and 5xFAD mice in a sex-specific manner
8. Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer’s Disease in Relation to Therapeutic Editing Tools
9. Faculty Opinions recommendation of Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
10. Identification of miRNA–mRNA Pairs in the Alzheimer’s Disease Expression Profile and Explore the Effect of miR-26a-5p/PTGS2 on Amyloid-β Induced Neurotoxicity in Alzheimer’s Disease Cell Model
11. Insulin Deficiency Increases Sirt2 Level in Streptozotocin-Treated Alzheimer’s Disease-Like Mouse Model: Increased Sirt2 Induces Tau Phosphorylation Through ERK Activation
12. Interventionelle Therapie eines spontanen intrahepatischen portosystemischen Shunts ohne zugrunde liegende Leberzirrhose – vollständige Rückbildung einer vermeintlichen Alzheimer-Demenz
13. Learning Strategies and Verbal Memory Deficits on the Shiraz Verbal Learning Test in Patients with Alzheimer’s Disease and Amnestic Mild Cognitive Impairment
14. Long-term time trends in reactivated herpes simplex infections and treatment in Sweden
15. Machine learning for comprehensive prediction of high risk for Alzheimer’s disease based on chromatic pupilloperimetry
16. Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer’s Disease in Rat and Dog
17. Plasticity of Membrane Binding by the Central Region of α-Synuclein
18. Quality of life predictors in patients with Alzheimer's disease dementia
19. Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease
20. Risks and risk mitigation in homecare for people with dementia—A two‐sided matter: A systematic review
21. Systematic assessment of pathophysiological mechanisms and their interrelation in progression of Alzheimer’s disease
22. Targeting the Cation-Chloride Co-Transporter NKCC1 to Re-Establish GABAergic Inhibition and an Appropriate Excitatory/Inhibitory Balance in Selective Neuronal Circuits: A Novel Approach for the Treatment of Alzheimer’s Disease
23. Who Volunteers? Results From an Internet-Based Cognitive Monitoring Study of Community-Based Older Adults

1. A Cobalt-Containing Compound as a Stronger Inhibitor than Galantamine to Inhibit Acetylcholinesterase Activity: A New Drug Candidate for Alzheimer’s Disease Treatment
2. A Stacking Framework for Multi-Classification of Alzheimer’s Disease Using Neuroimaging and Clinical Features
3. A concise review of common plant-derived compounds as potential therapy for Alzheimer's disease and Parkinson's disease: Insight into Structure-Activity-Relationship.
4. Alzheimer's Disease
5. Alzheimer’s Disease Association with Metals and Metalloids Concentration in Blood and Urine
6. Alzheimer’s Disease Connected Genes in the Post-Ischemic Hippocampus and Temporal Cortex
7. Alzheimer’s Disease Mortality as a Function of Urbanization Level: 1999–2019
8. Alzheimer’s Disease-Related Genes Identified by Linking Spatial Patterns of Pathology and Gene Expression
9. An Alternatively Spliced TREM2 Isoform Lacking the Ligand Binding Domain is Expressed in Human Brain
10. Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds
11. Author response: Impaired astrocytic Ca2+ signaling in awake-behaving Alzheimer’s disease transgenic mice
12. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults
13. Brain Photobiomodulation Improves Sleep Quality in Subjective Cognitive Decline: A Randomized, Sham-Controlled Study
14. CNN Technique For Detecting Alzheimer’s Disease by using MRI Images
15. Cancer History Is Associated with Slower Speed of Cognitive Decline in Patients with Amnestic Cognitive Impairment
16. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non‐Alzheimer's disease pathophysiology
17. Clustering Analysis of the Care Problems of People with Dementia Based on the Minimum Spanning Tree Algorithm: A Cross-Sectional Study
18. Combination Therapy in Alzheimer’s Disease: Is It Time?
19. CompositeView: A Network-Based Visualization Tool
20. Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits
21. Cultural Adaptation of the Reducing Disability in Alzheimer’s Disease (RDAD) Protocol for an Intervention to Reduce Behavioral and Psychological Symptoms of Dementia in Thailand
22. Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer’s Disease
23. DNA-Compatible Suzuki-Miyaura Cross-Coupling Reaction of Aryl Iodides With (Hetero)Aryl Boronic Acids for DNA-Encoded Libraries
24. Designing a Small Fluorescent Inhibitor to Investigate Soluble Epoxide Hydrolase Engagement in Living Cells
25. Detection of Alzheimer’s disease in MRI images using different transfer learning models and improving the classification accuracy
26. EEG sinyallerini kullanarak Alzheimer hastalığının otomatik tespiti için bilgisayar destekli tanı sistemi
27. Elevated brain-derived cell-free DNA among patients with first psychotic episode – a proof-of-concept study
28. Evolution of Clinical-Pathological Correlations in Early-Onset Alzheimer’s Disease Over a 25-Year Period in an Academic Brain Bank
29. Far infrared light irradiation enhances Aβ clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer’s disease-like mice
30. Genome wide association neural networks (GWANN) identify novel genes linked to family history of Alzheimer’s disease in the UK Biobank
31. Ghrelin regulates crosstalk between apoptosis, necroptosis and autophagy programmed cell death pathways in the hippocampal neurons of amyloid-β 1–42-induced rat model of Alzheimer’s disease
32. Implementing a Financial Decision-Making Scale in APS Financial Exploitation Investigations: Use of the PARIHS Conceptual Framework
33. Importance of Task Selection for Connected Speech Analysis in Patients with Alzheimer’s Disease from an Ethnically Diverse Sample
34. Integrating the Synergy of the Gut Microbiome into Regenerative Medicine: Relevance to Neurological Disorders
35. Lifestyle Affects Amyloid Burden and Cognition Differently in Men and Women
36. Mechanistic insight of the potential of geraniol against Alzheimer’s disease
37. Mild Traumatic Brain Injury Is Related to Elevated Cerebrospinal Fluid Tau in Alzheimer’s Disease Dementia
38. New Insights into Neuroinflammation Involved in Pathogenic Mechanism of Alzheimer’s Disease and Its Potential for Therapeutic Intervention
39. Ontology Specific Alternative Splicing Changes in Alzheimer’s Disease
40. Oxysterols and Oxysterol Sulfates in Alzheimer’s Disease Brain and Cerebrospinal Fluid
41. PSEN2 Mutation Spectrum and Novel Functionally Validated Mutations in Alzheimer’s Disease: Data from PUMCH Dementia Cohort
42. Plasma pTau-217 in preclinical Alzheimer’s disease
43. Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy
44. Psychobiological Monitoring of a Home-Based Dyadic Intervention for People Living with Dementia and Their Caregivers: Added Value to Evaluate Treatment Success and Understand Underlying Mechanisms
45. Reach-to-Grasp Kinematics and Kinetics in Early- Stage Alzheimer’s Disease
46. Saliva is a Good Candidate to be the New Gold-Standard Sample for Neurodegenerative Diseases
47. Sleep Disturbances, Changes in Sleep, and Cognitive Function in Low-Income African Americans
48. Small RNA Sequencing in the Tg4–42 Mouse Model Suggests the Involvement of snoRNAs in the Etiology of Alzheimer’s Disease
49. Strategies Associated with Retaining Participants in the Longitudinal National Alzheimer’s Coordinating Center Uniform Data Set Study
50. Synthesis and biological evaluation of thieno[3,2-c]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer’s disease
51. Tasks and Activities of an Effective Collaborative Dementia Care Management Program in German Primary Care
52. Test-Retest Reliability and Minimal Detectable Change of Four Cognitive Tests in Community-Dwelling Older Adults
53. Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
54. The Association Among Inflammatory Diet, Glycohemoglobin, and Cognitive Function Impairment in the Elderly: Based on the NHANES 2011–2014
55. The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging
56. The Boston Process Approach and Digital Neuropsychological Assessment: Past Research and Future Directions
57. The Correlation Between White Matter Hyperintensity Burden and Regional Brain Volumetry in Patients With Alzheimer's Disease
58. The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer’s Disease Risks
59. Using SVM for Alzheimer’s Disease detection from 3D T1MRI
60. Utilization of Cholinesterase Inhibitors for Alzheimer Disease in Canada

1. AAV-mediated neuronal expression of a scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models
2. ASSISTÊNCIA DE ENFERMAGEM AO IDOSO PORTADOR DE ALZHEIMER
3. Acute OSA Impacts Diurnal Alzheimer’s Biomarkers Through Nocturnal Hypoxemia and State Transitions
4. Association of Healthy Lifestyles With Risk of Alzheimer Disease and Related Dementias in Low-Income Black and White Americans
5. Automated brain volumetric program measuring regional brain atrophy in diagnosis of mild cognitive impairment and Alzheimer’s disease dementia
6. Biomarkers and Mindfulness: A Way Forward
7. CAT – A Computational Anatomy Toolbox for the Analysis of Structural MRI Data
8. Can Syndecan-1 Be Used As A Biomarker In Alzheimer’s Disease?
9. Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer’s tau pathology
10. Comparing the Diagnostic Value of Four Dementia Tests in the Amnestic and Healthy Elderly
11. Comparison of Visual Rating Scale Based on Brain 18F-FDG-PET and Montreal Cognitive Assessment Test in Probable Alzheimer’s Disease
12. Correction: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
13. Efficient Deep Learning Algorithm for Alzheimer's Disease Diagnosis using Retinal Images
14. Evaluating the effectiveness of stepwise swallowing training on dysphagia in patients with Alzheimer’s disease: study protocol for a randomized controlled trial
15. Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease
16. Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts
17. Identify Biomarkers of Alzheimer's Disease Based on Multi-task Canonical Correlation Analysis and Regression Model
18. Including General Audiences in a Virtual Scientific Dementia Conference: Will They Get Anything From It?
19. Live Demonstration: Efficient Deep Learning Algorithm for Alzheimer's Disease Diagnosis using Retinal Images
20. Longitudinal Consumption of Ergothioneine Reduces Oxidative Stress and Amyloid Plaques and Restores Glucose Metabolism in the 5XFAD Mouse Model of Alzheimer’s Disease
21. Lymphatic dysfunction sustains memory impairment despite Aβ reduction by reactive astrocytes in an Alzheimer’s disease model
22. Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels
23. Mitochondrial genome mutations and neuronal dysfunction of induced pluripotent stem cells derived from patients with Alzheimer's disease
24. Molecular Hydrogen Neuroprotection in Post-Ischemic Neurodegeneration in the Form of Alzheimer’s Disease Proteinopathy: Underlying Mechanisms and Potential for Clinical Implementation—Fantasy or Reality?
25. Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
26. Strategies for developing Alzheimer’s disease treatments: application of population pharmacokinetic and pharmacodynamic models
27. Telomere Attrition in Induced Pluripotent Stem Cell-Derived Neurons From ALS/FTD-Related C9ORF72 Repeat Expansion Carriers
28. The Brilliance of the Zebrafish Model: Perception on Behavior and Alzheimer’s Disease
29. To smooth or not to smooth: One step closer to single-voxel accuracy without spatial smoothing
30. Toward the Noninvasive Diagnosis of Alzheimer’s Disease: Molecular Basis for the Specificity of Curcumin for Fibrillar Amyloid-β
31. Tβ4 and PDTC displayed recovery on the glial and neuronal alterations in an early Alzheimer’s disease model
32. Ultrasound-Mediated Bioeffects in Senescent Mice and Alzheimer’s Mouse Models

1. APOE ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease
2. Alzheimer’s disease biomarker profiling in a memory clinic cohort without common comorbidities
3. Decision letter for "Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta‐analysis"
4. Homology Modelling, Molecular Docking and Molecular Dynamics Simulation Studies of CALMH1 against Secondary Metabolites of Bauhinia variegata to Treat Alzheimer’s Disease
5. Innate and adaptive immune basis of mental health effect on Alzheimer’s disease progression
6. Proteína tau como biomarcador en Alzheimer preclínico
7. Review for "Is Alzheimer's disease an infectious neurological disease? A review of the literature"
8. Review for "White matter integrity and key structures affected in Alzheimer’s disease characterized by diffusion tensor imaging"

1. Alzheimer Type I Astrocytes: Still Mysterious Cells
2. Application of curcumin nanoformulations in Alzheimer’s disease: prevention, diagnosis and treatment
3. Association of perturbation of oral bacterial with incident of Alzheimer's disease: A pilot study
4. Correction: Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)—study protocol for a randomized controlled trial
5. Future of Alzheimer’s Disease: Nanotechnology-Based Diagnostics and Therapeutic Approach

1. Ameliorative effects of phytomedicines on Alzheimer’s patients
2. Bulk and Single-Nucleus Transcriptomics Highlight Intra-Telencephalic and Somatostatin Neurons in Alzheimer’s Disease
3. CDiP technology for reverse engineering of sporadic Alzheimer’s disease
4. Coenzyme A-Dependent Tricarboxylic Acid Cycle Enzymes Are Decreased in Alzheimer’s Disease Consistent With Cerebral Pantothenate Deficiency
5. DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
6. Data on multiple post-translational modifications in Alzheimer's disease
7. Gene expression profiling and protein–protein interaction analysis reveals the dynamic role of MCM7 in Alzheimer's disorder and breast cancer
8. Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer’s-like pathology in mouse and fly APP overexpression models
9. Individualized identification of sexual dysfunction of psychiatric patients with machine-learning
10. Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease
11. MPC-STANet: Alzheimer’s Disease Recognition Method Based on Multiple Phantom Convolution and Spatial Transformation Attention Mechanism
12. Neuroprotective Effect of Caffeine in Alzheimer’s Disease
13. Review for "Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta‐analysis"
14. Roles of Altered Macrophages and Cytokines: Implications for Pathological Mechanisms of Postmenopausal Osteoporosis, Rheumatoid Arthritis, and Alzheimer’s Disease
15. The Effect of Sub-chronic Administration of Brewed Coffee on Long-term Potentiation in a Rat Model of Alzheimer's Disease
16. The anti-Alzheimer potential of some novel Tacrine-Coumarin Derivatives as a Cholinesterase inhibitor
17. Whole Exome Sequencing Reveals a Novel APOE Mutation in a Patient With Sporadic Early-Onset Alzheimer's Disease

1. Ginkgo biloba extract mitigates the neurotoxicity of AlCl₃ in alzheimer rat’s model: role of apolipoprotein E4 and clusterin genes in stimulating ROS generation and apoptosis
2. A fuzzy membership based comparison of the grey matter (GM) in cognitively normal (CN), mild cognitive impairment (MCI), and Alzheimer’s disease (AD) using brain images
3. Activation of the TREK-1 Potassium Channel Improved Cognitive Deficits in a Mouse Model of Alzheimer’s Disease by Modulating Glutamate Metabolism
4. Alterations in neural stem cell quiescence and activation in the 3xTG-AD model of Alzheimer’s Disease
5. Alzheimer's Disease Classification
6. Alzheimer’s disease diagnosis via 5-layer Convolutional Neural Network and Data Augmentation
7. An observation study of urinary biomarker exploratory in Alzheimer's disease using high‐resolution mass spectrometry
8. Approaches to Address PK–PD Challenges of Conventional Liposome Formulation with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update on Modified Liposomal Drug Delivery System
9. Combined long-term enriched environment and caffeine supplementation improve memory function in C57Bl6 mice
10. Decision letter for "Oral microbiome and serological analyses on association of Alzheimer's disease and periodontitis"
11. Dissecting the limited genetic overlap of Parkinson's and Alzheimer's disease
12. ENCSR010HNY
13. ENCSR125KVG
14. ENCSR128SVE
15. ENCSR157MPY
16. ENCSR185BMK
17. ENCSR194JAU
18. ENCSR245QRV
19. ENCSR252TQC
20. ENCSR262JRZ
21. ENCSR275JVX
22. ENCSR340OJR
23. ENCSR433PYM
24. ENCSR607IHY
25. ENCSR619TOU
26. ENCSR619WGF
27. ENCSR622MUH
28. ENCSR659MOZ
29. ENCSR691JHZ
30. ENCSR703AIO
31. ENCSR715FHW
32. ENCSR757DFT
33. ENCSR814QIV
34. ENCSR817PGE
35. ENCSR819WDZ
36. ENCSR841XDW
37. ENCSR857HWF
38. ENCSR914ETY
39. ENCSR946LTR
40. Effect of Ginkgo biloba leaf extract in combination with vitamin C, E and D on Aluminum Chloride induced Alzheimer in rats.
41. Eucommia ulmoides Olive Male Flower Extracts Ameliorate Alzheimer’s Disease-Like Pathology in Zebrafish via Regulating Autophagy, Acetylcholinesterase, and the Dopamine Transporter
42. Faculty Opinions recommendation of Analysis of Serum miRNAs in Alzheimer's Disease.
43. Identification of repurposed drugs targeting significant long non-coding RNAs in the cross-talk between Diabetes Mellitus and Alzheimer’s Disease
44. Interpretable ensemble deep learning model for early detection of Alzheimer's disease using local interpretable model‐agnostic explanations
45. Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography
46. Mild Cognitive Disorder in Post-COVID-19 Syndrome: A Retrospective Cohort Study of 67,000 Primary Care Post-COVID Patients
47. Natural language signatures of psilocybin microdosing
48. Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027
49. Possible Neuropathology of Sleep Disturbance Linking to Alzheimer’s Disease: Astrocytic and Microglial Roles
50. Red Blood Cell DHA Is Inversely Associated with Risk of Incident Alzheimer’s Disease and All-Cause Dementia: Framingham Offspring Study
51. Sample size calculators for planning stepped-wedge cluster randomized trials: a review and comparison
52. Tween-20 Induces the Structural Remodeling of Single Lipid Vesicles
53. Virtual Reality Zoo Therapy: An Interactive Relaxing System for Alzheimer’s Disease

1. Polyrhachis vicina Roger Alleviates Memory Impairment in a Rat Model of Alzheimer’s Disease Through the EGR1/BACE1/APP Axis
2. A peptide blocking the ADORA1-neurabin interaction is anticonvulsant and inhibits epilepsy in an Alzheimer’s model
3. Amygdalar and ERC Rostral Atrophy and Tau Pathology Reconstruction in Preclinical Alzheimer’s Disease
4. Combination of Acupoints for Alzheimer’s Disease: An Association Rule Analysis
5. Correction: Rivastigmine attenuates the Alzheimer's disease related protein degradation and apoptotic neuronal death signaling
6. Cross-cultural conceptualization of a good end of life with dementia: a qualitative study
7. Decision letter for "VEGF Paradoxically Reduces Cerebral Blood Flow in Alzheimer’s Disease Mice"
8. Estresse e recursos de enfrentamento na família com membros acometidos pela Doença de Alzheimer
9. Family Caregiving for People Living With Dementia During COVID-19: A Thematic Analysis
10. High Fall Risk Associated With Memory Deficit and Brain Lobes Atrophy Among Elderly With Amnestic Mild Cognitive Impairment and Mild Alzheimer’s Disease
11. Impact of COVID-19 Pandemic on Research Participation Among Older African Americans
12. In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails
13. Jogos eletrônicos: instrumento de intervenção em idosos com a Doença do Alzheimer
14. Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome
15. Neuropathological and behavioral features of an APP/PS1/MAPT (6xTg) transgenic model of Alzheimer’s disease
16. Non-invasive visualization of amyloid-beta deposits in Alzheimer amyloidosis mice using magnetic resonance imaging and fluorescence molecular tomography
17. Probabilistic principal component analysis and long short-term memory classifier for automatic detection of Alzheimer’s disease using MRI brain images
18. Sex influences clinical phenotype in frontotemporal dementia
19. Structural Dynamics and Susceptibility of Anti-Alzheimer’s Drugs Donepezil and Galantamine against Human Acetylcholinesterase
20. What are the effects of antipsychotics for people with Alzheimer's disease and vascular dementia with agitation and psychosis?

1. A National Assessment of Alzheimer Disease and Antipsychotic Medication Prescribing Among Older Adults in Ambulatory Care Settings
2. Automated High-Definition MRI Processing Routine Robustly Detects Longitudinal Morphometry Changes in Alzheimer’s Disease Patients
3. Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer’s Disease
4. Building a Network of Adverse Outcome Pathways (AOPs) Incorporating the Tau-Driven AOP Toward Memory Loss (AOP429)
5. Classification of Alzheimer’s Disease Based on Core-Large Scale Brain Network Using Multilayer Extreme Learning Machine
6. Comparison of dynamic susceptibility contrast enhanced MR and FDG-PET brain studies in patients with Alzheimer’s disease and amnestic mild cognitive impairment
7. Correlating tau pathology to brain atrophy using a physics-based Bayesian model
8. Cyanidin-3-O-Glucoside Regulates the M1/M2 Polarization of Microglia via PPARγ and Aβ42 Phagocytosis Through TREM2 in an Alzheimer’s Disease Model
9. Decision letter for "Structural synaptic signatures of Alzheimer’s Disease and Dementia with Lewy Bodies in the male brain"
10. Decision letter for "Targeted brain delivery of <scp>RVG29‐modified rifampicin‐loaded</scp> nanoparticles for Alzheimer's disease treatment and diagnosis"
11. ENCSR018KWK
12. ENCSR103IXF
13. ENCSR243LHN
14. ENCSR373OML
15. ENCSR405NKC
16. ENCSR515MED
17. ENCSR530ESE
18. ENCSR572GRM
19. ENCSR993YSN
20. Elaboração de jogo digital como recurso para estimulação da memória recente em idosos com Alzheimer / Developing a digital game as a resource for stimulation of recent memory in elderly with Alzheimer
21. Ex vivo Expanded Human Regulatory T Cells Modify Neuroinflammation in a Preclinical Model of Alzheimer’s disease
22. Exploring the zinc-related transcriptional landscape in Alzheimer’s disease
23. Investigation of Underlying Association Between Whole Brain Regions and Alzheimer’s Disease: A Research Based on an Artificial Intelligence Model
24. Isorhamnetin improves cognitive impairment of Alzheimer’s disease through Sirt1/AKT/ERK/CREB signaling pathway
25. Memantine associated with parkisonism in a patient with Alzheimer's disease: A case study and the review of the literature
26. Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the 5XFAD Alzheimer's Disease Model
27. Neuronal Rubicon Represses Extracellular APP/Amyloid β Deposition in Alzheimer’s Disease
28. Plasma Levels of Tissue-Type Plasminogen Activator (tPA) in Normal Aging and Alzheimer's Disease: Links With Cognition, Brain Structure, Brain Function and Amyloid Burden
29. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency
30. Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches

1. A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study
2. A comprehensive computational perspective in drug discovery for Alzheimer's disease.
3. A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
4. Alzheimer’s Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus
5. Anti-apoptotic effect of memantine in a rat hippocampal cell model of Alzheimer's disease: morphology and cellular mechanism
6. Association of neighborhood socioeconomic disadvantage and cognitive impairment
7. Design, Synthesis, and biological evaluation of pyrazolo-benzothiazole derivatives as a potential therapeutic agent for the treatment of Alzheimer’s disease
8. Discovery of Tryptophan‐tetrahydroisoquinoline Derivatives as Multifunctional Agents for Treatment of Alzheimer's Disease
9. Effect of acetylcholine deficiency on neural oscillation in a brainstem-thalamus-cortex model related with Alzheimer's disease
10. Efficient Deep Neural Networks for Classification of Alzheimer’s Disease and Mild Cognitive Impairment from Scalp EEG Recordings
11. Functional Connectivity and Complexity in the Phenomenological Model of Mild Cognitive-Impaired Alzheimer's Disease
12. Increasing Brain Gamma Activity Improves Episodic Memory and Restores Cholinergic Dysfunction in Alzheimer's Disease
13. Machine learning and Serious Game for the Early Diagnosis of Alzheimer’s Disease
14. Neuroimmune contributions to Alzheimer’s disease: a focus on human data
15. Nursing Students’ Knowledge Levels of Alzheimer’s Disease and Related Factors
16. Retinal Vascular Study Using OCTA in Subjects at High Genetic Risk of Developing Alzheimer’s Disease and Cardiovascular Risk Factors
17. Review for "Oral microbiome and serological analyses on association of Alzheimer's disease and periodontitis"
18. Review for "Structural synaptic signatures of Alzheimer’s Disease and Dementia with Lewy Bodies in the male brain"
19. Sex difference in general cognition associated with coupling of whole-brain functional connectivity strength to cerebral blood flow changes during Alzheimer’s disease progression
20. Signatures of glial activity can be detected in the CSF proteome
21. Spatial Distribution and Hierarchical Clustering of β-Amyloid and Glucose Metabolism in Alzheimer’s Disease
22. Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's Disease

1. A REABILITAÇÃO NEUROPSICOLÓGICA COMO TRATAMENTO NÃO FARMACOLÓGICO A PACIENTES DIAGNOSTICADOS COM ALZHEIMER (DA): UMA REVISÃO BIBLIOGRÁFICA
2. Decision letter for "Cognitive functioning, cerebrospinal fluid Alzheimer’s disease biomarkers and cerebral glucose metabolism in late‐onset epilepsy of unknown aetiology: a prospective study"
3. Review for "Structural synaptic signatures of Alzheimer’s Disease and Dementia with Lewy Bodies in the male brain"